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Toxicological profiles are revised and republished as necessary, but no less than once every three years. 
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This toxicological profile is prepared in accordance with guidelines* developed by the Agency for 
Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary. 
The ATSDR to&ological profile succinctly characterizes the toxicologic and adverse health 
effects information for the hazardous substance described therein. Each peer-reviewed profile identifies 
and reviews the key literature that describes a hazardous substance's toxicologic properties. Other 
pertinent literature is also presented, but is described in less detail than the key studies. The profile is not 
intended to be an exhaustive document; however, more comprehensive sources of specialty information 
are referenced. 
The focus of the profiles is on health and toxicologic information; therefore, each toxicological 
profile begins with a public health statement that describes, in nontechnical language, a substance's 
relevant toxicological properties. Following the public health statement is information concerning levels 
of Significant human exposure and, where known, significant health effects. The adequacy of 
information to determine a substance's health effects is described in a health effects summary. Data 
needs that are of significance to protection of public health are identified by ATSDR and EPA. 
Each profile includes the following: 
The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a hazardous substance to ascertain the levels of significant 
human exposure for the substance and the associated acute, subacute, and chronic health 
effects; 
A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and 
Where appropriate, identification of toxicologic testing needed to identify the types or levels 
of exposure that may present significant risk of adverse health effects in humans. 
The principal audiences for the toxicological profiles are health professionals at the federal, state, 
and local levels; interested private sector organizations and groups; and members of the public. 
This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that 
has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other federal 
scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a 
nongovernmental panel and was made available for public review. Final responsibility for the contents 
and views expressed in this toxicological profile resides with ATSDR. 
Administrator 




The toxicological profiles are developed in response to the Superfund Amendments and 
Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive 
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund).  This 
public law directed ATSDR to prepared toxicological profiles for hazardous substances most commonly 
found at facilities on the CERCLA National Priorities List and that pose the most significant potential 
threat to human health, as determined by ATSDR and the EPA.  The availability of the revised priority 
list of 275 hazardous substances was announced in the Federal Register on November 17, 1997 (62 FR 
61332). For prior versions of the list of substances, see Federal Register notices dated April 29, 1996 (61 
FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 
43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 
48801); and February 28, 1994 (59 FR 9486).  Section 104(i)(3) of CERCLA, as amended, directs the 
Administrator of ATSDR to prepare a toxicological profile for each substance on the list. 
 
    
  
vii BERYLLIUM 
QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of 
available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by 
route of exposure, by type of health effect (death, systemic, immunologic, reproductive), and by 
length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies 
are reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in 
the clinical setting. Please refer to the Public Health Statement to identify 
general health effects observed following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children?
 
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
 
Section 3.7 Children’s Susceptibility
 
Section 6.6 Exposures of Children
 
Other Sections of Interest: 
Section 3.8 Biomarkers of Exposure and Effect 
Section 3.11 Methods for Reducing Toxic Effects 
ATSDR Information Center 
Phone:  1-888-42-ATSDR or (404) 498-0110 Fax: (404) 498-0057 
E-mail: atsdric@cdc.gov Internet:  http://www.atsdr.cdc.gov 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided. Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 





is a three-volume set of recommendations for on-scene (prehospital) and hospital medical 
management of patients exposed during a hazardous materials incident.  Volumes I and II are 
planning guides to assist first responders and hospital emergency department personnel in 
planning for incidents that involve hazardous materials.  Volume III—Medical Management 
Guidelines for Acute Chemical Exposures—is a guide for health care professionals treating 
patients exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341­
3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.     Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or  NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • 
FAX: 202-347-4950 • e-mail: aoec@dgs.dgsys.com • AOEC Clinic Director: http://occ-env­
med.mc.duke.edu/oem/aoec.htm. 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 55 West Seegers Road, Arlington Heights, IL 






ATSDR, Division of Toxicology, Atlanta, GA
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
1.	 Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
2.	 Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific minimal risk levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
3.	 Data Needs Review. The Research Implementation Branch reviews data needs sections to assure 






A peer review panel was assembled for beryllium.  The panel consisted of the following members: 
1.	 Dr. Derek J. Hodgson, University of Nebraska at Omaha, Omaha, NE. 
2.	 Dr. Laurence Holland, Private Consultant, Los Alamos, NM. 
3.	 Dr. Hanspeter Witschi, Center for Health and the Environment, University of California Davis, 
CA 95615. 
4.	 Dr. Finis Cavendar, Adjunct Professor, Curriculum in Toxicology, University of North Carolina 
at Chapel Hill, Chapel Hill, NC. 
These experts collectively have knowledge of beryllium's physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.  A list of databases reviewed and 
a list of unpublished documents cited are also included in the administrative record. 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content. The responsibility for the content of this profile lies with the ATSDR. 
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1. PUBLIC HEALTH STATEMENT 
This public health statement tells you about beryllium and the effects of exposure. 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites make up the National Priorities List (NPL) and are the sites targeted for 
long-term federal cleanup activities.  Beryllium has been found in at least 535 of the 
1,613 current or former NPL sites.  However, the total number of NPL sites evaluated for this 
substance is not known. As more sites are evaluated, the sites at which beryllium is found may 
increase. This information is important because exposure to this substance may harm you and 
because these sites may be sources of exposure. 
When a substance is released from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  This release does not always lead to 
exposure. You are exposed to a substance only when you come in contact with it.  You may be 
exposed by breathing, eating, or drinking the substance, or by skin contact. 
If you are exposed to beryllium, many factors determine whether you’ll be harmed.  These 
factors include the dose (how much), the duration (how long), and how you come in contact with 
it. You must also consider the other chemicals you’re exposed to and your age, sex, diet, family 
traits, lifestyle, and state of health. 
1.1 WHAT IS BERYLLIUM? 
Beryllium is an element that occurs naturally.  It is present in a variety of materials, such as 
rocks, coal and oil, soil, and volcanic dust. Two kinds of mineral rocks, bertrandite and beryl, 
are mined commercially for the recovery of beryllium.  Very pure gem-quality beryl is better 
known as either aquamarine (blue or blue-green) or emerald (green).  Beryllium is the lightest 
metal.  A key distinction among beryllium compounds is that some are soluble in water, but 
many are not. 
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Most of the beryllium ore that is mined is converted into alloys (mixtures of metals).  Most of 
these alloys are used in making electrical and electronic parts or as construction materials for 
machinery and molds for plastics.  Beryllium alloys are also used in automobiles, computers, 
sports equipment (such as golf clubs and bicycle frames), and dental bridges.  Pure beryllium 
metal is used in nuclear weapons and reactors, aircraft and space vehicle structures, instruments, 
x-ray machines, and mirrors.  Beryllium oxide is also made from beryllium ores and is used to 
make specialty ceramics for electrical and high-technology applications.  More information on 
the chemical and physical properties, production, and uses of beryllium is found in Chapters 4, 5, 
and 6. 
1.2 WHAT HAPPENS TO BERYLLIUM WHEN IT ENTERS THE ENVIRONMENT? 
Beryllium enters the air, water, and soil as a result of natural and human activities.  Emissions 
from burning coal and oil increase beryllium levels in the air.  In air, beryllium compounds are 
present mostly as fine dust particles.  The dust eventually settles over land and water. Rain and 
snow aid in removing beryllium from air.  Extremely small beryllium particles may remain in the 
air for about 10 days. Beryllium enters waterways from the wearing away of rocks and soil. 
Most beryllium products of human origin that enter waterways come from industry discharges of 
waste water and from beryllium dust in the air from industrial activities settling over water. 
Most of the beryllium in water settles in the material on the bottom with sediment.  Insoluble 
beryllium compounds remain in ocean water for a few hundred years before settling to the 
bottom of the ocean.  Beryllium, as a chemical component, occurs naturally in soil; however, 
disposal of coal ash, incinerator ash, and industrial wastes may increase the amount of beryllium 
in soil. A major portion of beryllium in soil does not dissolve in water and remains bound to 
soil, so it is not likely to move deeper into the ground and enter groundwater.  In the 
environment, chemical reactions can change the water-soluble beryllium compounds into 
insoluble forms.  In some cases, water-insoluble beryllium compounds can change to soluble 
forms.  Exposure to water-soluble beryllium compounds in the environment, in general, will 
pose a greater threat to human health than exposure to water-insoluble forms. 
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The amount of beryllium that has been measured in the air in different parts of the United States 
by EPA ranges from not detected to 2 millionths of a gram per cubic meter (g/m3). Very small 
dust particles of beryllium in the air fall out of the air onto surface water, plant surfaces, and soil 
either by themselves or when rain or snow falls.  These beryllium particles eventually end up 
back in the soil or in the bottoms of lakes, rivers, and ponds, where they stay and mix with 
beryllium that is already there. 
Beryllium in water comes from different sources.  Most of it comes from dissolving beryllium 
out of rocks and soil that water runs over and through. Only a very small part is from the settling 
of beryllium dust out of the air.  Some beryllium is suspended in muddy-like (cloudy) water. 
EPA has found that the levels of beryllium in drinking water in different parts of the United 
States are extremely low in most cases, and that water containing beryllium at these commonly 
observed levels is safe to drink. Fish do not accumulate beryllium from water into their bodies 
to any great extent. Some fruits and vegetables such as garden peas, kidney beans, and pears 
may have above average levels of beryllium (see Chapter 6).  Most of the beryllium that gets into 
livestock is eliminated quickly in urine and feces. 
Beryllium is found in soil in amounts that vary over a wide range, but the typical concentration is 
3 thousandths of a gram/kilogram (g/kg) of soil.  Additional beryllium can be added by industrial 
activities. Soluble beryllium compounds can combine with other substances in the environment 
to form other beryllium compounds.  Beryllium compounds may stay in the soil for thousands of 
years without moving downward into groundwater.  In addition to the beryllium found naturally 
in minerals, beryllium metal and compounds that are left after humans mine and process the 
minerals can be released back into the environment as landfill waste.  More information about 
the fate and movement of beryllium in the environment is found in Chapter 6. 
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1.3 HOW MIGHT I BE EXPOSED TO BERYLLIUM? 
You can be exposed to normal levels of beryllium by breathing air, eating food, or drinking 
water that contains beryllium.  In the United States, the average concentration of beryllium in air 
is 0.03 nanograms (ng) (1 ng=1 billionth of a gram) in a cubic meter (ng/m3) of air. In U.S. 
cities, the average air concentration is higher, and its value is 0.2 ng in a cubic meter (m3) of air. 
Cities have higher levels of beryllium in the air because beryllium is released from burning coal 
and fuel oil. The amount of beryllium that has been measured in drinking water in different parts 
of the United States by EPA is generally less than 2 trillionths of a gram for every liter of water. 
Beryllium was found in only 5% of 1,577 drinking water samples obtained throughout the 
United States. Of these positive samples, the average beryllium concentration was only 190 ng 
in a liter (L) of water. Beryllium, as a chemical component, is found naturally in some food. 
The concentration of beryllium in both raw carrots and field corn grown in the United States is 
less than 25 micrograms (µg) (1 µg=1 millionth of a gram) in a kilogram (kg) of the fresh 
vegetables. Thus, in comparison with other harmful elements, such as lead and chromium, to 
which we are (by necessity) exposed on a daily basis, beryllium exposure is not significant. 
In certain workplaces, you can be exposed to higher-than-normal levels of beryllium, mostly in 
the form of beryllium oxide and beryllium metal.  Occupational exposure to beryllium occurs at 
places where the chemical is mined, processed, or converted into metal, alloys, and other 
chemicals.  Workers engaged in machining metals containing beryllium, recycling beryllium 
from scrap alloys, or using beryllium products may also be exposed to higher levels of beryllium.
The number of workers exposed to beryllium or beryllium compounds has been estimated to be 
21,000. 
As a member of the general public, you may be exposed to higher-than-normal levels of 
beryllium if you live near an industry that processes or uses beryllium.  People who live near 
hazardous landfill sites that contain high concentrations of beryllium may also be exposed to 
higher-than-normal levels of beryllium.  Beryllium, as a chemical component, occurs naturally in 
tobacco and may be inhaled from cigarette smoke.  People who smoke may breathe higher-than­
normal levels of beryllium than people who do not smoke. 
 
5 BERYLLIUM 
1. PUBLIC HEALTH STATEMENT 
Beryllium metal and metal alloys may be found in consumer products such as electronic devices 
(e.g., televisions, calculators, and personal computers) and special nonsparking tools.  Direct 
contact with beryllium metal and metal alloys is not likely, since these materials are typically 
enclosed within a protected case that prevents exposure. No other consumer products or 
products used in crafts, hobbies, or cottage industries contain significant amounts of beryllium.
It is therefore unlikely that beryllium present in consumer products poses any hazard.  More 
information about beryllium exposure can be found in Chapter 6. 
1.4 HOW CAN BERYLLIUM ENTER AND LEAVE MY BODY? 
Beryllium can enter your body if you breathe air, eat food, or drink water containing it. 
Beryllium will not enter your body from skin contact with the metal unless the skin is scraped or 
cut and beryllium particles become imbedded in the wound.  Only a small amount of beryllium 
may enter your body if your skin comes into contact with a beryllium salt dissolved in water. 
When you breathe air containing beryllium, beryllium particles can be deposited in the lungs. 
The beryllium that you breathe in slowly dissolves in the lungs and moves slowly into the 
bloodstream.  Some of the beryllium deposited in the lungs can be moved to the mouth and then 
swallowed; the rest can remain in your lungs for a long time.  If you eat food or drink water that 
contains beryllium, less than 1% passes from your stomach and intestines into the bloodstream. 
Therefore, most of the beryllium that you swallow leaves your body through the feces without 
entering the bloodstream.  The small amount of beryllium that moves from the lungs, stomach, 
and intestines into the bloodstream is carried by the blood to the kidneys.  Beryllium leaves the 
kidneys by the urine. Some beryllium can also be carried by the blood to the liver and bones 
where it may remain for long periods.  If you swallow beryllium, beryllium leaves the body in a 
few days. However, if you inhale beryllium, it may take months to years before your body rids 
itself of beryllium.  This is because it takes a long time before all the beryllium in the lungs 
enters the bloodstream.  For more information, please read Chapter 3. 
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1.5 HOW CAN BERYLLIUM AFFECT MY HEALTH? 
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people 
who have been harmed, scientists use many tests. 
One way to see if a chemical will hurt people is to learn how the chemical is absorbed, used, and 
released by the body; for some chemicals, animal testing may be necessary.  Animal testing may 
also be used to identify health effects such as cancer or birth defects. Without laboratory 
animals, scientists would lose a basic method to get information needed to make wise decisions 
to protect public health. Scientists have the responsibility to treat research animals with care and 
compassion.  Laws today protect the welfare of research animals, and scientists must comply 
with strict animal care guidelines. 
Beryllium is a metal that can be harmful when you breathe it.  The effects depend on how much 
and how long you are exposed to it. When you breathe it in, beryllium can damage your lungs. 
When you breathe in large amounts of soluble beryllium compounds (greater than 1 mg 
beryllium per cubic meter of air, 1 mg/m3), the lung damage resembles pneumonia with 
reddening and swelling of the lungs. This condition is called acute beryllium disease.  The lung 
damage may heal if beryllium exposure is stopped.  Human studies have shown that occupational 
and community ambient air standards were effective in eliminating most acute lung disease. 
Some people can become sensitive to beryllium.  This is known as hypersensitivity or allergy. If 
you become sensitive (allergic) to beryllium, you may develop an immune or inflammatory 
reaction to small amounts of beryllium that do not cause effects in people who are not sensitive 
to beryllium.  When this occurs, white cells accumulate around the beryllium and form a chronic 
inflammatory reaction called granulomas (granulomas are not tumors).  This condition is called 
chronic beryllium disease (CBD).  This disease can occur long after exposure (10–15 years) to 
small amounts of either soluble or insoluble forms of beryllium (greater than 0.0005 mg/m3). If 
you have this disease, you may feel weak, tired, and have difficulty breathing.  Some individuals 
that have CBD may experience anorexia, weight loss, and blueness of hands and feet.  This 
disease could also lead to heart enlargement and heart disease in advanced cases. 
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Both the short-term, pneumonia-like disease and the chronic beryllium disease can be fatal. 
Exposure levels associated with acute or chronic beryllium disease are more 100,000 times 
higher than normal air levels of beryllium.  Long periods of exposure to beryllium have been 
reported to cause cancer in laboratory animals.  Some studies of workers reported an increased 
risk of lung cancer. The U.S. Department of Health and Human Services and the International 
Agency for Research on Cancer have determined that beryllium and beryllium compounds are 
human carcinogens.  EPA has determined that beryllium is a probable human carcinogen.  EPA 
has estimated that lifetime exposure to 0.00004 mg beryllium/m3 can result in a one in a 
thousand chance of developing cancer. We do not know if breathing air, eating food, or drinking 
water that contains beryllium or having skin contact with beryllium has any effects on 
reproduction or causes birth defects in humans or animals.  Swallowing beryllium has not been 
reported to cause effects in humans because very little beryllium can move from the stomach or 
intestines into the bloodstream.  Ulcers have been seen in dogs ingesting soluble beryllium salts 
in the diet. Beryllium contact with skin that has been scraped or cut may cause rashes or ulcers. 
If you have developed an allergy to beryllium and have skin contact with it, you can get 
granulomas on the skin.  These skin granulomas appear as a rash or as nodules.  The skin 
granulomas are formed in the same way that lung granulomas are formed in sensitive people. 
For more information on how beryllium can affect your health, please read Chapter 3. 
1.6 HOW CAN BERYLLIUM AFFECT CHILDREN? 
This section discusses potential health effects from exposures during the period from conception 
to maturity at 18 years of age in humans. 
It is likely that the health effects seen in children exposed to beryllium will be similar to the 
effects seen in adults; chronic beryllium disease was found in a child living near a beryllium 
factory. We do not know whether children differ from adults in their susceptibility to beryllium. 
We do not know if exposure to beryllium will result in birth defects or other developmental 
effects in people. The studies on developmental effects in animals are not conclusive.  We have 
no information to suggest that there are any differences between children and adults in terms of 
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how much beryllium will enter the body, where beryllium can be found in the body, and how fast 
beryllium will leave the body.  It is likely that beryllium can be transferred from the mother to an 
infant in breast milk or that it can cross the placenta. 
1.7	 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO BERYLLIUM? 
If your doctor finds that you have been exposed to significant amounts of beryllium, ask whether 
your children might also be exposed.  Your doctor might need to ask your state health 
department to investigate. 
Higher-than-normal levels of beryllium may be in soil at hazardous waste sites.  Some children 
eat a lot of dirt. You should prevent your children from eating dirt.  Make sure they wash their 
hands frequently, and before eating. If you live near a hazardous waste site, discourage your 
children from putting their hands in their mouths or from engaging in other hand-to-mouth 
activities. Some children may be exposed to beryllium by contact with a family member who 
works in a facility using beryllium.  If you work at a facility that uses beryllium, make sure you 
change your clothes and clean your hair and skin before leaving your job and returning home. 
Also, do not bring objects home such as works tools that may be contaminated with beryllium. 
1.8	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 
EXPOSED TO BERYLLIUM? 
Beryllium can be measured in the urine and blood, but the amount of beryllium in the urine or 
blood may not reflect the amount to which you were exposed.  The measurement of beryllium in 
urine and blood may not determine how recently you were exposed.  Small amounts of human 
lung and skin can be removed from the body and examined to determine whether beryllium is 
present in these tissues. These tests can be done in a doctor's office or in a hospital.  While high 
levels of beryllium in urine, blood, or tissues indicate that you were exposed to an excessive 
amount of beryllium, low levels of beryllium do not necessarily mean that you were not exposed 
to an excessive amount.  A blood test called the beryllium lymphocyte proliferation test (BeLPT) 
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can determine if you have become sensitive to beryllium and may have chronic beryllium 
disease. For more information, please read Chapters 3 and 7. 
1.9	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH ? 
The federal government develops regulations and recommendations to protect public health. 
Regulations can be enforced by law. Federal agencies that develop regulations for toxic 
substances include the Environmental Protection Agency (EPA), the Occupational Safety and 
Health Administration (OSHA), and the Food and Drug Administration (FDA). 
Recommendations provide valuable guidelines to protect public health but cannot be enforced by 
law. Federal organizations that develop recommendations for toxic substances include the 
Agency for Toxic Substances and Disease Registry (ATSDR) and the National Institute for 
Occupational Safety and Health (NIOSH). 
Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or 
food that are usually based on levels that affect animals; then they are adjusted to help protect 
people. Sometimes these not-to-exceed levels differ among federal organizations because of 
different exposure times (an 8-hour workday or a 24-hour day), the use of different animal 
studies, or other factors. 
Recommendations and regulations are also periodically updated as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for beryllium include the following: 
OSHA has set a limit of 2 µg beryllium/m3 of workroom air for an 8-hour work shift.  NIOSH 
recommends a standard for occupational exposure of 0.5 µg beryllium/m3 of workroom air 
during an 8-hour shift to protect workers from the increased cancer risk associated with 
beryllium exposure.  EPA restricts the amount of beryllium released into the air to 0.01 µg 
beryllium/m3 of air, averaged over a 30-day period. The Department of Energy (DOE) has 
developed a program to reduce beryllium exposure in workers at DOE facilities.  EPA has set a 
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maximum allowable amount of 0.004 mg/L beryllium in drinking water.  For more information, 
please read Chapter 8. 
1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department or 















ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses resulting from exposure to 
hazardous substances. 
* To order toxicological profiles, contact 
National Technical Information Service
 




Phone: 1-800-553-6847 or 1-703-605-6000
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2.1	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO BERYLLIUM IN THE 
UNITED STATES 
Beryllium is an extremely lightweight metal that occurs naturally in rocks, coal, soil, and volcanic dust. 
Commercially, bertrandite and beryl ore are mined for the recovery of beryllium.  Because beryllium is 
one of the lightest metal and is very rigid, it has many uses in the electronics, aerospace, and defense 
industries. Beryllium is released into the atmosphere by windblown dust, volcanic particles, and the 
combustion of coal and fuel oil.  Beryllium particulates in the atmosphere will settle out or be removed by 
precipitation. The annual average concentration of beryllium in ambient air in the United States is 
typically below the detection limit of 0.03 ng/m3. Beryllium concentration in urban air is usually higher 
due primarily to burning of coal and fuel oil; for example, the annual average concentrations in 
1982–1992 ranged from 0.02 to 0.2 ng/m3 in Detroit, Michigan. Beryllium can be released into 
waterways by the weathering of soil and rocks.  Beryllium entering surface water bodies and soil will be 
retained in the sediment and soil and will be generally immobile.  The average concentration of beryllium 
in drinking water samples that were found to contain it was 190 ng/L.  The mean concentration of 
beryllium in soil in the United States is 0.6 mg/kg. 
Human exposure to beryllium and its compounds occurs primarily in the workplace.  People who work in 
beryllium manufacturing, fabricating, and reclaiming industries have a greater probability of inhalation 
exposure than non-occupational groups. The general population can be exposed to trace amounts of 
beryllium through inhalation of air, consumption of food and water, and skin contact with air, water, or 
soil that contains beryllium.  Individuals living near sources of beryllium emissions are likely to be 
exposed to higher levels of beryllium than the general population.  Beryllium has been identified in at 
least 535 of the 1,613 hazardous waste sites that have been proposed for inclusion on the EPA NPL. 
2.2	 SUMMARY OF HEALTH EFFECTS 
The general population can be exposed to beryllium via inhalation, oral, and dermal routes of exposure. 
The inhalation route is of greatest concern for systemic effects because beryllium and its compounds are 
poorly absorbed after oral and dermal exposure.  The respiratory tract in humans and animals is the 
primary target of beryllium toxicity following inhalation exposure.  Occupational exposure to high 
concentrations of soluble beryllium compounds can result in acute beryllium disease, while exposure to 
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relatively low concentrations ($0.5 µg/m3) of soluble or insoluble beryllium compounds can result in 
chronic beryllium disease.  Acute beryllium disease is characterized by inflammation of the respiratory 
tract tissues and is usually resolved within several months of exposure termination.  In contrast, chronic 
beryllium disease is an immune response to beryllium and is only observed in individuals who are 
sensitized to beryllium (usually <15% of an exposed population).  Other systemic effects that have been 
observed in individuals with severe cases of chronic beryllium disease include damage to the right heart 
ventricle, hepatic necrosis, kidney stones, and weight loss; these effects are probably secondary to chronic 
beryllium disease rather than a direct effect on the tissues. 
As with inhalation exposure, dermal contact with beryllium can result in an allergic response, typically 
skin granulomas, in certain individuals.  Dermatitis, which may be due to direct irritation rather than an 
immune response, has also been observed in workers exposed to high concentrations of airborne 
beryllium. 
Unlike inhalation and dermal exposure routes, the primary effects observed after oral exposure is not an 
immune response to beryllium.  The most sensitive effects appear to be ulcerative gastrointestinal lesions 
in dogs and beryllium rickets in rats exposed to beryllium carbonate; no reliable human oral exposure 
data were identified. The beryllium rickets are not due to a direct effect on bone; they are secondary to 
phosphorus deficiency.  Beryllium in the gut binds to soluble phosphorus compounds to form insoluble 
beryllium phosphate, thus decreasing the amount of soluble phosphorus compounds available for 
absorption. 
The available data on the potential of beryllium to induce reproductive and/or developmental effects are 
inconclusive. The data come from several animal studies; no reliable human data were located.  No 
histological alterations have been observed in reproductive tissues of animals orally exposed to beryllium 
sulfate and no alterations in fertility were observed in dogs exposed to beryllium sulfate in the diet. 
Similarly, no reproductive effects were observed in rats exposed to beryllium oxide via intratracheal 
injection. Some developmental effects (fetal mortality, decreased fetal body weight, increased prevalence 
of internal abnormalities) were observed in the offspring of rats receiving a single intratracheal injection 
of beryllium oxide or beryllium chloride.  No developmental effects were observed in the offspring of 
dogs orally exposed to beryllium sulfate, although the study is limited because cannibalized and stillborn 
animals were not examined.  Human and animal data provide evidence that inhaled beryllium is a human 
lung carcinogen; oral data are inadequate for the assessment of carcinogenic potential. 
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Thus, the primary adverse health of effects of beryllium are respiratory effects and lung cancer following 
inhalation exposure, gastrointestinal effects following oral exposure, and skin effects following dermal 
exposure; these effects are discussed in greater detail below.  The reader is referred to Section 3.2, 
Discussion of Health Effects by Route of Exposure, for additional information on other health effects. 
Respiratory Effects. The toxicity of beryllium to the respiratory tract is usually manifested in one of 
two syndromes: acute beryllium disease and chronic beryllium disease.  Acute beryllium disease is 
usually observed at relatively high beryllium exposure levels, has a short period of induction, and is 
usually resolved within a couple of months of exposure termination.  It is believed to be an inflammatory 
response to beryllium and most regions of the respiratory tract are affected; some reported symptoms 
include nasopharyngitis, shortness of breath, labored breathing, and chemical pneumonitis. 
Chronic beryllium disease is a systemic granulomatous disorder that predominantly affects the lungs.  In 
general, the occurrence of this disease has been confined to workers exposed to beryllium metal and to 
less soluble beryllium compounds, such as beryllium oxide.  However, there have been cases among 
residents living near beryllium manufacturing facilities and in families of workers who wore 
contaminated clothing at home.  Chronic beryllium disease is caused by an immune reaction to the 
inhaled beryllium that is deposited in lung airspaces and retained for a prolonged period.  In certain 
individuals who become sensitized to beryllium, the beryllium in the lungs acts as a hapten, binds to 
protein/peptides in the lungs, and elicits a proliferation of T lymphocytes, a release of inflammatory 
mediators, and an accumulation of inflammatory cells in the lungs.  This results in the formation of 
noncaseating granuloma, the accumulation of mononuclear cell infiltrates, and the development of 
fibrosis. Susceptibility to chronic beryllium disease is believed to have a genetic component.  The human 
leukocyte antigen (HLA) class II marker, HLA-DPB1 Glu69, has been found in a large number of 
individuals with chronic beryllium disease. 
When chronic beryllium disease was first recognized, affected individuals had a number of signs and 
symptoms including weight loss, dyspnea, cough, chest pain, fatigue, and cor pulmonale (hypertrophy of 
the right heart ventricle). Impaired lung function was detected in most of the affected individuals.  The 
typical lung function abnormalities were decreased vital capacity and total lung capacity and/or reduction 
in diffusing capacity for carbon monoxide (DLCO). It is likely that these cases of chronic beryllium 
disease were diagnosed at a late stage. Technological advances in the development of methods to detect 
chronic beryllium disease, in particular the beryllium lymphocyte proliferation test (BeLPT) and fiber 
optic bronchoscopy and transbronchial biopsy methods, now allows for the early detection of the disease. 
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Chronic beryllium disease can be classified into three stages: beryllium sensitization, subclinical chronic 
beryllium disease, and clinical chronic beryllium disease.  Beryllium sensitization, usually diagnosed as 
consistently abnormal BeLPT results, can progress to chronic beryllium disease, but not all sensitized 
individuals develop chronic beryllium disease.  Individuals with subclinical chronic beryllium disease are 
sensitized to beryllium and have histological evidence of lung granulomas, but no clinical signs. 
Although no clinical signs are observed, there is evidence to suggest that there may be some impairment 
of lung function. Slight alterations in lung function during exercise were observed in approximately 60% 
of individuals with subclinical chronic beryllium disease, no other consistent alterations in lung function 
were found. Individuals with clinical chronic beryllium disease are beryllium sensitized, and have 
histological evidence of lung granulomas and respiratory symptoms, changes on chest radiographs, and/or 
altered lung function. 
A number of large-scale screening studies have examined beryllium workers and found beryllium 
sensitization rates of 1–15% in workers involved in the production of beryllia ceramics and nuclear 
weapons. More than half of the beryllium sensitized workers were diagnosed with chronic beryllium 
disease. Several studies attempted to establish associations between beryllium sensitization and/or 
chronic beryllium disease and mean, cumulative, and peak exposure levels and duration of employment. 
In general, no consistent associations were found.  Although the data are insufficient for establishment of 
concentration-response relationships, the available occupation exposure studies do provide exposure 
levels that may result in beryllium sensitization.  Beryllium sensitization and/or chronic beryllium disease 
have been detected at exposure levels of $0.5 µg/m3. Respiratory disease is not likely to occur from 
exposure to beryllium levels in the general environment because ambient air levels of beryllium 
(0.03–0.2 ng beryllium/m3) are very low.  
Gastrointestinal Effects. No human data were located regarding gastrointestinal effects following 
exposure to beryllium.  In dogs exposed to beryllium sulfate in the diet for 143–172 weeks, extensive 
ulcerative and inflammatory lesions were observed in the small intestine, stomach, and large intestine; the 
small intestine was the most severely affected.  No gastrointestinal tract lesions were observed in rats 
exposed to similar concentrations of beryllium sulfate in the diet for 2 years.  One possible explanation 
for the apparent species difference is the manner in which rats and dogs consumed the beryllium-
containing diet. The dogs only had access to the diet for 1 hour/day, in contrast to the rats with unlimited 
access to the diet. Thus, immediately after eating, the dogs had a higher concentration of beryllium in the 
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Dermal Effects. Two types of dermal effects have been observed in beryllium exposed workers: an 
inflammatory reaction and an immune reaction.  Edematous papulovesicular dermatitis was observed in 
workers exposed to airborne beryllium sulfate, beryllium fluoride, or beryllium oxyfluoride; this is likely 
an inflammatory response to beryllium.  Beryllium exposure may also cause a delayed, hypersensitive 
reaction in the skin. Biopsied skin granulomas from beryllium workers had the same mononuclear 
infiltrates as detected in the lungs. Sensitized guinea pigs also developed granulomatous lesions and 
other delayed hypersensitive reactions following dermal exposure to beryllium sulfate, beryllium fluoride, 
beryllium oxide, or beryllium chloride. 
Cancer. A number of epidemiology studies have been conducted to assess the carcinogenic potential 
of beryllium.  Increased incidences of lung cancer deaths were reported in retrospective cohort mortality 
studies of workers at beryllium extraction, processing, and fabrication facilities.  Increased lung cancer 
mortality was also seen in entrants to the Beryllium Case Registry.  No correlation between the incidence 
of lung cancer deaths and exposure has been established because historical exposure levels were not 
reported. A positive association between length of latency and lung cancer deaths was found, with the 
highest cancer risks among workers with a latency of $25 years.  Significant increases in the occurrence 
of lung cancer has also been observed in rats and monkeys exposed to beryllium. 
The National Toxicology Program lists beryllium and certain beryllium compounds (beryllium-aluminum 
alloy, beryllium chloride, beryllium fluoride, beryllium hydroxide, beryllium oxide, beryllium phosphate, 
beryllium sulfate, beryllium zinc silicate, and beryl ore) as human carcinogens.  Based on sufficient 
evidence for carcinogenicity in humans and animals, the International Agency for Research on Cancer has 
classified beryllium and beryllium compounds in Group 1, carcinogenic to humans.  In contrast, the EPA 
concluded that the human data only provided limited evidence and classified inhaled beryllium in Group 
B1, a probable human carcinogen. 
No human studies investigating the carcinogenicity of ingested beryllium were located.  Animal studies 
have not found significant associations between ingestion of beryllium in the diet and drinking water and 
increased incidence of neoplasms in rats, mice, or dogs.  It should be noted that no toxic effects were 
observed in rat and mouse chronic-duration studies tested at low doses, and the duration of the dog study 
was too short to be predictive of late-term cancer.  The EPA concluded that the human carcinogenic 
potential of ingested beryllium cannot be determined. 
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2.3 MINIMAL RISK LEVELS 
Inhalation MRLs 
The available human and animal data clearly identify the respiratory tract as the critical target of 
beryllium toxicity following inhalation exposure.  In humans, symptoms of acute beryllium disease (e.g., 
nasopharyngitis, pneumonia) have been reported in workers exposed to high concentrations of soluble 
beryllium compounds (Eisenbud et al. 1948a; VanOrdstrand et al. 1945).  Longer-term exposure to 
relatively low concentrations of beryllium can result in chronic beryllium disease (Cotes et al. 1983; 
Cullen et al. 1987; Eisenbud et al. 1949). More recent studies are able to detect subclinical chronic 
beryllium disease and beryllium sensitization (Deubner et al. 2001; Henneberger et al. 2001; Kelleher et 
al. 2001; Kreiss et al. 1993a, 1996, 1997; Newman et al. 2001; Stange et al. 1996b, 2001; Viet et al. 
2000). There is evidence to suggest that the occurrence of chronic beryllium disease is not related to 
duration of exposure, and can have a long latency period.  Very few studies assessing the occurrence of 
chronic beryllium disease also measured airborne beryllium levels.  Eisenbud et al. (1949) found no cases 
of chronic beryllium disease in residents living at least 0.75 miles away from a beryllium manufacturing 
facility.  The airborne beryllium concentration at this distance was estimated to range from 0.01 to 0.1 µg 
beryllium/m3. Studies by Cullen et al. (1987), Kreiss et al. (1996), and Stange et al. (1996b) reported 
chronic beryllium disease (and/or beryllium sensitization) in workers exposed to average beryllium 
concentrations of 0.52, 0.55, or 1.04 µg beryllium/m3, respectively. 
Respiratory tract effects have also been observed in animals exposed to airborne beryllium.  Emphysema, 
pneumonitis, and lung granulomas are the most commonly reported effects following acute-, 
intermediate-, and chronic-duration exposure (Haley et al. 1989; Hall et al. 1950; Robinson et al. 1968; 
Schepers et al. 1957; Sendelbach et al. 1986; Stokinger et al. 1950; Wagner et al. 1969).  In general, the 
animal studies have not identified a reliable no-observed-adverse-effect level (NOAEL) for respiratory 
effects, and the lowest-observed-adverse-effect levels (LOAELs) are several orders of magnitude higher 
than the LOAEL identified in the Kreiss et al. (1996) occupational exposure study. 
Although the critical target of beryllium toxicity has been identified, the available database does not 
support derivation of acute-, intermediate-, or chronic-duration inhalation MRLs.  As discussed in 
Section 3.4.3, an animal model that mimics all aspects of chronic beryllium disease has not been 
identified; thus, it is inappropriate to derive inhalation MRLs from the animal data.  No human acute- or 
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Eisenbud et al. (1949) study, found no cases of chronic beryllium disease among community residents 
chronically exposed to 0.01–0.1 µg beryllium/m3. This study was not selected as the basis of a chronic-
duration MRL because it utilized relatively insensitive methods to detect chronic beryllium disease; in 
particular, it is not known if residents exposed to 0.01 µg beryllium/m3 would test positive for beryllium 
sensitization or subclinical chronic beryllium disease.  The LOAELs identified in the Cullen et al. (1987), 
Kreiss et al. (1996), and Stange et al. (1996b) studies cannot be used to derive a chronic MRL because the 
observed effects were classified as serious health effects. 
Oral MRLs 
The only available data on the acute-duration toxicity of ingested beryllium are from lethality studies in 
rats and mice.  Thus, an acute-duration oral MRL cannot be derived.  The available data from 
intermediate-duration studies have identified rickets (Guyatt et al. 1933; Jacobson 1933; Kay and Skill 
1934) as a critical target of beryllium toxicity.  The rickets do not appear to be due to a direct effect of 
beryllium on the bone.  Rather, the rickets are due to a phosphorus deficiency, which results from the 
binding of beryllium to dietary phosphorus in the gut.  Additionally, these effects have only been 
observed following exposure to beryllium carbonate.  Thus, the available data are inadequate for 
derivation of an intermediate-duration oral MRL. 
An MRL of 0.002 mg beryllium/kg/day has been derived for chronic-duration oral exposure 
(>365 days) to beryllium. 
A chronic-duration oral MRL of 0.002 mg beryllium/kg/day was derived for beryllium.  The MRL is 
based on a chronic dog feeding study in which groups of five male and five female dogs were exposed to 
beryllium sulfate in the diet for 143–172 weeks (Morgareidge et al. 1976).  Ulcerative lesions of the small 
intestine were observed in 9 of 10 dogs exposed to the highest dose (500 ppm; 12 and 17 mg 
beryllium/kg/day for the males and females, respectively); similar lesions were also observed in 1 of 
10 dogs exposed to 50 ppm (1 mg beryllium/kg/day).  No gastrointestinal effects were observed at the 
lower dose levels. Other effects observed in the 500 ppm group included erythroid hyperplasia of the 
bone marrow, slight anemia, bile stasis and vasculitis in the liver, and acute inflammation of the lymph 
nodes; these effects were considered secondary to the gastrointestinal hemorrhages and a likely systemic 
bacterial invasion through the damaged intestinal mucosa.  The 500 ppm test dose was discontinued after 
33 weeks due to high mortality and morbidity.  The MRL was derived using a benchmark dose method, 
which involves fitting mathematical models to the dose-response data for the ulcerative lesions of the 
small intestine.  For this analysis, the incidence data for the male and female dogs were combined and the 
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calculated doses for the males and females were averaged.  A benchmark dose (defined as the 95% lower 
confidence limit of the dose corresponding to a 10% increase in the incidence of small intestine lesions 
compared to controls) of 0.56 mg beryllium/kg/day was estimated using a probit model.  The benchmark 
dose was divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for 
human variability) and a modifying factor of 3 (to account for the lack of a study that supports the 
gastrointestinal effects found in the Morgareidge et al. [1976] dog study and the uncertainty as to whether 
the benchmark dose level is the NOAEL). 
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3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of beryllium.  It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or 
lowest-observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the 
studies. LOAELS have been classified into "less serious" or "serious" effects.  "Serious" effects are those 
that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory 
distress or death). "Less serious" effects are those that are not expected to cause significant dysfunction 
or death, or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
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the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAEL) or exposure levels below which no 
adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike. 
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of beryllium are 
indicated in Table 3-1 and Figure 3-1. Because cancer effects could occur at lower exposure levels, 
Figure 3-1 also shows a range for the upper bound of estimated excess risks, ranging from a risk of 1 in 
10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed by EPA. 
Estimates of exposure levels posing minimal risk to humans (or MRLs) have been made for beryllium.
An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.  MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure.  MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for 
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate 
methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
21 BERYLLIUM 
3. HEALTH EFFECTS 
Beryllium is a lightweight metal that has many uses, including some in the aerospace industry.  Beryllium 
is present in the earth as beryllium ores, such as beryl and bertrandite.  Most beryllium compounds are 
poorly soluble in water.  The most common compound is beryllium oxide, the solubility of which 
decreases in water as the temperature at which it is calcined increases.  Beryllium carbonate and 
hydroxide are also practically insoluble in water.  Beryllium chloride, fluoride, nitrate, phosphate, and 
sulfate (tetrahydrate) are all soluble in water.  Beryllium carbonate, sulfate (tetrahydrate), and hydroxide 
are formed during the processing of beryllium containing ores into beryllium metal.  Beryllium nitrate is 
used as a hardening agent for mantles on gas lanterns.  Beryllium phosphate has no commercial uses.  As 
seen in the discussions below, the solubility of beryllium compounds significantly impacts in the 
manifestation of toxic effects. 
3.2.1 Inhalation Exposure 
Most of the information regarding adverse effects in humans after inhalation exposure to beryllium or its 
compounds is available from studies of occupational exposure.  In 1952, a Beryllium Case Registry 
(BCR) was established to provide a central source for cases of diagnosed beryllium poisoning (acute 
berylliosis or chronic beryllium disease).  The criteria for entry in the BCR included either documented 
past exposure to beryllium or the presence of beryllium in lung tissue as well as clinical evidence of 
beryllium disease.  Dose-response relationships are difficult to establish in the case of occupational 
exposure because reported workroom beryllium levels have generally ranged widely from <0.002 to 
1.0 mg beryllium/m3, depending on when the measurements were made.  The higher beryllium levels 
generally have occurred in the past; improvements in industrial hygiene over the last 30–40 years have 
effectively reduced workroom beryllium levels.  Numerous studies provide concentration-response 
relationships for several end points in experimental animals.  However, as discussed in Section 3.5.3, an 
animal model has not been identified for the most sensitive health effect, chronic beryllium disease. 
3.2.1.1 Death 
A number of retrospective cohort studies were conducted from data taken from the Beryllium Case 
Registry.  The mortality rate among employees who worked at a major beryllium extraction, processing, 
and fabricating facility between 1942 and 1968 was higher than the national average, with respect to 
cardiovascular and pulmonary diseases (Wagoner et al. 1980).  The incidence of death due to 
nonneoplastic respiratory disease was higher among employees who remained in the industry for <5 years 




3. HEALTH EFFECTS 
Another retrospective cohort study of workers exposed to beryllium during 1952–1975 indicates that the 
overall mortality rates were significantly higher compared to the U.S. general mortality rate (Infante et al. 
1980). The incidence of death due to nonneoplastic respiratory disease was significantly higher in 
workers exposed for $15 years and who developed acute respiratory disease.  However, in workers with 
chronic respiratory disease, the excess number of deaths was not related to the number of years since 
exposure. According to case histories of 3 men and 14 women employed in the beryllium industry for an 
average of 17 months, 6 of the women died from pulmonary or cardiovascular disease (Hardy and 
Tabershaw 1946). Most of the workers reported having shortness of breath, general weakness (fatigue), 
and weight loss. Autopsies revealed granulomatous disease, lung fibrosis, and heart enlargement.  These 
were the first reported cases of chronic beryllium disease. 
As discussed in Section 3.2.1.2 under Respiratory Effects, exposure to beryllium can result in two types 
of nonneoplastic respiratory disease, acute beryllium disease and chronic beryllium disease.  Both forms 
can be fatal. Ten fatalities occurred among 93 cases of acute beryllium pneumonitis that were 
documented in two beryllium refineries prior to 1950 (American College of Chest Physicians 1965). 
Autopsy of six of the cases revealed that the death occurred only in people with fulminating disease and 
resulted from massive pulmonary edema.  The survival of workers diagnosed with chronic beryllium 
disease appears to be related to their pulmonary pathology.  Patients with well-formed granulomas but 
with slight or absent interstitial cellular infiltration appeared to have a higher rate of survival than patients 
with few or absent granulomas, but with moderate to marked interstitial cellular infiltration (Freiman and 
Hardy 1970). 
There are several studies regarding death in animals after acute inhalation exposure to beryllium 
compounds.  Exposure to 31 mg beryllium/m3 as beryllium oxide caused death in 2 of 20 rats (Hall et al. 
1950). A 50-minute exposure to an aerosol of beryllium metal at 0.8 mg beryllium/m3 resulted in the 
death of 20 of 74 rats 12–15 days after exposure (Haley et al. 1990).  Upon necropsy, the rats had 
hemorrhagic lungs.  All rats exposed to 4.3 mg beryllium/m3 (Stokinger et al. 1950) or 2.59 mg 
beryllium/m3 (Sendelbach and Witschi 1987a) as beryllium sulfate died by day 14 or 18, respectively.
Three of 10 guinea pigs and 2 of 10 hamsters died when exposed to 4.3 mg beryllium/m3 as beryllium 
sulfate for 14 days (Stokinger et al. 1950).  All monkeys exposed to $13 mg beryllium/m3 as beryllium 
hydrogen phosphate died after 8–10 days of exposure (Schepers 1964).  Two of four monkeys exposed to 
0.184 mg beryllium/m3 as beryllium fluoride died after 7–17 days of exposure.  Only one of four 
monkeys died after 7 days of exposure to 0.198 mg beryllium/m3 as beryllium sulfate. 
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The differences observed in the lethality values for certain beryllium compounds are primarily due to 
their various solubilities. Beryllium oxide was less toxic than beryllium sulfate, due to its relative 
insolubility in the lung.  Based on limited comparisons among compounds and species, rats and monkeys 
appear to be more sensitive than hamsters and guinea pigs. 
Exposure to 0.43 mg beryllium/m3 as beryllium sulfate for #100 days caused death in 23 of 47 rats 
(Stokinger et al. 1950). Death was reported in 15 of 23 rats exposed to 30 mg beryllium/m3 as beryllium 
oxide for 15 days (Hall et al. 1950).  When rats, hamsters, and monkeys were exposed to 0.62 mg 
beryllium/m3 as beryl or 0.21 mg beryllium/m3 as bertrandite ore for 6 months, 13, 25, and 11% died, 
respectively (Wagner et al. 1969).  Signs of toxicity included respiratory distress, anemia, and body 
weight depression. One of five cats and 2 of 34 guinea pigs died when exposed to 0.43 mg beryllium/m3 
as beryllium sulfate for #100 days (Stokinger et al. 1950).  Increased mortality was observed in mice, 
dogs, hamsters, and goats exposed to 2.0 mg beryllium/m3 as beryllium sulfate for #51 days.  The one 
monkey similarly exposed also died. 
Chronic exposure to 0.034 mg beryllium/m3 as beryllium sulfate for 72 weeks did not increase mortality 
among male rats; however, the mortality rate among exposed females was $4 times that of controls 
(Reeves et al. 1967). This indicates that female rats may be more sensitive than male rats to chronic 
inhalation exposure to beryllium. 
The LC50 values and concentrations associated with increased mortality in each species and duration 
category are recorded in Table 3-1 and plotted in Figure 3-1. 
3.2.1.2 Systemic Effects 
No studies were located regarding gastrointestinal or musculoskeletal effects in humans or animals after 
inhalation exposure to beryllium or its compounds.  The respiratory, cardiovascular, hematological, 
hepatic, renal, and dermal, and ocular effects observed in humans or animals after inhalation exposure to 
beryllium and its compounds are discussed below.  The highest NOAEL values and all reliable LOAEL 




a N O E L  Less Serious Serious Reference
Key to  Species Frequency 
(mglm3) Chemical Form figure (Strain) (Specific Route) System (mglm3) (mglm3) 
ACUTE EXPOSURE 
Death 















4 Rat 50 rnin Haley et al. 1990 rn 
0.8 (20174 died) 2 
(Fischer- 344) Be metal iI 





6 Rat 14 d 2hrld Sendelbach and Witschi 1987 
2.59 (20/20 died) 

(Fischer- 344) BeS04 

7 Rat 14 d Sdlwk Ghrld Stokinger et al. 1950 




8 Gn Pig 14 d 5dlwk 6hrld Stokinger et al. 1950 
















Table 3-1 Levels of Significant Exposure to Beryllium -
LOAEL 
System (mglm3) (mglm3) 













Monkey 8-10 d Ghrld 
(Macacus) 
Resp 13 (emphysema) 
Schepers 1964 
BeHP04 
Cardio 13 (enlarged heart) 
Hepatic 13 (hepatocyte degeneration) 
Renal 13 97 (degenerationof the nephrons) 
11 Monkey 
(Macacus) 
























Hepatic 0.1 84 (hepatocellular degeneration) 
Renal 0.184 (degenerationof the nephrons) 
Endocr 0.184 (adrenal hypotrophy) 
Bd Wt 0.184 (19-23% weight loss) 
m
Table 3-1 Levels of Significant Exposure to Beryllium - Inhalation (continued) rn 
2Exposure1 LOAEL I--
C
Duration1 za Serious ReferenceNOAEL Less Serious 
Chemical Form
Key to Species Frequency 
figure (Strain) (Specific Route) System (mglm3) (mglm3) (mglm3) 
ACUTE EXPOSURE 










Renal 0.198 (glornerular degeneration) 

Bd Wt 0.198 (24% average weight loss) 
 u 

13 Rat 50 min Haley et al. 1990 
Resp 0.8 (acute pneumonitis progressing 
(Fischer- 344) to chronic inflammation and Be metal iInecrosis) 
Hall et al. 1950 
Resp 31













15 Rat 1 hr Hart et al. 1984 
Resp 0.447 (lung inflammation) 
(Fischer- 344) Be0 
N m 
Table 3-1 Levels of Significant Exposure to Beryllium - Inhalation (continued) 




a NOAEL Less Serious Serious Reference
Key to Species Frequency 

Chemical Form 
figure (Strain) (Specific Route) System (mglm3) (mglm3) (mdm3) 
ACUTE EXPOSURE 
16 Rat 1 hr Sendelbach and Witschi 1987 

Resp 7 (increased lactic 

(Fischer- 344) BeS04dehydrogenase and alkaline 
phosphatase in bronchoalveolar 
lavage fluid) 
17 Rat 1 hr Sendelbach et al. 1986 
Resp 13 (pneurnonitis)

(Fischer- 344) BeS04 

18 Rat 1hr Sendelbach et al. 1989 
Resp 4.05 (pneurnonitis) w 
(Fischer- 344) BeS04 I rn
F
-I 
19 Mouse Ihr Sendelbach and Witschi 1987 I 
Resp 7.2 (increased lactic rn
(BALBlc) BeS04 n ndehydrogenase and alkaline 
phosphatase in bronchoalveolar rn 
lavage fluid) 
20 Mouse 1hr Sendelbach et al. 1986 

Resp 13 (lung inflammation) 

(BALBlc) BeS04 
21 Mouse 14 d 5dlwk 6hrId Stokinger et al. 1950 









Bd Wt 31 
C 
m






N O E L  Less Serious SeriousKey to  Species Frequency 




I d  
Resp 10 (granulomas in lung) 





Resp 115 (granulomatous foci, 
inflammationof the lung) 
Robinson et al. 1968 
BeF2, Be0 BeCI2 












31 (decreased erythrocyte count) 



















Dog I d  
Monkey 30d6hrld 
10 (lymph node hyperplasia. 
lymphocyte stimulation) 
0.198 (1/4 died) 






51-100 d Sdlwk Ghr/d 2 (111 died) 
Stokinger et al. 1950 
BeS04 
Table 3-1 Levels of Significant Exposure to Beryllium - Inhalation (continued) 




a NOAEL Less Serious Serious Reference
Key to Species Frequency 
Chemical Form figure (Strain) (Specific Route) System (mglm3) (mglm3) (mg/m3) 
INTERMEDIATE EXPOSURE 








31 Rat 51-100 d 5dlwk Ghrld Stokinger et al. 1950 





32 Rat 6 mo 5dlwk Ghrld Wagner et al. 1969 rn 
0.21 (increased mortality) F 




33 Mouse 51 d 5dlwk 6hrId Stokinger et al. 1950 m 
n 
2 (4138 died) 
(NS) BeS04 s 0) 

34 Gn Pig 51-100 d Sdlwk 6hrld Stokinger et at. 1950 









36 Hamster 6 mo 5dIwk 6hrId Wagner et at. 1969 

















Key to Species Frequency N O E L  Less Serious 
figure (Strain) (Specific Route) System (mglm3) (mglm3) (mglm3) Chemical Form 
INTERMEDIATE EXPOSURE 
38 Dog 51-100 d 5dlwk 6hrId 	 Stokinger et at. 1950 




39 Cat 51-100 d 5d/wk 6hr/d 	 Stokinger et al. 1950 





40 Monkey 15 d 5dlwk 6hr/d Hall et al. 1950 
Resp 30 
(Rhesus) B e 0  
0 




41 Monkey 30d6hrld Schepers 1964 I 
Resp 0.198 (emphysema) m 
(Macacus) BeHP04 -n -n 
m 
Hepatic 0.198 2 
(n 
Renal 0.198 
Bd Wt 	 0.198 (15-39% weight loss) 
42 Monkey 51-100 d 5dlwk Ghrld 	 Stokinger et al. 1950 




Bd Wt 	 0.43 (31% weight loss) 
w 
0 
(continued)Table 3-1 Levels of Significant Exposure to Beryllium - Inhalation 








(Specific Route) System 












6 mo 5dIwk 6hrld 
Resp 0.21 (inflammationof lungs) 















0.62 (inflammationof lungs) 










Bd Wt 0.62 
45 Rat 
(Wistar) 





Hall et al. 1950 
(respiratory distress, increased 









180 d 5-6dlwk 4-8hrld 
10 wk 6hrld 
Resp 
Dermal 0.5 (inflammatory reaction on skin) 
0.035 (metaplasia, granulomas) 
Schepers et al. 1957 
BeS04 




Table 3-1 Levels of Significant Exposure to  Beryllium - Inhalation (continued) 	 rn 
~ ~~ ~ 
Exposure/ 
Duration/ 
aKey to Species Frequency 
figure (Strain) (Specific Route) 
INTERMEDIATE EXPOSURE 
48 	 Rat 51-100 d 5dlwk 6hrId 
(NS) 
49 	 Rat 6 mo 5dlwk 6hrld 
Charles River 
50 	 Rat 6 mo 5dlwk 6hrId 
Charles River 









































2 	 (increased serum albumin and 
globulin) 
2 	 (proteinurea) 
0.5 (inflammatory reaction on skin) 
Serious 
(mglm3) 
0.21 	 (granuloma in lung) 
Reference 
Chemical Form 
Stokinger et al. 1950 
BeS04 
Wagner et al. 1969 
Be0 
Wagner et al. 1969 
Be0 
































i i r ian) 
6 mo 5d/wk 6hr/d 
Resp 0.62 
















0.21 (granulomasof the lung) 











Bd Wt 0.21 
54 Dog 
(Mongrel) 
17.5 d 5dlwk 6hr/d 
Resp 31 (emphysema, atelectasis, 
inflammation) 








Key to Species Frequency
a 
figure (Strain) (Specific Route) 
INTERMEDIATE EXPOSURE 
Table 3-1 Levels of Sianificant ExDosure to Beryllium 
LOAEL 
N O E L  Less Serious 












15 d 5dlwk 6hrId 
Cardio 30 (decrease in arterial oxygen 
tension) 
Hall et al. 1950 
Be0 
Hemato 30 (leukocytosis) 
Bd Wt 30 (7-14% body weight loss) 
56 Dog 
(Mongrel) 









(decrease in arterial oxygen 
(macrocytic anemia) 
(decreased serum protein) 
tension) 
3.6 (emphysema) 











Bd Wt 3.6 (anorexia and 25% weight loss) 





 Referencea 	 NOAEL Less Serious Serious
Key to Species Frequency Chemical Formfigure (Strain) (Specific Route) System (mglm3) (mglm3) 	 (mglm3) 
INTERMEDIATE EXPOSURE 
Stokinger et al. 1950
57 Dog 51-100 d 5dlwk Ghrld 0.04 (emphysema)Resp BeS04
(NS) 
Cardio 0.04 	 (decreased arterial oxygen 
tension) 
Hemato 0.43 	 (leukocytosis) 
0.04 (macrocytic anemia) 
Hepatic 0.04 (increased serum albumin and 
globulin) I 
m 
Renal 0.04 0.43 (proteinurea) 5
I 




Hall et al. 1950 2
58 Rabbit 60 d 5dlwk Ghrld 	 CJ-JResp 30 Be0(New 
Zealand) 
Hemato 30 	 (macrocytic anemia) 
Bd Wt 30 
Stokinger et al. 1950 
59 Rabbit 51-100 d 5dlwk Ghrld 	 0.04 (actelectasis)Resp BeS04(NS) 

Hemato 0.04 0.43 	 (macrocytic anemia; 
leu kocytosis) 
Bd Wt 2 
w cn 















figure (Strain) (Specific Route) System (mglm3) (mglm3) (mglm3) Chemical Form 
INTERM EDlATE EXPOSURE 
60 Cat 
(Mongrel) 
15 d 5dIwk 6hrld 
Resp 30 
Hall et al. 1950 
Be0 




51-100 d 5dlwk 6hrId 
Resp 0.04 (emphysema) 
Stokinger et at. 1950 
BeS04 




Pig 51 5dIwk 6hrId 
(NS) 
lmmunol Lymphoret 
Rat 10 wk 6hrld 
(Wistar) 
Bd Wt 
0.5 (increased T-cell activity) 
2 (28% weight loss) 
Stokinger et al. 1950 
BeS04 







64 Gn Pig 
(NS) 
10 wk 6hrld 
0.5 (increased T-cell activity) 






Rat 180 d 5-6dlwk 4-8hrld 
0.035 (CEL: lung cancer) 







72 wk 5dlwk 7hrld 
0.034 
Reeves et al. 1967 
BeS04 
(increased mortality of females) 
Systemic 
67 Human 12.6 yr average 
Resp 0.001 2 (breathing difficulties, scarring 
of the lung) 





Key to Species Frequency 
figure (Strain) (Specific Route) 
CHRONIC EXPOSURE 
Table 3-1 Levels of Significant Exposure to Beryllium - Inhalation 
LOAEL 
N O E L  Less Serious Serious 











68 Human (OCCUP) Resp 0.00052 (chronic beryllium disease) 
Cullen et al. 1987 
mix 
69 Human occup 
Resp 0.00055 (beryllium sensitization and 
chronic beryllium disease) 














0.62 (inflammationof lungs) 












12-23 mo 5dlwk 6hrId Resp 0.21 (inflammationof lungs) 














(inflammation and proliferation 
in lung) 
(decrease in body weight) 
Reeves et al. 1967 
BeS04 
Exposure1 

























6-18 mo 5dIwk 6hrId 
Resp 0.0547 (inflammation and fibrosis of the 
lung) 




6-18 mo 5dlwk 6hrld 
Resp 0.006 (inflammation and fibrosis of the 
lung) 
Vorwald and Reeves 1959 
Be0 
75 Rat 12-17 mo 5dlwk 6hrId 
Charles River 
Resp 0.21 (granuloma in lung) 













rn n n 
Fl
2 
76 Rat 12-1 7 mo 5dIwk 6hrld 
Charles River 
Resp 0.62 (consolidation of lung) 





Bd Wt 0.62 (decreased body weight gain) 
m



























12-17 rno 5dlwk 6hrId 
Resp 0.21 (granulomas in the lung) 































0.00052 (increased T-cell activity) 











72 wk 5dlwk 7hrld 
0.034 (CEL: lung cancer) 




mTable 3-1 Levels of Significant Exposure to Beryllium - Inhalation (continued) 
3 
rn 





a NOAEL Less Serious Serious Reference IKey to  Species Frequency 
figure (Strain) (Specific Route) System (mglm3) (mg/m3) (mdm3) Chemical Form 
CHRONIC EXPOSURE 
82 Rat 6-18 mo 5dIwk 6hrId Vorwald and Reeves 1959 




83 Rat 6-18 mo 5dlwk Ghrld Vorwald and Reeves 1959 




84 Rat 12-17 mo 5dIwk 6hrId Wagner et al. 1969 
0.62 (CEL: lung cancer) 







a The number corresponds to entries in Figure 3-1. ?-I
I 
Bd Wt = body weight; Be = Beryllium; BeC12 = beryllium chloride; BeF2 = beryllium fluoride; BeHP04 = beryllium hydrogen phosphate; Be(N03)2 = beryllium nitrate; rn n
Be0 = beryllium oxide; BeP04 = beryllium phosphate; BeS04 = beryllium sulfate; Cardio = cardiovascular; CEL = cancer effect level; d = day@); Endocr = endocrine; n 
Gn pig = guinea pig; hemato = hematological: hr = hour(s); LC50 = lethal concentration, 50% kill; LOAEL = lowest-observed-adverse-effectlevel; min = minute(s); mix = beryllium 0 m 




Figure 3-1. Levels of Significant Exposure to Beryllium - Inhalation 
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Figure 3-1. Levels of Significant Exposure to Beryllium - Inhalation (Confinued) 
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Figure 3-1.Levels of Significant Exposure to Beryllium - Inhalation (Continued) 
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Figure 3-1. Levels of Significant Exposure to Beryllium - Inhalation (Continued) 
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values for each systemic effect in each species and duration category are recorded in Table 3-1 and 
plotted in Figure 3-1. 
Respiratory Effects. There is extensive evidence in humans that the respiratory tract is one of the 
primary targets of beryllium toxicity following inhalation exposure.  In general, noncancerous respiratory 
effects can be divided into two categories: acute beryllium disease and chronic beryllium disease, also 
referred to as berylliosis or chronic berylliosis.  Acute beryllium disease is a fulminating inflammatory 
reaction of the entire respiratory tract.  The respiratory tract symptoms range from mild nasopharyngitis to 
a severe chemical pneumonitis, which may be fatal.  Acute beryllium disease is usually associated with 
exposure to high concentrations of soluble beryllium compounds.  VanOrdstrand et al. (1945) describe a 
number of cases of acute beryllium disease among workers exposed to beryllium sulfate, beryllium oxide, 
beryllium fluoride, and beryllium oxyfluoride.  Signs and symptoms observed in the affected workers 
included irritation of the nasal and pharyngeal mucous membranes, sore nose and throat, weight loss, 
labored breathing, decreased vital capacity, anorexia, and increased fatigue.  In a 1948 investigation of 
acute beryllium pneumonitis in three U.S. plants producing beryllium compounds from the ore and in 
laboratories and shops engaged in research in ceramics and metallurgy of beryllium, all cases of beryllium 
pneumonitis were associated with concentrations >0.1 mg beryllium/m3, primarily as beryllium sulfate or 
beryllium fluoride (Eisenbud et al. 1948a).  The syndrome of acute beryllium disease has been virtually 
eliminated in workers first exposed to beryllium after 1950 (initiation of strict exposure limits), except in 
instances where there is accidental exposure to high levels of beryllium (Eisenbud and Lisson 1983). 
Chronic beryllium disease (CBD) is an inflammatory lung disease characterized by the formation of 
granulomas with varying degrees of interstitial fibrosis.  Chronic beryllium disease is a beryllium-specific 
immune response with primary manifestations in the lung.  The symptoms associated with chronic 
beryllium disease include chest pain, cough, and/or dyspnea with relatively mild exertion.  The clinical 
syndrome of chronic beryllium disease was first described by Hardy and Tabershaw (1946) in fluorescent 
lamp workers.  Seventeen chronically exposed workers developed anorexia, dyspnea, cough, easy fatigue, 
and weakness. An autopsy on one of the workers revealed increased lung weight, diffuse fibrosis, 
granuloma, abnormal epithelial lining of the bronchioles, and abnormal alveoli and vasculature.  Prior to 
the adoption of stringent industrial hygiene measures, the incidence of chronic beryllium disease among 
beryllium workers was high.  Historically, a number of criteria were used for the diagnosis of chronic 
beryllium disease: evidence of beryllium exposure, evidence of lower respiratory tract disease and clinical 
course consistent with chronic beryllium disease, reticulonodular infiltrates on chest x-ray, obstructive or 
restrictive deficits in lung function or a low diffusing capacity for carbon monoxide, and pathological 
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evidence of non-caseating granulomas and/or mononuclear cell interstitial infiltrates (Newman et al. 
1989). Technological developments in the 1980s (e.g., fiber optic bronchoscopy and transbronchial 
biopsy methods, development of the beryllium lymphocyte proliferation test) now allow for the detection 
of subclinical cases of chronic beryllium disease and beryllium sensitization in the absence of chronic 
beryllium disease.  Newman et al. (1989) proposed that chronic beryllium disease can be classified into 
three stages: (1) beryllium sensitization—consistent abnormal results for blood and/or lung BeLPT) 
results, (2) subclinical chronic beryllium disease—sensitized individuals with histopathological evidence 
but no clinical signs, and (3) clinical chronic beryllium disease—sensitized individuals with 
histopathological evidence with respiratory symptoms, changes on chest radiographs, or altered 
pulmonary physiology. 
Although instituting regulatory exposure limits and improved hygiene practices has decreased the number 
of cases of chronic beryllium disease among beryllium workers, new cases of chronic beryllium disease 
are still being identified in beryllium workers.  Cotes et al. (1983) examined 130 workers employed at a 
beryllium manufacturing facility for at least 6 months during the period of 1952–1963.  Based on clinical 
evaluation including chest x-rays and lung function tests, there were four definite cases of chronic 
beryllium disease and one probable case of chronic beryllium disease.  Another two workers had chest 
x-rays consistent with chronic beryllium disease, but did not have any other alterations.  Beryllium 
exposure levels were estimated using facility records for total airborne concentrations over the period of 
1952–1960. The mean exposure levels for different job processes were 0.029–0.72 µg beryllium/m3 in 
1952 and 0.022–0.21 µg beryllium/m3 in 1960. Two of the confirmed cases of chronic beryllium disease 
worked in an area of the facility where beryllium concentrations were 0.04 and 0.18 µg beryllium/m3 in 
1952 and 1960, respectively.  Because these exposure levels were based on general air samples, they may 
not be representative of breathing zone beryllium levels.  
Five cases of chronic beryllium disease were reported among workers exposed to beryllium oxide fumes 
at a precious metals refinery (Cullen et al. 1987).  The five workers had abnormal chest x-rays, 
noncaseating granulomas, pulmonary fibrosis, and abnormal results for the bronchoalveolar lavage 
beryllium lymphocyte proliferation test (BeLPT).  A health survey of 45 workers at the same facility was 
also conducted (Cullen et al. 1987). Eighteen workers reported lower respiratory tract symptoms (cough, 
dyspnea, wheezing).  Among these 18 workers, 7 also had abnormal x-rays, such as focal scarring.  Time 
weighted-average personal air samples, measured during a 2-week period in 1983, throughout the refinery 
ranged from 0.22 to 43 µg beryllium/m3, with a mean of 1.2 µg beryllium/m3. Four of the five workers 
with chronic beryllium disease worked in the furnace area, where the mean concentration was 0.52 µg 
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beryllium/m3. This concentration is considered a LOAEL for chronic beryllium disease.  However, it is 
possible that the air samples collected during a 2-week period may not be reflective of current or past 
exposure conditions. 
Reversible respiratory effects were observed in a group of beryllium extraction workers examined by 
Sprince et al. (1978). Health surveys (including measurement of lung function and x-rays) were 
conducted in 1971 and 1974. When lung function test results and arterial blood gas results were 
compared to the 1971 values, a slight statistically significant decrease in peak expiratory flow rate, 
increase in alveolar-arterial O2 tension and decrease in alveolar-arterial CO2 tension were observed in a 
group of 111 workers. When workers with radiological abnormalities suggestive of interstitial disease 
were re-examined in 1974, nine workers had normal radiographs and nine had radiographs suggestive of 
interstitial disease; it should be noted that some of these workers had previous exposure to asbestos, silica, 
or soft coal. Improvement in hypoxia and decreased alveolar-arterial O2 tension were observed among 
13 workers diagnosed with hypoxia in 1971; no change in lung function was observed in this group.  The 
improvement in respiratory effects corresponded to a dramatic decrease in peak air concentrations of 
beryllium. 
Several investigators have conducted screening studies to assess the occurrence of beryllium sensitization 
and subclinical chronic beryllium disease among beryllium workers.  Kreiss et al. (1993a) and Stange et 
al. (1996b, 2001) examined workers at the Rocky Flats Technology site involved in the production of 
nuclear weapons, Kreiss et al. (1997) and Newman et al. (2001) examined workers at other beryllium 
production facilities, and Deubner et al. (2001b) examined beryllium mine workers and workers at a 
beryllium extraction facility.  In the Kreiss et al. (1993a) study, 895 current workers were examined and 
beryllium sensitization, defined as consistently abnormal BeLPT results, was detected in 17 workers 
(1.9%). All of these workers had normal chest x-rays.  Sixteen of the subjects with beryllium 
sensitization underwent clinical evaluation (bronchoalveolar lavage BeLPT and transbronchial lung 
biopsy).  Chronic beryllium disease (defined as having granulomas on lung biopsy and abnormal blood or 
bronchoalveolar lavage [BAL] BeLPT results) was diagnosed in 13 of the subjects.  Forty-two subjects 
had abnormal chest x-rays, 40 of which underwent clinical evaluation.  An additional case of chronic 
beryllium disease was detected in this group (this subject had inconsistently abnormal BeLPT results). 
Thus, the incidence of chronic beryllium disease in this population was 15/895 (1.7%; one worker 
refusing clinical evaluation was included in the beryllium disease group because he had ventilatory 
abnormalities suggestive of restrictive disease).  The beryllium sensitized individuals did not significantly 
differ from the whole cohort in terms of gender, age, history of atopic disease, cigarette smoking status or 
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pack years, prevalence of respiratory symptoms, spirometric abnormalities, or profusion of small 
opacities on chest x-rays. 
Stange et al. (1996b) examined 4,397 current and former employees at the same facility; it is not known if 
any of the workers were also included in the Kreiss et al. (1993a) study.  Beryllium sensitization was 
found in 78 of the workers (1.8%); the beryllium sensitization rate was similar in the current and former 
employees (1.2 versus 1.9%).  Of the beryllium sensitized workers, 29 were diagnosed as having chronic 
beryllium disease (29/4397, 0.66%); chronic beryllium disease was defined as having histologic evidence 
of pulmonary granulomatous disease and a positive BAL BeLPT result.  Environmental beryllium levels 
were measured in the main beryllium production building using fixed airhead samplers (measured for the 
period of 1970–1988) and personal air monitoring devices (1984–1987); the mean concentrations were 
0.016 and 1.04 µg beryllium/m3, respectively; the 1.04 µg beryllium/m3 is considered a LOAEL because 
it more accurately reflected beryllium concentrations in the breathing zone.  However, this value does not 
take into consideration beryllium levels prior to 1984 and may not be representative of historical 
beryllium levels. 
A more recent study by this group examined 5,173 workers at the Rocky Flats facility (Stange et al. 
2001). Confirmed abnormal blood BeLPT results were found in 98 workers (3.33%).  Three years after 
the initial screening, 2,891 workers were re-examined; an additional 56 workers had abnormal blood 
BeLPT results. The total beryllium sensitization rate was 4.54% (154/5173).  The workers with abnormal 
BeLPT results or with a small opacity profusion of 1/0 or greater in their chest x-ray underwent medical 
evaluations for chronic beryllium disease.  The criteria for diagnosis of chronic beryllium disease were 
history of beryllium exposure, histopathologic evidence on biopsy of noncaseating granulomas or 
mononuclear cell infiltrates in the lung, and a positive blood or BAL BeLPT.  Seventy-four cases of 
chronic beryllium disease were diagnosed during the initial screening period and 7 additional cases were 
diagnosed at the 3-year screening.  Beryllium sensitization and chronic beryllium disease were found in 
male and female workers employed at the facility for <5 years.  Increased odds ratios for beryllium 
sensitization were found for workers in the health physics (odds ratio=2.867; 95% confidence interval 
[CI]=1.12–7.36), beryllium machinist (odds ratio=3.044; 95% CI=1.95–4.77), construction trades (odds 
ratio=2.426; 95% CI=1.48–3.97), and general machinist (odds ratio=1.345; 95% CI=1.00–1.82) job group 
categories. 
Viet et al. (2000) designed a case control study of workers at the Rocky Flats facility to evaluate the risks 
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beryllium sensitive and 50 workers with chronic beryllium disease were matched by age, smoking status, 
gender, and race to an equal number of controls.  Workers were diagnosed as beryllium sensitive if two 
blood BeLPT results were positive and the clinical evaluation did not reveal chronic beryllium disease; 
the criteria used to diagnosis chronic beryllium disease were exposure to beryllium, positive blood and 
lung BeLPT results and noncaseating granulomas on lung biopsy.  Historical beryllium exposure levels 
were estimated using fixed airhead samples in one building (beryllium machine shop); annual exposure 
levels were estimated by averaging air samples from 2 random days each month.  An individual’s 
exposure level was estimated using annual exposure levels; the individual’s work history by job location, 
task, and time period; and assignment of relative exposure estimates to each combination of job location, 
task, and time period as compared with the beryllium shop machinists.  For the chronic beryllium disease 
cases, the mean exposure level (0.070 versus 0.025 µg/m3), cumulative exposure level (1.35 versus 
0.38 µg-years/m3), and duration of employment (19.1 versus 14.4 years) were significantly higher than 
for the controls. For the beryllium sensitive cases, the mean exposure level (0.036 versus 0.026 µg/m3) 
was significantly higher than for controls, but there was no significant differences for cumulative 
exposure level (0.54 versus 0.40 µg-years/m3) or duration of employment (13.2 versus 14.5 years). 
Employment start date was not significantly different for the cases versus control comparisons. 
Comparisons between the chronic beryllium disease cases and beryllium sensitive cases revealed 
significant differences in mean exposure level (0.070 versus 0.036 µg/m3), cumulative exposure level 
(1.35 versus 0.54 µg-years/m3), duration of employment (19.1 versus 13.2 years), and employment start 
date (1964.9 versus 1970.2). Significant relationships between chronic beryllium disease and both 
cumulative and mean beryllium exposure were also found using logistic regression analysis; significant 
relationships were not found for beryllium sensitization.  This study cannot be used to establish a LOAEL 
for chronic beryllium disease or beryllium sensitization because method used to assess beryllium 
exposure (fixed airhead samples) may not be representative of beryllium levels in personal breathing 
zones. The study authors note that fixed airhead sampling may underestimate breathing zone levels by a 
factor of 0.5–9. 
Beryllium sensitization and subclinical chronic beryllium disease has also been found in workers exposed 
to beryllium oxide at beryllia ceramics plants.  Eight cases of beryllium sensitization were found among 
136 current employees at the plant (Kreiss et al. 1996).  Five of these workers had consistently abnormal 
BeLPT results and were diagnosed with chronic beryllium disease based on the observation of 
granulomas.  Two workers had inconsistently abnormal BeLPT results and no granulomas; however, 
2 years after the initial examination, one of these workers had symptoms of chronic beryllium disease (the 
other refused clinical follow-up). A seventh case of chronic beryllium disease was detected in a worker 
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who initially had normal BeLPT results but later developed a nonhealing granulomatous response to a 
beryllium-contaminated skin wound and an abnormal BeLPT result.  Seven of the eight beryllium 
sensitized workers were machinists; the beryllium sensitization rate among the machinists was 
14.3 versus 1.2% for all other workers. The beryllium exposure levels for the beryllium-sensitized 
workers ranged from 0.2 to 1.1 µg beryllium/m3; the median concentration was 0.55 µg/m3, this is a 
LOAEL for beryllium sensitization and chronic beryllium disease.  
Additional cases of beryllium sensitization and chronic beryllium disease were identified in a follow-up 
to this study (Henneberger et al. 2001).  This study examined 151 workers employed at a beryllium 
ceramics manufacturing facility; 77 of the workers were employed before 1992 (long-term workers, 76 of 
them participated in the first beryllium screening study [Kreiss et al. 1996]) and the remaining workers 
began employment at the facility after 1992 (short-term workers).  Breathing zone and general area 
sample measurements taken from 1981 (when full production of beryllium ceramics began) to 1998 were 
used to estimate mean, cumulative, and peak exposure levels.  The median and mean exposure levels were 
0.39 and 14.9 µg/m3, respectively, for long-term workers and 0.28 and 6.1 µg/m3, respectively, for short-
term workers.  Using blood BeLPT, 15 cases of beryllium sensitization were diagnosed; 8 cases among 
long-term workers and 7 among short-term workers.  Six of these workers were diagnosed as having 
chronic beryllium disease (defined as borderline or abnormal BAL BeLPT and/or characteristic 
granulomas on lung biopsy).  Seven of the eight workers with chronic beryllium disease were long-term 
workers. Among long-term workers, no relationships between the prevalence of beryllium sensitization 
and time since first exposure, mean exposure level, or cumulative exposure level were found.  However, a 
higher prevalence of beryllium sensitized workers was seen in the workers with the highest peak exposure 
levels. For the short-term workers, positive associations between prevalence of beryllium sensitization 
and mean, cumulative, and peak exposure levels were found. 
A study of 627 workers at a beryllium manufacturing facility found 43 cases of beryllium sensitization 
(6.9%) (Kreiss et al. 1997). Chronic beryllium disease was diagnosed in 24 of the beryllium sensitized 
workers (incidence of 4.6%). The highest incidence of chronic beryllium disease was found in ceramic 
workers exposed to beryllium oxide (9.0%).  The only available monitoring data for this facility is 
historic environmental beryllium measurements taken between 1984–1993.  However, these monitoring 
data can not be used to establish a LOAEL for chronic beryllium disease because ceramic product 
manufacturing (the workers with the highest disease incidence) was terminated before 1984. 
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Newman et al. (2001) conducted a medical surveillance in a beryllium metal machining facility following 
the detection of an index case of chronic beryllium disease in 1995.  All current employees were tested 
with the blood BeLPT between 1995 and 1997 and were retested 2 years after the initial screening.  The 
mean age of the current workers was 39 years and the mean duration of exposure was 11.7 years.  Of the 
235 workers initially tested, 15 had confirmed abnormal blood BeLPT results.  Eleven of these workers 
underwent clinical evaluation; 8 were found to have chronic beryllium disease with granulomas and/or 
mononuclear cell infiltrates on transbronchial lung biopsy.  One worker had an abnormal BAL 
(bronchioalveolar lavage) BeLPT and lymphocytes in the BAL fluid, but no evidence of granulomas or 
infiltrates; this worker was classified as having probable chronic beryllium disease.  The remaining three 
workers were classified as beryllium sensitized without evidence of chronic beryllium disease.  During 
the first 2-year interval testing phase (187 workers were retested), five additional workers had 
consistently abnormal BeLPT results; three of these workers were diagnosed as having chronic beryllium 
disease and one was classified as probably having chronic beryllium disease.  During the second interval 
testing phase, 109 workers were tested and two cases of abnormal BeLPT results were found.  Both of 
these individuals were diagnosed as having chronic beryllium disease.  Thus, the total number of 
beryllium-sensitized workers was 22.  Of the 19 undergoing clinical evaluation, 13 workers were 
diagnosed with chronic beryllium disease characterized as granulomas and/or mononuclear cell infiltrates 
on lung biopsy, and 2 workers were diagnosed with probable chronic beryllium disease.  No difference in 
duration of employment was found between the workers with chronic beryllium disease and the beryllium 
sensitized workers. The workers with chronic beryllium disease were older than the beryllium sensitized 
workers (41 years versus 33.5 years); three of the workers were employed for <3 months.  With the 
exception of the index case, most of the workers with chronic beryllium disease were at the very early 
stages and had minimal abnormalities on pulmonary function or on exercise capacity testing. 
Kelleher et al. (2001) expanded the results of the Newman et al. (2001) by examining the relationship 
between beryllium exposure and beryllium sensitization and chronic beryllium disease.  Beryllium 
exposure levels for 20 of the beryllium workers with beryllium sensitization (7 workers) or chronic 
beryllium disease (13 workers; includes 2 workers with probable chronic beryllium disease) were 
compared with beryllium exposure levels for 206 workers employed at the same facility who were 
negative for beryllium sensitization.  No significant differences in age, employment duration, or smoking 
status were found between the cases and controls. A significantly higher proportion of the cases worked 
as machinists (odds ratio=4.4; 95% CI=1.1–17.6).  The median total beryllium exposure level based on 
personal samplers was 0.13 µg/m3. The cases tended to have higher cumulative and median beryllium 
exposure levels and cumulative exposures to particle sizes of <6 or <1 µm, but the differences were not 
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statistically significant.  The respective mean and median cumulative exposures were 6.09 and 
2.93 µg/m3-years for the cases and 2.27 and 1.24 µg/m3-years for the controls.  None of the cases had 
lifetime-weighted average beryllium exposure levels of <0.02 µg/m3; 60% of the cases had lifetime-
weighted averages of >0.20 µg/m3. In the control group, 11% of the workers were exposed to 
<0.02 µg/m3 and 48% were exposed to >0.20 µg/m3. 
Deubner et al. (2001b) examined 75 workers at a beryllium ore mining and milling facility in Utah.  The 
workers involved in the mining operation were primarily exposed to beryl ore or bertrandite ore and the 
milling operation workers were exposed to these ores and beryllium hydroxide.  Three of the workers had 
abnormal blood BeLPT results and one had an unconfirmed positive test.  The four workers were long-
term employees involved in the facility’s milling operations.  Two of the workers with confirmed BeLPT 
results underwent biopsy and BAL BeLPT; one of these workers was diagnosed with chronic beryllium 
disease (granulomatous lung disease on biopsy).  The worker with chronic beryllium disease also worked 
at another beryllium facility for 10 years where he was involved in beryllium metal and beryllium oxide 
production. General area, breathing zone, and personal lapel samples were used to estimate historical 
beryllium exposure.  The mean general area, breathing zone, and personal lapel samples ranges were 
0.3–1.1, 1.1–8.1, and 0.05–6.9 µg/m3, respectively.  Because no cases of beryllium sensitization or 
chronic beryllium disease were found in workers who only worked in the mines, the study author 
suggested that the form of beryllium may influence the risk for developing beryllium sensitization or 
chronic beryllium disease. 
Although chronic beryllium disease is usually associated with occupational exposure to beryllium at 
manufacturing facilities, it has also been reported in dental technicians (Brancaleone et al. 1998; Kotloff 
et al. 1993), in individuals living near beryllium manufacturing facilities, and in families of beryllium 
workers who wore contaminated clothing at home (Chesner 1950; Dattoli et al. 1964; Eisenbud et al. 
1949; Lieben and Metzner, 1959; Lieben and Williams 1969).  Eisenbud et al. (1949) examined 
10,000 residents living within 1 mile of a beryllium manufacturing facility.  Eleven cases of chronic 
beryllium disease (based on radiological evidence) were initially detected; one case was eliminated due to 
exposure to beryllium dust on work clothes.  Three more cases were detected in a follow-up study 
(Sterner and Eisenbud 1951). The study authors estimated that the beryllium concentrations 0.75 miles 
from the facility were 0.01–0.1 µg beryllium/m3. Because the affected residents lived within 0.75 miles 
of the facility, the 0.01–0.1 µg/m3 concentration range is a NOAEL for clinical chronic beryllium disease. 
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Clinical chronic beryllium disease is associated with impaired lung function.  Lung function testing in 
individuals with chronic beryllium disease has shown reduced vital capacity and total lung capacity, 
increased alveolar-arterial oxygen tension difference, arterial hypoxemia, and decreased carbon monoxide 
diffusion capacity (Andrews et al. 1969; Johnson 1983; Rossman et al. 1988).  A study by Pappas and 
Newman (1993) investigated whether early beryllium disease was also associated with impaired lung 
function. In this study, lung function test results from 21 “surveillance-identified” subjects (individuals 
with abnormal BeLPT results who did not seek medical attention prior to the diagnosis of beryllium 
sensitization) were compared with the results in 15 “clinically-identified” subjects (individuals who 
sought medical attention because of respiratory problems or abnormal x-rays).  The lung function tests 
consisted of spirometry, lung volumes, diffusing capacity for carbon monoxide, arterial blood gases, and 
maximal exercise capacity.  No alterations in spirometry, lung capacity, blood gases, or diffusing capacity 
were found in the surveillance-identified subjects. However, subtle alterations in exercise capacity were 
found in 52% of the surveillance-identified subjects, the most common effect was a rise in dead space to 
tidal volume ratio during exercise.  In contrast, 93% of the clinically-identified subjects had alteration in 
lung function. The alterations included mild to moderate airway obstruction, evidence of restriction, 
abnormal resting blood gas analysis, and impaired exercise capacity (able to perform less work than 
surveillance-identified subjects). 
In animals, the respiratory system is also the primary target for inhalation exposure to beryllium.  Rats 
exposed to 1–100 mg beryllium/m3 as beryllium oxide (calcined at 1,000 EC) for 30–180 minutes had 
initial alveolar deposition of 1–63 µg beryllium in the lungs (Sanders et al. 1975).  The exact exposure 
concentrations were not clearly specified.  Rats developed only slight to moderate granulomatous lesions 
in the lungs, depending on the amount of alveolar deposition.  Dust laden or degenerative macrophages 
and a moderate infiltration of lymphocytes were noted in the lungs of rats exposed to beryllium oxide. 
Hamsters, similarly exposed until an initial lung burden of 16–17 µg beryllium was achieved, developed 
only a few small areas of granuloma formation and degenerating macrophages.  Pulmonary lavage fluid 
from rats exposed to 0.447 mg beryllium/m3 as beryllium oxide (calcined at 560 EC) for 1 hour was 
examined at various intervals for #21 days after exposure for cell populations, acid and alkaline 
phosphatase enzyme activity of lysozyme and lactic dehydrogenase, and biochemical analysis of protein, 
lipid, phosphorus, phosphatidyl choline, and sialic acid (Hart et al. 1984).  Microscopic examination of 
the cell populations revealed inflammation characterized by increased interstitial mononuclear cells and a 
thickening of the alveolar septa. Increases in the lipids and proteins and levels of acid and alkaline 
phosphatase, lysozyme, and lactic dehydrogenase indicated cellular damage to the type II cells or the 
alveolar epithelium.  Similar analyses of rats exposed to $3.3 mg beryllium/m3 and mice exposed to 
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7.2 mg beryllium/m3 as beryllium sulfate for 1 hour and examined for #12 months indicated the 
occurrence of pneumonitis with thickening of the alveolar walls and inflammation of the lung 
(Sendelbach et al. 1986, 1989; Sendelbach and Witschi 1987b).  Increased levels of acid and alkaline 
phosphatase, and lactic dehydrogenase in the lavage fluid of the lungs of treated rats and mice indicated 
damage to the cellular populations; the increase in protein indicated alveolar damage.  These studies 
demonstrate the ability of soluble beryllium compounds to damage the lung long after exposure ceases. 
Dogs exposed to 10 mg beryllium/m3 as beryllium oxide calcined at 500 or 1,000 EC developed 
granulomas in the lung (Haley et al. 1989).  Histopathology also revealed intense alveolar septal fibrosis 
and epithelial hyperplasia.  Beryllium oxide calcined at 500 EC was associated with higher incidences of 
lesions, due to its greater solubility.  Dogs exposed to 115 mg beryllium/m3 as a mixture of beryllium 
oxide, beryllium fluoride, and beryllium chloride for 20 minutes, had inflamed lungs and granulomatous 
foci (Robinson et al. 1968). Increased lung weight, inflammation, emphysema, and fibrosis of the lung 
were observed in monkeys exposed to 0.198 mg beryllium/m3 as beryllium sulfate for 7–17 days 
(Schepers 1964). Monkeys exposed to $13 mg beryllium/m3 as beryllium hydrogen phosphate for 
8–10 days, and 0.184 mg beryllium/m3 as beryllium fluoride for 7–18 days had severely inflamed and 
fibrotic lungs with granulomas.  Histology revealed pleuritis, congestion, emphysema, consolidation, and 
edema of the lung.  The severity of these effects was more notable with beryllium fluoride than with 
beryllium sulfate or beryllium hydrogen phosphate, partly due to the fluoride component which may form 
hydrofluoric acid in the lung as beryllium fluoride dissociates.  Rats, rabbits, and guinea pigs exposed to 
31 mg beryllium/m3 as beryllium oxide for 10 days did not have any histological evidence of lung 
damage (Hall et al. 1950). 
Animals exposed to beryllium compounds for intermediate durations had health effects similar to those 
caused by acute exposure.  Rats and hamsters exposed to 0.21 mg beryllium/m3 as bertrandite ore for 
6 months developed granulomatous lesions composed of several large, tightly packed, dust laden 
macrophages and a few lymphocytes (Wagner et al. 1969).  However, when the rats were exposed to 
0.620 mg beryllium/m3 as beryl ore, the lungs were largely unaffected except for a few small areas of 
atypical alveolar wall cell  proliferation. Monkeys exposed to 0.210 or 0.620 mg beryllium/m3 as 
bertrandite or beryl ore, respectively, had relatively minor changes in the lung.  The changes observed 
were aggregates of dust-laden macrophages, lymphocytes, and plasma cells near respiratory bronchioles 
and small blood vessels.  Vascular congestion, emphysema, and pneumonitis were observed during 
histological examination of the lungs of dogs exposed to 3.6 mg beryllium/m3 as beryllium oxide for 
40 days or to 31 mg beryllium/m3 as beryllium oxide for 17.5 days (Hall et al. 1950).  Epithelialization of 
the alveoli, focal metaplasia, and granulomas were observed in rats exposed to beryllium sulfate for 
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6 months (Schepers et al. 1957); however, a nonexposure-related outbreak of pneumonia limits the 
interpretation of these results. Exposure of rabbits, dogs, cats, and monkeys to 0.04 mg beryllium/m3 as 
beryllium sulfate for 100 days caused distortion of the lung structure (Stokinger et al. 1950).  The lung 
appeared to be severely inflamed and emphysematous, resulting in an increase in dead air space.  No 
respiratory effects were observed in rabbits, cats, and monkeys exposed to 30 mg beryllium/m3 as 
beryllium oxide for 15 days; however, rats experienced respiratory distress (Hall et al. 1950). 
Chronic exposure to beryllium and its compounds causes similar health effects as those observed after 
shorter exposure durations. Hamsters and monkeys exposed chronically to 0.210 and 0.620 mg 
beryllium/m3 as bertrandite or beryl ore, respectively, had relatively normal lung morphology, except that 
monkeys had inflamed lungs and hamsters exposed to the bertrandite ore had a few granulomatous lesions 
(Wagner et al. 1969). Rats exposed to 0.210 mg beryllium/m3 as bertrandite ore had bronchial 
lymphocytic infiltrates, abscesses, consolidated lobes, and granulomatous lesions.  Inflamed lungs and 
areas of fibrosis and granuloma were observed in rats exposed to 0.620 mg beryllium/m3 as beryl ore. 
Proliferative responses of the alveolar epithelium were also observed.  Although the beryllium exposure 
levels were fairly low in this study, the animals were exposed to 15 mg/m3 of bertrandite ore or beryl ore, 
which was the TLV for inert dust. Additionally, the beryllium ores contained high levels of silica 
(approximately 64%).  It is possible that the high dust and silica exposure levels may have contributed to 
the observed effects; it should be noted that silicosis was not observed.  Rats exposed to levels as low as 
0.006 mg beryllium/m3 as beryllium oxide had inflamed lungs and some fibrosis (Vorwald and Reeves 
1959). Chronic exposure of rats to other beryllium compounds caused health effects similar to those 
caused by beryllium oxide.  Rats exposed to 0.034 mg beryllium/m3 as beryllium sulfate for 72 weeks had 
inflamed lungs, emphysema, arteriolar wall thickening, granulomas, fibrosis, and proliferative responses 
within the alveoli (Reeves et al. 1967). Rats exposed to 0.0547 mg beryllium/m3 as beryllium sulfate for 
6–18 months had inflamed lungs and fibrosis (Vorwald and Reeves 1959). 
Cardiovascular Effects. Data regarding the cardiovascular effects of beryllium and its compounds 
in humans are limited.  Severe cases of chronic beryllium disease can result in cor pulmonale, which is 
hypertrophy of the right heart ventricle.  In a case history study of 17 individuals exposed to beryllium in 
a plant that manufactured fluorescent lamps, autopsies revealed right atrial and ventricular hypertrophy 
(Hardy and Tabershaw 1946).  An increase in deaths due to heart disease or ischemic heart disease was 
found in workers at a beryllium manufacturing facility (Ward et al. 1992).  It is not likely that the cardiac 
effects are due to direct toxicity to the heart, but rather are a response to impaired lung function. 
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Heart enlargement was observed in monkeys after acute inhalation exposure to $13 mg beryllium/m3 as 
beryllium hydrogen phosphate, 0.184 mg beryllium/m3 as beryllium fluoride, or 0.198 mg beryllium/m3 
as beryllium sulfate (Schepers 1964).  Decreased arterial oxygen tension was observed in dogs exposed to 
30 mg beryllium/m3 beryllium oxide for 15 days, 3.6 mg beryllium/m3 as beryllium oxide for 40 days 
(Hall et al. 1950), or 0.04 mg beryllium/m3 as beryllium sulfate for 100 days (Stokinger et al. 1950).  The 
effects of beryllium compounds on the cardiovascular system probably represent compensatory increases 
in cardiac musculature due to pulmonary fibrosis caused by inhalation exposure.  The decrease of arterial 
oxygen tension reflects the reduced ability of the lung to oxygenate blood. 
Hematological Effects. Information regarding the hematological effects of beryllium and its 
compounds in humans is limited to case histories.  No difference in white blood cell counts, hematocrit, 
or differential white blood cell percentages was observed in a machinist with chronic beryllium disease 
who worked with beryllium metal (Johnson 1983).  A study involving 170 case histories of beryllium 
workers in the Cleveland area reported few differences in erythrocyte sedimentation rates, blood counts, 
or blood chemistry (VanOrdstrand et al. 1945). 
Acute exposure of animals to beryllium and its compounds had little effect on hematological parameters; 
however, intermediate-duration exposures caused anemia in several species.  Hematological evaluation of 
rats and hamsters exposed to 1–100 mg beryllium/m3 for 30–180 minutes to achieve initial alveolar 
deposition of 1–63 µg beryllium revealed no statistical difference between treated animals and controls 
(Sanders et al. 1975). The exact exposure concentration and duration were not clearly reported. 
Exposure to 31 mg beryllium/m3 as beryllium oxide did not cause effects on the hematopoietic system in 
rats (Hall et al. 1950). No significant differences in leukocyte counts were observed in rabbits similarly 
exposed to beryllium oxide for 10 days.  However, erythrocyte counts decreased slightly during the 
course of exposure. 
Rabbits exposed to 307 mg beryllium/m3 as beryllium oxide for 60 days developed macrocytic anemia 
(Hall et al. 1950). The erythrocyte counts decreased over time, and there was a tendency to develop 
hypochromia, indicated by transient decreases in the average mean corpuscular hemoglobin 
concentration. Dogs exposed to 30 mg beryllium/m3 as beryllium oxide for 15 days exhibited a moderate, 
progressive leukocytosis, while dogs exposed to 3.6 mg beryllium/m3 for 40 days developed macrocytic 
anemia manifested as an increased mean corpuscular volume and decreased erythrocyte count.  The bone 
marrow was almost exhausted.  Differential counting of the bone marrow smears indicated a decrease in 
erythroblasts and an increase in normoblasts.  Exposure to the more soluble compounds of beryllium 
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caused effects similar to those of beryllium oxide.  Macrocytic anemia developed in rats and rabbits 
exposed to 0.43 mg beryllium/m3 and dogs exposed to 0.04 mg beryllium/m3 as beryllium sulfate for 
100 days (Stokinger et al. 1950).  Exposure to 2.0 and 0.43 mg beryllium/m3 as beryllium sulfate in rats, 
rabbits, and dogs caused transient leukocytosis; exposure to 2.0 mg beryllium/m3 caused mild 
thrombocytosis.  With increasing exposure durations, dogs exposed to 0.04 mg beryllium/m3 as beryllium 
sulfate had decreased phospholipid and cholesterol content of the red blood cells.  The changes in the 
biochemical constituents of the red blood cells may reflect a toxic effect on erythropoietic processes in the 
bone marrow. 
Hematological effects were not observed in rats, hamsters, or monkeys exposed to 0.21 or 0.62 mg 
beryllium/m3 as bertrandite or beryl ore, respectively, for 6–23 months (Wagner et al. 1969). 
Hepatic Effects. Information regarding hepatic effects in humans after inhalation exposure to 
beryllium and its compounds is limited.  Following an accidental leakage of beryllium dust, 25 laboratory 
workers were exposed to an undetermined concentration of beryllium chloride over a period of 
10–20 hours (Zorn et al. 1986). During a 10-month follow-up, no increase was observed in liver 
enzymes, serum glutamic oxaloacetic transaminase, or serum glutamic pyruvic transaminase.  In another 
study involving case histories of 17 individuals exposed to beryllium in a plant that manufactured 
fluorescent lamps, autopsy revealed hepatic necrosis in one individual (Hardy and Tabershaw 1946). 
Few hepatic effects have been observed in animals after inhalation exposure to beryllium and its 
compounds, except at lethal exposure levels.  Acute exposure to $13 mg beryllium/m3 as beryllium 
hydrogen phosphate causes hepatocellular degeneration in monkeys (Schepers 1964).  Hepatocellular 
degeneration was also observed in monkeys exposed to 0.184 mg beryllium/m3 as beryllium fluoride for 
7–18 days.  These exposure levels were lethal to monkeys.  Histological examination revealed no hepatic 
changes in rats, rabbits, guinea pigs or hamsters following acute inhalation exposure to either beryllium 
oxide or beryllium sulfate (Hall et al. 1950; Sanders et al. 1975). 
Intermediate-duration exposure of rats, monkeys, and hamsters to 0.210 and 0.620 mg beryllium/m3 as 
bertrandite or beryl ore did not result in histological evidence of hepatic damage (Wagner et al. 1969). 
Decreases in serum protein concentration and the albumin/globulin ratio in the blood indicated that some 
liver damage occurred in dogs exposed to 3.6 mg beryllium/m3 as beryllium oxide (Hall et al. 1950).  Rats 
and dogs exposed to 2.0 and 0.04 mg beryllium/m3 as beryllium sulfate, respectively, had increased serum 
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albumin and globulin levels (Stokinger et al. 1950).  Histological examination of rats exposed to 
0.035 mg beryllium/m3 as beryllium sulfate for 30 days revealed no hepatic damage (Schepers et al. 
1957). 
No adverse hepatic effects were revealed by histological examination or liver enzyme analysis of rats, 
hamsters, and monkeys chronically exposed to beryllium oxide as bertrandite or beryl ore (Wagner et al. 
1969). 
Renal Effects. Kidney stones were observed in .10% of the cases of chronic beryllium disease 
collected by the Beryllium Case Registry up to 1959 (Hall et al. 1959).  In addition, an excess of calcium 
in the blood and urine has been seen quite frequently in patients with chronic beryllium disease.  These 
effects are only suggestive and cannot be absolutely attributed to beryllium disease (Stoeckle et al. 1969). 
In a cohort mortality study of workers employed at beryllium manufacturing facilities, an increased risk 
of death from chronic and unspecified nephritis, renal failure, and other renal sclerosis was observed 
(Ward et al. 1992). 
Renal effects in animals after inhalation exposure to beryllium and its compounds are minor, except at 
lethal concentrations. No adverse renal effects were detected by urinalysis, kidney weight measurement, 
or histological examination in rats, rabbits, hamsters, and guinea pigs exposed to beryllium oxide for 
acute durations (Hall et al. 1950; Sanders et al. 1975).  Guinea pigs, mice, hamsters, and rats exposed to 
4.3 mg beryllium/m3 as beryllium sulfate had protein in the urine; however, there was no protein in the 
urine of similarly exposed rabbits (Stokinger et al. 1950).  No other measures of renal integrity were 
conducted in this study.  Histological examination revealed glomerular degeneration in the kidneys of 
monkeys exposed to 0.198 mg beryllium/m3 as beryllium sulfate, 0.184 mg beryllium/m3 as beryllium 
fluoride, or $13 mg beryllium/m3 as beryllium hydrogen phosphate (Schepers 1964).  These 
concentrations were lethal to the monkeys.  No histological evidence of renal damage was observed in 
rats exposed to 0.035 mg beryllium/m3 as beryllium sulfate. 
Intermediate-duration exposure (6 months) of rats, hamsters, and monkeys to 0.210 or 0.620 mg 
beryllium/m3 as bertrandite or beryl ore, respectively, did not result in evidence of renal effects during 
histological examination or enzyme analysis (Wagner et al. 1969).  No renal effects were observed in 
dogs exposed to 31 mg beryllium/m3 as beryllium oxide for #40 days.  Urinary protein increased in dogs 
exposed to 0.43 mg beryllium/m3 and rats exposed to 2.0 mg beryllium/m3 as beryllium sulfate for 
51–100 days (Stokinger et al. 1950). 
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No renal effects were identified by histological examination or enzyme analysis in rats, hamsters, and 
monkeys exposed for 12–17 months to 0.21 or 0.62 mg beryllium/m3 as bertrandite or beryl ore (Wagner 
et al. 1969). 
Endocrine Effects. Evidence of the effects of beryllium and its compounds on the endocrine system 
has been observed in humans and animals.  One out of 17 workers exposed to beryllium in a fluorescent 
lamp manufacturing plant died from chronic beryllium disease (Hardy and Tabershaw 1946). 
Histological examination of the adrenal glands revealed marked hyperemia and vacuolization. 
Effects on the adrenal gland have also been observed in animals exposed to beryllium compounds. 
Histological examination of monkeys exposed to 13 mg beryllium/m3 as beryllium hydrogen phosphate or 
0.184 mg beryllium/m3 as beryllium fluoride revealed marked hypoplasia and hypotrophy of the adrenal 
gland (Schepers 1964). However, the adrenal glands of monkeys exposed to 0.196 mg beryllium/m3 as 
beryllium sulfate were normal.  Rats and hamsters exposed to 1–100 mg beryllium/m3 as beryllium oxide 
for 30–180 minutes had increased adrenal weight (Sanders et al. 1975).  The exact exposure 
concentrations were not specified. 
Dermal Effects. Skin biopsies revealed granulomas containing beryllium in twins occupationally 
exposed to beryllium (McConnochie et al. 1988).  Positive patch tests with soluble beryllium compounds 
were obtained in all 32 patients tested with known chronic beryllium disease, indicating that the patch test 
is useful in the diagnosis of chronic beryllium disease (Curtis 1959).  However, the patch test using 
soluble beryllium compounds itself may be sensitizing and may exacerbate the condition in patients with 
chronic beryllium disease (Cotes et al. 1983; Epstein 1983; Stoeckle et al. 1969; Tepper 1972), 
contraindicating the use of patch testing in humans. 
Rats and guinea pigs exposed to 0.5 mg beryllium/m3 as beryllium nitrate for 10 weeks had a typical 
delayed allergic reaction 24–48 hours after beryllium salts were applied to the skin (Stiefel et al. 1980). 
Ocular Effects. There is limited information on the ocular toxicity of beryllium.  According to a case 
history, twins occupationally exposed to beryllium had reduced tear secretions (McConnochie et al. 
1988). 
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Body Weight Effects. Effects on body weight have been observed in humans after inhalation 
exposure to beryllium or its compounds.  Weight loss was common among workers with acute beryllium 
disease (VanOrdstrand et al. 1945). Weight loss was also reported in workers at a fluorescent lamp 
manufacturing plant with chronic beryllium disease (Hardy and Tabershaw 1946). 
Weight loss, severe at times, has been observed in monkeys, rats, mice, dogs, and cats after acute-, 
intermediate-, and chronic-duration inhalation exposure to a variety of beryllium compounds.  Due to 
impaired food consumption and “metabolic changes” (no additional information was provided), monkeys 
exposed for acute durations to $13 mg beryllium/m3 as beryllium hydrogen phosphate for 8–10 days, 
0.184 mg beryllium/m3 as beryllium fluoride for 7–18 days, or 0.198 mg beryllium/m3 as beryllium 
sulfate for 7 days lost 8–34, 19–23, or 24%, respectively, of their original body weight (Schepers 1964). 
Mice exposed to 4.3 mg beryllium/m3 as beryllium sulfate for 14 days had a 13% decrease in body weight 
(Stokinger et al. 1950). Dogs exposed to 115 mg beryllium/m3 as beryllium fluoride, beryllium oxide, 
and beryllium chloride for 20 minutes had transient weight loss the first 7 days after exposure (Robinson 
et al. 1968). No effect on body weight was observed in rabbits exposed to 31 mg beryllium/m3 as 
beryllium oxide for 10 days (Hall et al. 1950). 
Most of the available information on the effect of beryllium on body weight following intermediate-
duration exposure comes from three studies that tested a variety of animal species.  In monkeys, weight 
loss was seen following exposure to 0.198 mg beryllium/m3 as beryllium phosphate for 30 days (Schepers 
1964), 30 mg beryllium/m3 as beryllium oxide for 15 days (Hall et al. 1950), or 0.43 mg beryllium/m3 as 
beryllium sulfate for 51–100 days (Stokinger et al. 1950); but not in monkeys exposed to 0.620 mg 
beryllium/m3 as beryllium oxide for 6 months (Wagner et al. 1969).  The magnitude of weight loss ranged 
from 15 to 39%.  A 3–9% weight loss was observed in rats exposed to 30 mg beryllium/m3 as beryllium 
oxide for 15 days (Hall et al. 1950); however, a series of studies by Wagner et al. (1969) did not find any 
alterations in body weight gain in rats exposed to 0.210 or 0.620 mg beryllium/m3 as beryllium oxide. 
This study also did not find body weight alterations in hamsters exposed to the same concentrations of 
beryllium oxide.  Weight loss was also observed in dogs exposed to 3.6 or 30 mg beryllium/m3 as 
beryllium oxide for 40 or 15 days, respectively (Hall et al. 1950) or 0.4 mg beryllium/m3 as beryllium 
sulfate for 51–100 days (Stokinger et al. 1950).  Severe weight loss was also observed in cats exposed to 
0.04 mg beryllium/m3 as beryllium sulfate for 51–100 days (Stokinger et al. 1950) or 30 mg beryllium/m3 
as beryllium oxide for 15 days (Hall et al. 1950).  No effect was observed in rabbits exposed to 0.04 mg 
beryllium/m3 as beryllium oxide for 30 days or 2.0 mg beryllium/m3 as beryllium sulfate for 51–100 days 
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Exposure to 0.034 mg beryllium/m3 as beryllium sulfate for 72 weeks caused more severe body weight 
loss among female rats than among males (Reeves et al. 1967).  Rats exposed to 0.62 mg beryllium/m3 as 
beryl ore for 17  months also had significantly reduced body weights, compared to controls (Wagner et al. 
1969). 
3.2.1.3 Immunological and Lymphoreticular Effects 
While acute beryllium disease is a chemical pneumonitis, chronic beryllium disease appears to be an 
immunological disease.  The evidence that chronic beryllium disease is an immunological disease is 
supported by the following.  Beryllium can induce classic cell-mediated immune responses in humans and 
animals (Barna et al. 1981, 1984; Curtis 1951, 1959; Epstein et al. 1982; Haley et al. 1989; Marx and 
Burrell 1973; Saltini et al. 1989, 1990; Stiefel et al. 1980).  Beryllium sensitized cells accumulate at sites 
of chronic beryllium disease, resulting in granulomas in the lungs (Rossman et al. 1988; Saltini et al. 
1989, 1990). Beryllium has been identified within the granulomas of patients with chronic beryllium 
disease (Williams and Kelland 1986).  Virtually all patients with chronic beryllium disease have a cell-
mediated immune response to beryllium (Rossman et al. 1988; Saltini et al. 1989), and therapy that 
controls the immune response (i.e., corticosteroids) can ameliorate the disease (Aronchick et al. 1987). 
Nonspecific immunologic findings in chronic beryllium disease include an increase in serum gamma-
globulin levels (Resnick et al. 1970). The existence of specific antibodies to beryllium have been 
reported (Clarke 1991), and further research to confirm and identify the antibodies is continuing.  
While the results of peripheral blood lymphocyte proliferative responses to beryllium have been variable 
in patients with chronic beryllium disease (Kreiss et al. 1989; Newman et al. 1989; Saltini et al. 1989; 
Stokes and Rossman 1991; Williams and Williams 1983), the results of lung lymphocyte proliferative 
responses to beryllium have been consistently positive (Rossman et al. 1988; Saltini et al. 1989). 
Lung lavage studies in patients with chronic beryllium disease have revealed that there is an accumulation 
of CD4+T cells in the lungs (Rossman et al. 1988) and that these cells are memory T cells (Saltini et al. 
1989). Antibodies to Class II antigens but not Class I antigens will block the beryllium-specific 
proliferative response. In addition, antibodies to the IL-2 receptor will also block the beryllium 
proliferative response. 
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Immunological effects have also been observed in animals after inhalation exposure to beryllium.  Dogs 
exposed to 10 mg beryllium/m3 as beryllium oxide had a greater immune response to beryllium oxide 
calcined at 500 EC than at 1,000 EC, due to the greater solubility of the 500 EC calcined beryllium oxide 
(Haley et al. 1989).  The dogs exposed to beryllium oxide calcined at 500 EC had higher cell counts in the 
bronchoalveolar lavage fluid as a result of an increased lymphocyte population.  There was also a greater 
response of pulmonary lymphocytes in vitro to beryllium salts.  The tracheobronchial lymph nodes had 
moderate cortical and paracortical lymphoid hyperplasia resulting from B and T cell activation.  The 
lymph nodes examined 365 days after treatment were characterized by lymphoid depletion, marked 
congestion, and medullary fibrosis.  Histological examination of monkeys exposed for 8–10 days to 
$13 mg beryllium/m3 or for 30 days to 0.198 mg beryllium/m3 as beryllium hydrogen phosphate revealed 
hypoplasia of the lymph nodes (Schepers 1964).  The hypoplasia may be a result of the nutritional status 
of the animal since most of the monkeys lost body weight and were anorexic.  Histological examination 
of monkeys exposed for 7–18 days to either 0.198 or 0.184 mg beryllium/m3 as beryllium sulfate or 
beryllium fluoride, respectively, revealed marked hyperplasia of the lymph nodes, typical of immune 
activation. On the other hand, exposure of rats to 0.035 mg beryllium/m3 as beryllium sulfate for <7 or 
30 days did not cause histopathological changes in the suprarenal, pulmonary, or hepatic lymph nodes 
(Schepers et al. 1957); the high incidence on non-exposure-related pneumonia limits the interpretation of 
this study.  
Similar immunological effects have been observed in animals exposed to beryllium for intermediate 
durations. Rats and guinea pigs exposed to 0.5 mg beryllium/m3 as beryllium nitrate for 10 weeks had 
inflammations typical of delayed hypersensitivity, as assessed by skin tests and lymphocyte proliferation 
tests (Stiefel et al. 1980). Lymphocytes exposed in vitro to beryllium salts had increased proliferation 
rates greater than those of the controls. Gross and histological examination of the thymus and spleen of 
rats, hamsters, and monkeys exposed to 0.21 or 0.62 mg beryllium/m3 as bertrandite or beryl ore, 
respectively, for 6–23 months revealed no pathological alterations (Wagner et al. 1969). 
The highest NOAEL values and all reliable LOAEL values for immunological effects in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
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3.2.1.4 Neurological Effects 
No studies were located regarding neurological effects in humans or animals after inhalation exposure to 
beryllium or its compounds. 
3.2.1.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans or animals after inhalation exposure to 
beryllium or its compounds.  Male and female rats were intratracheally injected with 0.6 mg beryllium/kg 
as radioactive beryllium oxide and allowed to mate over a 15-month period (Clary et al. 1975).  There 
were no consistent effects on reproductive performance as determined by the average number of 
pregnancies per female, live pups per litter, dead pups per litter, live pups per female, lactation index, or 
average weight of live pups per female. 
3.2.1.6 Developmental Effects 
No studies were located regarding developmental effects in humans or animals after inhalation exposure to 
beryllium or its compounds.  A study conducted by Selivanova and Savinova (1986) examined the 
developmental toxicity of 50 mg beryllium/kg as beryllium chloride and beryllium oxide administered via 
intratracheal injection on gestational days 3, 5, 8, or 20.  An increase in fetal mortality was observed in rats 
dosed on gestational day 3 with beryllium oxide and in rats dosed on gestational day 5 with either beryllium 
compound.  Exposure to beryllium oxide or beryllium chloride on gestational day 3 resulted in decreased 
fetal body weights and an increased percentage of pups with internal abnormalities.  The latter effect was 
also observed in the pups of rats exposed to beryllium chloride or beryllium oxide on gestational day 5 and 
beryllium oxide on gestational day 8.  There were no differences in the number of live births per dam or in 
fetal length. 
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3.2.1.7 Cancer 
A number of retrospective cohort mortality studies examining workers at beryllium processing facilities in 
Pennsylvania and Ohio have been conducted by Mancuso and Associate (Mancuso 1970, 1979, 1980; 
Mancuso and El-Attar 1969) and the National Institute of Occupational Safety and Health (NIOSH) (Bayliss 
et al. 1971; Sanderson et al. 2001a; Wagoner et al. 1980; Ward et al. 1992); many of these studies examined 
one or two facilities and others looked at seven facilities. One of the earliest cancer mortality studies of these 
workers was conducted by Mancuso and El-Attar (1969).  This study examined a cohort of 3,685 Caucasian 
male workers employed at two beryllium facilities in Ohio and Pennsylvania from 1937 to 1948; the cohort 
was followed through 1966. Social Security Administration data, Beryllium Registry data, and death 
certificates were used to identify employees, deaths, and causes of death.  A group of workers in the rubber 
industry were used as a control group (no additional information on this cohort was provided).  The study 
authors note that a “slightly higher” rate of deaths from malignant neoplasms of the lung, trachea, and 
bronchus were observed in the beryllium workers; no statistical analyses of the data were conducted. 
Interpretation of these data is limited by the inclusion of nonexposed workers (no data were available on 
which departments the workers were employed in), lack of information on exposure characterization, 
incomplete reporting of deaths or cause of death, large employee turnover rate (78% of the workers were 
employed for <2 years), and lack of statistical analysis.  An additional limitation of the study is the selection 
of rubber workers as the comparison group, as increased incidence of lung cancer has been found in other 
studies of rubber workers (Mancuso 1979). 
In the second phase of the cohort mortality study (Mancuso 1970), duration of employment and age as of 
1940 were considered and the observation period was extended to 1967.  The small number of deaths in each 
duration category, as well as the limitations discussed above in the Mancuso and El-Attar (1969) study, 
precludes drawing conclusions from this study.  A third study by this group (Mancuso 1979) restricted 
the cohort to workers employed during the period of 1942–1948, extended the observation period to 
1974 for the Ohio cohort and 1975 for the Pennsylvania cohort, and compared mortality in the beryllium 
workers to mortality for the U.S. white male population (using vital statistics data for the period ending in 
1967). An increase in the number of lung cancer deaths was observed in workers with a latency period of 
15 years or higher (22 observed versus 9.86 expected in the Ohio cohort and 36 observed versus 
22.02 expected in the Pennsylvania cohort); the study author notes that the differences are statistically 
significant. EPA (1987) and MacMahon (1994) have criticized this study.  In particular, EPA (1987) 
notes that using U.S. white male lung cancer death rates for the period ending in 1967 to estimate 
expected cases for 1968–1975 resulted in a 10–11% underestimation of expected lung cancer deaths 
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because nationwide lung cancer rates were increasing. EPA (1987) and MacMahon (1994) comment that 
Mancuso (1979) did not account for the potential confounding effect of cigarette smoking on lung cancer 
mortality. 
To determine whether the increased lung cancer deaths that have been observed in the previous papers by 
Mancuso and Associate (Mancuso 1970, 1979; Mancuso and El-Attar 1969) were due to beryllium 
exposure, or the excess risk could be attributed to personal characteristics of workers having unstable 
employment patterns, Mancuso (1980) conducted a fourth study of the Ohio and Pennsylvania cohorts 
followed through 1976. Employees in the viscose rayon industry served as a comparison group.  A 
significant increase in lung cancer deaths was observed in the beryllium workers when compared to the 
entire cohort of rayon workers (standardized mortality ratio [SMR]=140) or a subcohort of workers who 
did not transfer between departments during their employment in the viscose rayon industry (SMR=158). 
When the cohorts were divided into employment durations, significant increases in lung cancer deaths 
were observed in the workers employed for <12 months (SMRs=138 and 164 for total rayon cohort and 
those not transferring departments, respectively) and workers employed for >49 months (SMRs=222 and 
172, respectively), but not in workers employed for 13–48 months.  As with the other Mancuso studies, 
the design of this study has been criticized.  One limitation of this study is the lack of adjustment for the 
potential confounding effect of smoking.  EPA (1987) questioned whether there was an adjustment for 
potential age differences between the beryllium cohort and noted that NIOSH re-analyzed the data from 
this study and found “serious problems with Mancuso’s analysis”.  
NIOSH studies have examined workers at the same facilities as Mancuso, as well as several other 
beryllium processing facilities.  The study by Bayliss et al. (1971) examined workers at a number of 
beryllium processing facilities in Ohio and Pennsylvania.  The original cohort consisted of over 
10,000 male and female workers who had employment of at least a few days or longer in the beryllium 
industry.  Removal of approximately 2,000 workers with inadequate records and all female workers 
(approximately 1,100 workers) resulted in a study cohort of approximately 7,000 workers.  The number 
of deaths among the beryllium workers was lower than expected (SMR=92.2), which was attributed to a 
healthy worker effect.  An increased number of deaths due to lung cancer was observed in the beryllium 
workers (SMR=105.7), but the increase was not statistically significant.  Limitations of this study include 
lack of analysis for potential effect of latency, elimination of over 2,000 workers due to incomplete 
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A subsequent study sponsored by NIOSH and the Occupational Safety and Health Administration 
(OSHA) (Wagoner et al. 1980) examined beryllium workers at one facility in Reading, Pennsylvania. 
The study cohort of 3,055 white males employed between 1942 and 1967 were followed through 1975, 
and mortality rates were compared to the U.S. white male population (using NIOSH vital statistics data 
for the period ending in 1967). A significant increase in lung cancer deaths (47 observed versus 
34.29 expected) was observed in the beryllium workers.  When deaths from lung cancer were segregated 
by latency period, significant increases in lung cancer deaths were found in workers with a latency period 
of at least 25 years (20 observed versus 10.79 expected); significant increases in lung cancer deaths were 
also observed in workers employed for <5 years and a latency period of at least 25 years (17 observed 
versus 9.07 expected). To assess the influence of lowering beryllium exposure concentrations, lung 
cancer deaths were segregated by date of initial employment.  A significant increase in lung cancer deaths 
was observed in workers initially hired before 1950 (when strict beryllium controls were instituted) and a 
25-year or higher latency period (20 observed versus 10.76 expected).  An increase in lung cancer deaths 
was also observed in workers initially employed after 1950, across latency periods, but the difference was 
not statistically significant (7 observed versus 4.60 expected).  The study authors note that using national 
mortality rates probably resulted in a 19% underestimation of cancer risk because Berks County, 
Pennsylvania (where 87% of the workers resided) has a lower age-adjusted lung cancer rate than the U.S. 
general population (31.8 per 100,000 versus 38.0 per 100,000).  However, EPA (1987) notes that most of 
the beryllium workers residing in Berks County lived in the city of Reading, Pennsylvania with a lung 
cancer mortality rate 12% higher than the national rate.  Thus, using the national rates may have resulted 
in an underestimation of expected deaths.  Wagoner et al. (1980) attempted to account for the contribution 
of cigarette smoking to lung cancer deaths by comparing smoking histories of the beryllium cohort 
(obtained during a 1968 medical survey) with U.S. white male smoking history (obtained by the 
1964–1965 Health Interview Survey conducted by the Public Health Service).  Using these data, the study 
authors estimated that the smoking habits of the beryllium workers would result in a 14% higher risk of 
lung cancer than the comparison population.  The study authors note that the frequency of cigarette 
smoking and the distribution of lung cancer cell type distribution support the conclusion that it is unlikely 
that “cigarette smoking per se could account for the increased risk of lung cancer among beryllium-
exposed workers in this study.”  EPA (1987), MacMahon (1994), and Bayliss (1980) have discussed a 
number of severe limitations of this study: (1) using male mortality data for the period of 
1941–1967 resulted in a 10–11% underestimation of expected lung cancer deaths, (2) the influence of 
cigarette smoking was probably underestimated by the study authors, EPA estimated that differences in 
cigarette smoking patterns would result in a 4.6–18.8% underestimation of expected deaths, and (3) the 
inclusion of one individual who died of lung cancer but did not work at the beryllium facility because he 
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failed the pre-employment physical.  After adjusting for use of outdated mortality data and cigarette 
smoking, EPA (1987) estimated that the rightful omission of this worker would result in a nonstatistically 
significant association between beryllium exposure and lung cancer mortality (46 observed versus 
41.90 expected deaths for all workers and 20 observed and 14.67 expected deaths for workers with a 
$2 year latency period). 
In a more recent study, Ward et al. (1992) examined mortality data for a cohort of 9,225 male workers 
employed at seven beryllium processing facilities in Ohio and Pennsylvania for at least 2 days in the 
period of 1940–1969; the workers were followed through 1988.  Mortality rates in the beryllium cohort 
were compared to the U.S. white male population.  Mortality from all causes was slightly elevated among 
the beryllium workers (SMR=1.05; 95% CI=1.01–1.08).  The elevated mortality rate was largely due to 
increases in respiratory tract cancer, nonmalignant respiratory disease, and deaths from ischemic heart 
disease. The SMRs for trachea, bronchii, and lung cancer, nonmalignant respiratory disease, and 
ischemic heart disease were 1.26 (95% CI=1.12–1.42), 1.21 (95% CI=1.06–1.38), and 1.08 (95% 
CI=1.01–1.14), respectively.  Analysis of mortality data for each individual plant revealed that significant 
increases in lung cancer deaths were only found in two facilities: Lorain, Ohio (SMR=1.69) and Reading, 
Pennsylvania (SMR=1.24). To assess the effect of duration of exposure and latency on lung cancer 
mortality, the total cohort and the Lorain and Reading cohorts were divided into several latency and 
duration of employment category.  For the total cohort, duration of employment was not associated with 
increased lung cancer deaths, but increased latency was associated with increased lung cancer deaths.  In 
the total cohort, statistically significant increases in lung cancer deaths were observed in the >30 year 
latency category (SMR=1.46), workers employed for <1 year with a >30 year latency (SMR=1.52), and in 
the 25–30 year latency period for workers employed for <1 year.  Among workers at the Lorain and 
Reading facilities, significant increases in cancer mortality were also observed in workers employed for 
<1 year with a 30-year latency (SMRs=1.68 and 1.42, respectively).  The decade of hire also influenced 
lung cancer deaths; this was independent of potential latency.  The highest cancer mortality rates were 
observed among workers hired before 1950.  Three of the seven beryllium-processing facilities were open 
in the 1940s; elevated cancer risks were observed at two of the facilities: Lorain (SMR=1.69; 95% 
CI=1.28–2.19) and Reading (SMR=1.26; 95% CI=1.02–1.56).  The cancer risk was not significantly 
elevated in the plants operating during the 1950s or 1960s (the Lorain plant closed in 1948).  The study 
authors also examined the influence of geographic variation in lung cancer mortality by comparing cancer 
mortality in the cohort with county lung cancer data.  This comparison did not change the overall 
conclusions of the study.  As with the Wagoner et al. (1980) study, Ward et al. (1992) used smoking habit 
data available from a 1968 Public Health Survey (included approximately 16% of cohort and four 
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facilities [including the Reading, Pennsylvania facility]) to account for this confounding variable.  A 
smoking adjustment factor of 1.1323 was estimated using the available data on the beryllium cohort and 
smoking habit data for the U.S. population (obtained from the National Center for Health Statistics, 1965 
and Office of Health, Research, Statistics, and Technology, 1970).  The smoking-adjusted SMRs for the 
entire cohort, the Reading cohort, and the Lorain cohort are 1.12, 1.09, and 1.49, respectively.
As a follow-up to this study, Sanderson et al. (2001a) conducted a case control study using workers from 
the Reading, Pennsylvania facility.  The study consisted of 142 lung cancer cases and 5 age-race matched 
controls for each lung cancer case. Three quantitative exposure metrics were used to estimate beryllium 
exposure levels: cumulative beryllium exposure, average beryllium exposure level, and maximum 
exposure level. Cumulative beryllium exposure was calculated by summing the products of the number 
of days a worker held a particular job times the estimated annual average beryllium exposure for the job 
on those specific days.  Average beryllium exposure was calculated by dividing the cumulative exposure 
level by the number of days the worker was employed.  The maximum exposure level was the highest 
time-weighted average (TWA) exposure of any job the worker held, regardless of duration.  As described 
in a companion paper (Sanderson et al. 2001b), historical measurements were estimated using actual 
industrial hygiene measurements and extrapolations from existing measurements over time and across 
jobs. No industrial hygiene measurements were available before 1947.  Data from 1947 to 1960 were 
used to estimate exposure during the period of 1935 to 1960 based on the assumption that exposure levels 
remained constant during this time period.  When job-specific exposure levels were not available, 
measurements from other areas of the facility that were expected to have similar types of exposures were 
used as surrogates. No measurements were available for general laborers, maintenance workers, or 
salaried personnel (e.g., managers, engineers, office workers).  Exposure levels for the general laborers 
and maintenance workers were estimated by averaging exposure estimates for a variety of jobs.  For the 
salaried personnel, the exposure levels were estimated using measured data for janitors.  The overall lung 
cancer mortality rate for the Reading plant through 1992 was 1.22 (95% CI=1.03–1.43), which is slightly 
lower than the mortality rate of this cohort through 1988 (see discussion of the Ward et al. 1992 study). 
Most of the cases and controls (approximately 60%) were hired during the 1940s when beryllium levels 
were uncontrolled. The average duration of employment was 3.7 years for the cases and 5.5 years for the 
controls; however, approximately 67 and 50% of the cases and controls, respectively, were employed for 
<1 year.  The difference in employment duration was statistically significant.  As compared to controls, a 
higher percentage of cases worked as general labor or maintenance departments where some of the 
highest beryllium exposures occurred; the difference was statistically significant when tenure was lagged 
10 or 20 years to discount exposures that may not have contributed to causing cancer because they 
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occurred after cancer induction. Cumulative, average, and maximum exposure levels were 4,606 µg/m3 
days, 22.8 µg/m3, and 32.4 µg/m3, respectively, for the cases and 6,328 µg/m3 days, 19.3 µg/m3, and 
27.1 µg/m3 for the controls; the differences between the two groups was not statistically significant. 
However, when the exposure was lagged 10 or 20 years, the exposure levels were significantly higher 
among the cases.  Cumulative beryllium exposure levels were 4,057 and 2,036 µg/m3 days for the cases 
and controls, respectively, when lagged 10 years and 844 and 305 µg/m3 days, respectively, when lagged 
20 years.  Average exposure levels for the cases and controls were 22.6 and 12.3 µg/m3, respectively, 
when lagged 10 years and 10.2 and 5.3 µg/m3 respectively, when lagged 20 years.  The maximum 
exposure levels were 30.8 and 16.1 µg/m3 for the cases and controls, respectively, when lagged 10 years 
and 13..1 and 6.5 µg/m3 when lagged 20 years.  Significantly elevated odds ratios were observed in three 
highest quartiles (when compared to the first quartile) of average exposure and maximum exposure when 
exposure was lagged for 10 or 20 years, but not when unadjusted exposure levels were used.  The odds 
ratios were significantly elevated in the three highest quartiles of maximum exposure when exposure was 
lagged 20 years and in the highest quartile of unadjusted maximum exposure.  Similarly, significantly 
elevated odds ratios were found when the average and maximum exposure levels were divided into three 
categories (#2, >2-20, and >20 µg/m3) when the exposure was lagged 10 or 20 years.  In general, no 
significant relationship between duration of employment and cancer risk were found.  Sanderson et al. 
(2001a) also attempted to address two potential confounding variables: cigarette smoking and exposure to 
other chemicals.  The workers were potentially exposed to a number of other chemicals including nitric 
acid aerosols, aluminum, cadmium, copper, fluorides, nickel, and welding fumes.  Significant odds ratios 
were found for copper and fluorides when exposure was lagged 10 or 20 years.  Interpretation of this 
finding is difficult because there were no workers exposed to fluorides or copper only and exposure to 
fluorides and copper was highly associated with exposure to several beryllium compounds.  Smoking 
history was only available for a small number of cases and controls.  Thus, the study authors used an 
indirect method for assess the possible association between smoking status and cancer risk.  The authors 
noted that in order for smoking to be a confounding variable, there would have to be an association 
between smoking status and beryllium exposure level; such an association was not found. 
In addition to these retrospective mortality studies of beryllium workers, there are two epidemiology 
studies of Beryllium Case Registry enrollees (Infante et al. 1980; Steenland and Ward 1992).  In the 
Infante et al. (1980) study, a cohort of 421 white male workers entered into the Beryllium Case Registry 
(BCR) between July 1952 and December 1975; the cohort consisted of workers in the beryllium 
extraction and smelting, metal production, and fluorescent tube production industries and individuals not 
exposed occupationally but living near a beryllium facility.  Mortality rates were compared to the U.S. 
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white male population for the period lung cancer (which includes trachea and bronchii cancers) was 
observed (7 observed compared to 2.81 expected), but the difference was not statistically significant. 
When the lung cancer rate was determined from workers with previously diagnosed respiratory problems, 
the number of observed deaths was 6 versus 1.91 expected (p<0.05).  As with the Mancuso (1979) and the 
Wagoner et al. (1980) studies, using lung cancer mortality data for the period ending in 1967 probably 
resulted in a 10–11% underestimation of the number of expected deaths.  The contribution of cigarette 
smoking to the observed increase in lung cancer deaths was not adjusted for because no smoking data 
were available for the cohort; the study authors note that it is unlikely that individuals with acute 
beryllium illness had smoking habits of sufficient magnitude to account for the excessive lung cancer risk 
in this group. 
A follow-up of the study by Infante et al. (1980) included female workers in the analysis and extended the 
follow-up period by 13 years to 1988 (Steenland and Ward 1992).  The cohort consisted of 689 patients, 
66% of which were men.  Of the entire cohort, 34% had been diagnosed with acute beryllium disease and 
64% with chronic beryllium disease (2% of the subjects had unknown disease type).  The mortality rates 
due to specific causes were compared with that of the U.S. population after stratification by age, race, sex, 
and calendar time.  Increases in mortality were observed among the beryllium workers; the primary cause 
of death was pneumoconiosis and other respiratory diseases (SMR=34.23; 95% CI=29.1–40.0), followed 
by deaths from beryllium poisonings (SMR=34.93; 95% CI=19.1–61.4), all cancers (1.51; 95% 
CI=1.17–1.91), and lung cancer (SMR=2.00; 95% CI=1.33–2.89).  There were 70 deaths from all types of 
cancer, 28 of which were due to lung cancer. Of these, 22 lung cancer deaths occurred in men 
(SMR=1.76, 95% CI=1.02–2.67), and 6 occurred in women (SMR=4.04, 95% CI=1.47–8.81).  No trend 
was found for duration of exposure or for time since initial exposure.  The lung cancer excess was more 
pronounced among those with acute beryllium disease (SMR=2.32; 95% CI=1.35–3.72) than those with 
chronic beryllium disease (SMR=1.57; 95% CI=0.75–2.89).  Data on smoking status were available for 
141 men and 82 women, and data on amount smoked were available for 51 men and 16 women.  Analysis 
showed that the cohort smoked less than the U.S. population, and there were more former smokers and 
fewer current smokers in the cohort than in the U.S. population.  Thus, the study authors concluded that 
the lung cancer excess was probably not due to smoking; the study authors also ruled out selection bias, 
concluding that excess exposure to beryllium was the causative factor.  It is also possible that the 
beryllium disease process (particularly the acute disease) contributes to the development of lung cancer. 
In general, the early (prior to 1987) studies that associated beryllium exposure with lung cancer have been 
inadequately controlled for confounding factors such as smoking, improperly calculated expected deaths 
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from lung cancer, included employees in the beryllium industry who were not actually exposed to 
beryllium (e.g., salesmen, clerks), or used inappropriate controls.  The more recent studies by Ward et al. 
(1992), Steenland and Ward (1992), and Sanderson et al. (2001a) have addressed many of these issues 
and provide strong data on the carcinogenic potential of beryllium in humans.  NTP (1999, 2002) and 
IARC (2001) have concluded that beryllium is a human carcinogen; EPA (IRIS 2002) classified it as a 
probably human carcinogen (group B1).  IARC (2001) noted that several aspects of the Ward et al. (1992) 
and Steenland and Ward (1992) studies support the conclusion that beryllium is a human carcinogen.  In 
particular IARC noted (a) the consistency of lung cancer excess in most of the locations, (b) greater 
excess cancer risk in workers hired prior to 1950 when beryllium levels were much higher than in 
subsequent decades, and (c) the highest risk of lung cancer in individuals with acute beryllium disease 
and at the facility with the greatest proportion of acute beryllium disease.  However, IARC (2001) also 
noted a number of limitations with the existing cancer database.  The limitations include poor exposure 
characterization, relatively low excess cancer risk, and the lack of discussion of exposure to other lung 
carcinogens. Additionally, several reviewers have criticized the conclusions of the Steenland and Ward 
(1992) and Ward et al. (1992) studies. In general, the criticism focuses on the relatively low excess of 
cancer risk and the inadequate adjustment for smoking habits (Eisenbud 1993, 1997; Kolanz 2001; Kotin 
1994; MacMahon 1994; Trichopoulos 2000). Using the data from the Ward et al. (1992) study, Levy et 
al. (n.d.) recalculated the SMRs for lung cancer using city mortality rates rather than county or U.S. rates 
and a different indirect method for adjusting for smoking and did not find significant increases in the 
incidence of lung cancer among beryllium workers.  A meta-analysis of the data did find a significant 
increase in lung cancer risk, although the SMRs were lower than those calculated by Ward et al. (1992). 
Some beryllium compounds are carcinogenic in animals exposed via inhalation.  A single nose-only 
exposure to 410–980 mg/m3 beryllium metal aerosol for 8–48 minutes resulted in a 64% incidence of lung 
tumors in rats; lung tumors were first observed 14 months after exposure (Nickell-Brady et al. 1994). 
Rats exposed to 0.035 mg beryllium/m3 as beryllium sulfate for 180 days had increased lung cancer rates, 
compared to controls (Schepers et al. 1957). 
Cancer incidence was not increased in hamsters exposed to 0.21 or 0.62 mg beryllium/m3 as bertrandite or 
beryl ore for chronic durations (Wagner et al. 1969).  In addition, rats similarly exposed to bertrandite ore 
did not have a greater incidence of lung cancer than that observed in the controls.  However, 18 of 19 rats 
exposed to 0.62 mg beryllium/m3 as beryl ore developed tumors that were classified as bronchial alveolar 
cell tumors, adenomas, adenocarcinomas, or epidermoid tumors.  Primary pulmonary cancer of the 
bronchiole was observed at 9 months in rats exposed to 0.006 or 0.0547 mg beryllium/m3 as beryllium 
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oxide (Vorwald and Reeves 1959). The rats were examined for signs of cancer at 6, 9, 12, and 
18 months.  Lung tumors, which appeared to be adenocarcinomas with a predominantly alveolar pattern, 
were observed after 13 months of exposure in 100% of rats exposed to 0.034 mg beryllium/m3 as 
beryllium sulfate (Reeves et al. 1967).  Monkeys exposed to 0.035 mg beryllium/m3 as beryllium sulfate 
had tumors in the hilus and peripheral portions of the lung, and scattered throughout the pulmonary tissue, 
as determined by histological examination (Vorwald 1968).  Moreover, there were extensive metastases 
to the mediastinal lymph nodes and to other areas of the body.  It should be noted that many of the studies 
conducted in animals have been criticized because of poor documentation, being conducted at single dose 
levels, or failure to include controls (EPA 1987).  However, collectively, the animal data indicate that 
beryllium is carcinogenic in animals. 
The CELs in each species are recorded in Table 3-1 and plotted in Figure 3-1. 





3. HEALTH EFFECTS 
3.2.2.1 Death 
No studies were located regarding death in humans after oral exposure to beryllium or its compounds. 
Oral LD50 values in animals vary according to the compound.  LD50 values for beryllium sulfate were 
120 mg beryllium/kg in rats (Lanchow University 1978) and 140 mg beryllium/kg in mice (Ashby et al. 
1990). The LD50 values for beryllium chloride in rats were 200 mg beryllium/kg (Kimmerle 1966).  The 
LD50 values for beryllium fluoride were 18–20 mg beryllium/kg in mice (Kimmerle 1966; Lanchow 
1978). The LD50 value for beryllium oxyfluoride was 18.3 mg beryllium/kg in rats.  The additional 
toxicity of the fluoride ion accounted for the lower LD50 value observed for beryllium fluoride and 
beryllium oxyfluoride.  The difference in the LD50 values for the other beryllium compounds is due to 
differences in solubility and the potential to form insoluble beryllium phosphate in the gastrointestinal 
tract. 
Increased mortality was observed in dogs exposed to 12 mg beryllium/kg/day as beryllium sulfate in the 
diet; the likely cause of death was severe ulcerative lesions in the gastrointestinal tract (Morgareidge et al. 
1976). In chronic studies, no effect on survival was observed in rats and dogs exposed to #31 or 1 mg 
beryllium/kg/day, respectively, as beryllium sulfate in the diet (Morgareidge et al. 1975, 1976) or in rats 
and mice exposed to 0.6–0.7 or 1 mg beryllium/kg/day, respectively, as beryllium sulfate in drinking 
water (Schroeder and Mitchener 1975a, 1975b). 
The LD50 values in rats and mice and doses associated with increased mortality in dogs are recorded in 
Table 3-2 and plotted in Figure 3-2. 
3.2.2.2 Systemic Effects 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, renal, or dermal, and ocular effects in humans after oral exposure to beryllium 
or its compounds.  The systemic effects observed in animals after oral exposure to beryllium compounds 
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Key to Species Frequency 
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aThe number corresponds to entries in Figure 3-2. 
b Used to derive a chronic-duration oral minimal risk level (MRL) of 0.002 mg Belkglday. The MRL was calculated using a benchmark dose method: the probit model was fit to the 
combined male and female incidence of ulcerative lesions in the small intestine and average doses for male and female dogs to estimate a BMDL (defined as the 95% lower 
confidence limit on the dose corresponding to a 10% increase in the incidence of small intestine lesions compared with controls) of 0.56 mglBelday. The BMDL was divided by an 
uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for intrahuman variability) and a modifying factor of 3 (to account for the lack of a study which supports u
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Figure 3-2. Levels of Significant Exposure to Beryllium - Oral 
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Figure 3-2. Levels of Significant Exposure to Beryllium - Oral (Continued) 
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Figure 3-2. Levels of Significant Exposure to Beryllium - Oral (Continued) 
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The highest NOAEL values and all reliable LOAEL values for each systemic effect in each species and 
duration category are recorded in Table 3-2 and plotted in Figure 3-2. 
Respiratory Effects. The respiratory system does not appear to be a target of oral exposure to 
beryllium or its compounds.  Thickening of the alveolar epithelium with areas of necrosis was observed in 
rats maintained on diets containing beryllium nitrate that provided 2 mg beryllium/kg every 3 days for 
40 days (Goel et al. 1980).  However, since the beryllium nitrate was mixed with food pellets, it is 
possible that the lung effects resulted from aspiration of the beryllium nitrate particulates into the lungs 
during feeding. 
No microscopic lung abnormalities were observed in dogs exposed to 12 mg beryllium/kg/day as 
beryllium sulfate in the diet for 143-172 weeks, respectively (Morgareidge et al. 1976) or in rats exposed 
to #31 mg beryllium/kg/day as beryllium sulfate in the diet for 2 years (Morgareidge et al. 1975). 
Furthermore, chronic exposure to 0.7 or 1 mg beryllium/kg/day as beryllium sulfate in the drinking water 
did not cause lung effects in rats and mice (Schroeder and Mitchener 1975a, 1975b). 
Cardiovascular Effects. Data regarding cardiovascular effects in animals after oral exposure to 
beryllium or its compounds are limited.  Dietary exposure to beryllium sulfate did not result in 
microscopic abnormalities in the heart or aorta of dogs exposed to 12 mg beryllium/kg/day for 143­
172 weeks (Morgareidge et al. 1976) or rats exposed to #31 mg beryllium/kg/day for 2 years 
(Morgareidge et al. 1975). Histological examination revealed that chronic exposure to 0.7 or 1 mg 
beryllium/kg/day as beryllium sulfate in the drinking water did not cause cardiac effects in rats or mice 
(Schroeder and Mitchener 1975a, 1975b). The results from these studies suggest that oral exposure to 
beryllium is not likely to cause cardiac effects.  However, other indices of cardiovascular effects, such as 
blood pressure determinations, were not examined. 
Gastrointestinal Effects. In a chronic exposure study, extensive ulcerative and inflammatory 
lesions were observed in the small intestine, stomach, and large intestine of dogs exposed to 12 mg 
beryllium/kg/day as beryllium sulfate in the diet; similar, but less severe, lesions were observed in 1 of 
10 dogs exposed to 1 mg beryllium/kg/day (Morgareidge et al. 1976).  No lesions were observed in dogs 
exposed to 0.1 mg beryllium/kg/day.  The dose-response data from this study were used to derive a 
chronic-duration MRL of 0.002 mg beryllium/kg/day. The only other study that examined gastrointestinal 
tract tissues was a chronic rat study conducted by the same group.  No microscopic abnormalities of the 
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stomach, small intestine, or large intestine were observed in rats exposed to #31 mg beryllium/kg/day as 
beryllium sulfate in the diet for 2 years (Morgareidge et al. 1975). 
Hematological Effects. Two studies examined hematological end points in animals after oral 
exposure to beryllium sulfate.  Erythroid hypoplasia of the bone marrow and slight decreases in 
erythrocyte, hemoglobin, and hematocrit levels were observed in dogs exposed to 12 mg 
beryllium/kg/day; no effects were observed at 1 mg beryllium/kg/day (Morgareidge et al. 1976).  It is 
likely that these effects were secondary to the severe gastrointestinal hemorrhages also observed in these 
animals rather than a direct effect on the hematological system.  No evidence of microscopic 
abnormalities of the bone marrow or spleen was observed in rats exposed to #31 mg beryllium/kg/day for 
2 years (Morgareidge et al. 1975). 
Musculoskeletal Effects. Early studies indicate that rats fed large amounts of beryllium carbonate 
in the diet developed rickets. Rickets were observed in rats fed diets supplemented with 35–840 mg 
beryllium/kg/day as beryllium carbonate (Guyatt et al. 1933; Jacobson 1933; Kay and Skill 1934).  The 
severity in the fragility of the bones increased with increasing concentrations of beryllium.  These 
“beryllium rickets” are likely due to impaired gastrointestinal phosphate absorption rather than a direct 
effect of beryllium on bone.  Following ingestion of beryllium carbonate, the beryllium in the gut binds to 
soluble phosphorus compounds and forms an insoluble beryllium phosphate; the rickets are a result of the 
decreased phosphorus levels. Although there are a number of methodological deficiencies in these 
studies, such as small numbers of animals per group and lack of statistical analysis, collectively, the 
studies suggest a relationship between beryllium carbonate ingestion and the occurrence of rickets.  No 
bone effects were observed in dogs chronically exposed to 12 mg beryllium/kg/day as beryllium sulfate in 
the diet (Morgareidge et al. 1976). Chronic exposure to #31 or #12 mg beryllium/kg/day as beryllium 
sulfate did not cause morphological abnormalities in the muscle tissue of rats (Morgareidge et al. 1975) or 
dogs (Morgareidge et al. 1976), respectively.
Hepatic Effects. Oral exposure to beryllium compounds causes few effects, if any, on the liver of 
animals.  Biochemical analysis of the lipid and protein contents of liver homogenates from rats exposed to 
0.2 mg beryllium/kg/day as beryllium sulfate did not reveal any hepatic damage (Reeves 1965), however, 
histological examination was not performed. 
Dogs fed 12 mg beryllium/kg/day as beryllium sulfate for 143-172 weeks (Morgareidge et al. 1976) and 
rats fed #31 mg beryllium/kg/day as beryllium sulfate for 2 years (Morgareidge et al. 1975) did not 
    
 
    
    
    
84 BERYLLIUM 
3. HEALTH EFFECTS 
develop morphological abnormalities of the liver or changes in liver weight.  Rats given 0.7 mg 
beryllium/kg/day as beryllium sulfate in drinking water for 3.2 years had transient increases in serum 
cholesterol (Schroeder and Mitchener 1975a). Histological examination of the livers of the exposed rats 
did not provide evidence of morphological alterations.  In mice exposed to beryllium sulfate via a similar 
regimen, no changes in serum cholesterol or morphological abnormalities were observed (Schroeder and 
Mitchener 1975b). 
Renal Effects. Oral exposure to beryllium compounds causes few renal effects, if any, in animals. 
Histological examination of rats fed #31 mg beryllium/kg/day as beryllium sulfate for 2 years established 
no evidence of morphological damage to kidney tissue; however, kidney weight increased slightly 
(Morgareidge et al. 1975). No significant alterations in kidney weight or histological examinations were 
observed in dogs exposed to 12 mg beryllium/kg/day as beryllium sulfate in the diet for 143- 172 weeks 
(Morgareidge et al. 1976). Morphological alterations of the kidney were not observed in either sex of rats 
or mice exposed to 0.6–1 mg beryllium/kg/day as beryllium sulfate, respectively (Schroeder and 
Mitchener 1975a, 1975b). Female rats, however, developed a transient glucosuria (Schroeder and 
Mitchener 1975a). 
Endocrine Effects. There is limited information on potential endocrine effects following oral 
exposure to beryllium.  No adverse effects were observed in the adrenal, thyroid, pituitary, or pancreas of 
dogs exposed to 12 mg beryllium/kg/day as beryllium sulfate in the diet for 143-172 weeks (Morgareidge 
et al. 1976) or in rats exposed to #31 mg beryllium/kg/day as beryllium sulfate in the diet for 2 years 
(Morgareidge et al. 1975). 
Dermal Effects. Information regarding dermal effects in animals after oral exposure to beryllium or 
compounds is limited.  Histological examination of the skin of rats exposed to #31 mg beryllium/kg/day 
as beryllium sulfate in the diet for 2 years (Morgareidge et al. 1975) or in dogs exposed to 12 mg 
beryllium/kg/day as beryllium sulfate in the diet for 143-172 weeks (Morgareidge et al. 1976) did not 
indicate morphological changes. 
Ocular Effects. Two studies examined the eyes of animals repeatedly exposed to beryllium sulfate in 
the diet. No ocular effects were observed in rats exposed to #31 mg beryllium/kg/day for 2 years 
(Morgareidge et al. 1975) or dogs exposed to 12 mg beryllium/kg/day for 143-172 weeks (Morgareidge et 
al. 1976). 
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Body Weight Effects. In general, exposure to beryllium sulfate in the diet or drinking water does not 
adversely affect body weight gain.  Intermediate-duration exposure to high doses of beryllium carbonate 
in the diet (480 mg beryllium/kg/day) resulted in an 18% decrease in body weight gain in rats 
(Matsumoto et al. 1991).  At lower doses (0.7 mg beryllium/kg/day), no body weight effects were 
observed (Freundt and Ibrahim 1990).  Anorexia and weight loss was observed in dogs exposed to 12 mg 
beryllium/kg/day as beryllium sulfate in the diet;  no effects on body weight gain were observed in dogs 
exposed to #1 mg beryllium/kg/day (Morgareidge et al. 1976).  The weight loss observed at the highest 
dose was probably secondary to the ulcerative gastrointestinal lesions present in these animals.  No 
alterations in weight gain were observed in rats (Morgareidge et al. 1975) chronically exposed via the diet 
to 31 mg beryllium/kg/day, or in rats (Schroeder and Mitchener 1975a) and mice (Schroeder and 
Mitchener 1975b) exposed via drinking water to 0.7 or 1 mg beryllium/kg/day, respectively.
Metabolic Effects. There are very limited data on metabolic effects in animals following oral 
exposure to beryllium or its compounds.  Decreases in serum phosphate levels and alkaline phosphatase 
activity were observed in rats exposed to $70 mg beryllium/kg/day as beryllium carbonate in the diet 
(Kay and Skill 1934; Matsumoto et al. 1991).  As discussed under Musculoskeletal Effects, it is likely 
that these effects are due to beryllium binding to soluble phosphorus compounds causing a decrease in 
phosphorus absorption. 
3.2.2.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological effects in humans after oral exposure to beryllium or its 
compounds. 
No histopathological lesions were observed in the spleen, lymph nodes, or thymus of rats chronically 
exposed to #31 mg beryllium/kg/day as beryllium sulfate in the diet (Morgareidge et al. 1975) or in dogs 
exposed to 12 mg beryllium/kg/day as beryllium sulfate in the diet for 143-172 weeks (Morgareidge et al. 
1976). More sensitive tests of the immune function were not conducted. 
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3.2.2.4 Neurological Effects 
No studies were located regarding neurological effects in humans after oral exposure to beryllium or its 
compounds. 
No changes in brain weight and no histopathological lesions were observed in the brain, nerve, or spinal 
cord of rats chronically exposed to #31 mg beryllium/kg/day as beryllium sulfate in the diet (Morgareidge 
et al. 1975) or in dogs exposed to 12 mg beryllium/kg/day as beryllium sulfate in the diet for 143­
172 weeks (Morgareidge et al. 1976). This information is insufficient to conclude that beryllium does not 
cause neurological effects because more sensitive neurological or neurobehavioral tests were not 
performed. 
3.2.2.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans after oral exposure to beryllium or its 
compounds. 
There is limited information available on beryllium effect on reproduction.  In a chronic duration dog 
study conducted by Morgareidge et al. (1976), male and female dogs were housed together at the time of 
the second heat, were allowed to mate and wean their pups; the study authors reported that there were no 
significant alterations in the number of pregnancies, number of pups, or number of live pups observed at 
doses of #1 mg beryllium/kg/day as beryllium sulfate in the diet.  The result of this study should be 
interpreted with caution because very few study details were provided.  Rats maintained for 2 years on 
diets containing beryllium sulfate had a significantly decreased average testes-to-body weight ratio at 
concentrations of 0.3 and 2.8 mg beryllium/kg/day, but not at #31 mg beryllium/kg/day (Morgareidge et 
al. 1975). Histological examination of the testes, prostate, seminal vesicles, and epididymis did not reveal 
any abnormalities.  No decrease in ovary weight was observed in female rats similarly exposed. 
Furthermore, histological examination of the ovaries, uterus, and oviducts did not reveal any 
abnormalities (Morgareidge et al. 1975).  The absence of further evidence of adverse effects of 
reproductive organs and of a positive dose relationship makes the toxicological significance of the 
decreased testes-to-body weight ratio unclear. 
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3.2.2.6 Developmental Effects 
No studies were located regarding developmental effects in humans after oral exposure to beryllium or its 
compounds. 
There is limited information on beryllium’s potential to induce developmental effects in animals 
following oral exposure. As discussed under Reproductive Effects, the Morgareidge et al. (1976) chronic 
dog study co-housed males and females, allowed them to mate, and wean their pups.  Pups in the first 
litter were examined for gross and skeletal malformations.  No significant alterations in the occurrence of 
gross or skeletal malformations, number of live pups, pup body weights, or pup survival were observed at 
1 mg beryllium/kg/day; however, stillborn or cannibalized pups dying within the first few postnatal days 
were not examined. 
3.2.2.7 Cancer 
No studies were located regarding cancer in humans after oral exposure to beryllium or its compounds. 
Beryllium has not been found to cause cancer in animals after oral exposure.  This could be due to the 
poor absorption of beryllium compounds from the gastrointestinal tract.  Nonsignificant increases in the 
number of lung reticulum cell carcinomas were observed in male rats exposed to 0.3 or 2.8 mg 
beryllium/kg/day as beryllium sulfate in the diet for 2 years; the incidences were 10/50, 17/50, 16/50, and 
5/50 in males and 5/50, 7/50, 7/50, and 5/50 in females in the 0, 0.3, 2.8, and 31 mg beryllium/kg/day 
groups, respectively (Morgareidge et al. 1975).  No differences in the number of reticulum cell carcinoma 
bearing rats were observed in the beryllium-exposed rats (18/50, 16/50, and 13/50 for males and 11/50, 
7/50, and 8/50 for females in the 0.3, 2.8, and 31 mg beryllium/kg/day groups, respectively) compared to 
controls (12/50 and 8/50 for males and females, respectively).  The incidence of tumors in rats or mice 
exposed chronically to 1 mg beryllium/kg/day as beryllium sulfate in the drinking water was not 
significantly altered, although the incidence of total tumors in treated male rats (9/33) was slightly 
increased, compared to controls (4/26) (Schroeder and Mitchener 1975a, 1975b).  The incidence of 
neoplasms was not significantly increased in dogs exposed to 12 or 1 mg beryllium/kg/day as beryllium 
sulfate in the diet for 33 or 172 weeks, respectively (Morgareidge et al. 1976). 
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3.2.3 Dermal Exposure 
3.2.3.1 Death 
No studies were located regarding death in humans or animals after dermal exposure to beryllium or its 
compounds. 
3.2.3.2 Systemic Effects 
No studies were located regarding cardiovascular, gastrointestinal, musculoskeletal, hepatic, renal, 
endocrine, ocular, or body weight effects in humans or animals after dermal exposure to beryllium or its 
compounds. 
Most of the available information on the systemic toxicity of beryllium following dermal exposure comes 
from a series of studies conducted by Marx and Burrell (1973).  In these studies, guinea pigs were 
sensitized via 12 biweekly intradermal injections of beryllium sulfate and/or received a single intradermal 
injection of beryllium oxide or a single intradermal injection of beryllium oxide, beryllium sulfate, and 
beryllium fluoride.  Another group of guinea pigs received two intraperitoneal injections of beryllium 
sulfate. The study authors note “a number of guinea pigs which were being sacrificed were examined for 
evidence of any systemic involvement of the disease state.”  No additional information was provided as to 
which group(s) of animals were examined; however, an assumption can be made that it was animals 
receiving intradermal doses.  The observed effects are described below, but are not presented in the LSE 
table or figure. 
Respiratory Effects. No studies were located regarding respiratory effects in humans after dermal 
exposure to beryllium or its compounds. 
Several respiratory effects were described in the Marx and Burrell (1973) study; the observed effects 
included mild to moderate interstitial fibrosis of the alveolar wall, mild to moderate emphysema with 
dilatation of the respiratory bronchioles, hypertrophy of smooth muscle, and mucosal hypertrophy of the 
terminal bronchioles. 
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Hematological Effects. No studies were located regarding hematological effects in humans after 
dermal exposure to beryllium or its compounds. 
Splenic effects were observed in the guinea pigs examined by Marx and Burrell (1973).  The observed 
effects in the spleen included follicular hyperplasia and focal hematopoietic tissue hyperplasia and large 
deposits of hemosiderin in the medullary area. 
Dermal Effects. Dermatological abnormalities due to beryllium exposure were reported in the case 
histories of 42 workers exposed to beryllium sulfate, beryllium fluoride, or beryllium oxyfluoride 
(VanOrdstrand et al. 1945). The dermatological manifestations were characterized as edematous, 
papulovesicular dermatitis.  Ulceration occurred only after the skin was accidentally abraded.  These 
ulcers began as small indurated papules surrounded by an area of erythema which later underwent 
necrosis. Conjunctivitis occurred only as a splash burn or in association with contact dermatitis of the 
face. Granuloma formation was reported in the case histories of 26 beryllium workers with skin lesions 
resulting from cuts and abrasions sustained at work (Williams et al. 1987).  Skin biopsies of six workers 
showed that the granulomatous lesions of the skin contained beryllium.  Eight other workers had skin 
lesions only.  Twelve of the workers had nonspecific inflammation of the skin without granuloma 
(Williams et al. 1987).  An allergic contact dermatitis can occur and is most frequently caused by 
beryllium fluoride (Curtis 1951) (see Section 3.2.3.3). 
Delayed hypersensitivity reactions, as described under Immunological and Lymphoreticular Effects, were 
observed in beryllium-sensitized guinea pigs dermally exposed to beryllium sulfate, beryllium fluoride, 
beryllium oxide, or beryllium chloride (Belman 1969; Marx and Burrell 1973). 
3.2.3.3 Immunological and Lymphoreticular Effects 
Thirteen patients with dermatitis as a result of occupational dermal contact with beryllium fluoride, 
ground metallic beryllium, or water drippings from overhead pipes coated with dust of various 
compounds were evaluated with patch tests using different beryllium compounds to determine whether 
the dermatitis was due to an immune response (Curtis 1951).  Positive patch tests were obtained in 5 of 
13 patients challenged with 0.019 mg beryllium/mL as beryllium fluoride.  The incidence and severity of 
positive reactions increased with increasing concentrations of test substance.  The relative ability of the 
compounds to elicit reactions was as follows:  beryllium fluoride > beryllium sulfate=beryllium chloride 
> beryllium nitrate. 
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Sensitization of guinea pigs with 12 biweekly intradermal injections of 0.0019 or 0.0005 mg beryllium as 
either beryllium fluoride or beryllium sulfate increased the amount of macrophage inhibition factor and 
lymphotoxin when the lymphocytes were cultured with beryllium salts (Marx and Burrell 1973).  The 
sensitivity of the lymphocytes to beryllium salts, as noted by the increase in lymphokine levels, could be 
passively transferred from a sensitized donor to a naive recipient.  Delayed hypersensitivity reactions also 
developed in guinea pigs tested with beryllium fluoride or beryllium chloride after dermal or 
intracutaneous sensitization with beryllium fluoride (Belman 1969) and in guinea pigs tested with 
beryllium sulfate or metallic beryllium after intradermal sensitization with beryllium sulfate (Zissu et al. 
1996). The LOAEL values for immunological effects in each species and duration category are recorded 
in Table 3-3. 
No studies were located regarding the following health effects in humans or animals after dermal 
exposure to beryllium or its compounds: 
3.2.3.4 Neurological Effects 
3.2.3.5 Reproductive Effects 
3.2.3.6 Developmental Effects 
3.2.3.7 Cancer 
3.2.4 Other Routes of Exposure 
Animal models of chronic beryllium disease have increased our understanding about the potential 
pathogenesis of chronic beryllium disease in humans.  Hartley guinea pigs that were injected 
intratracheally with 16 mg beryllium/kg as beryllium oxide calcined at 560 EC developed slight edema 
and had focal interstitial lymphomononuclear infiltration at 1 week after injection (Barna et al. 1981). 
Granulomatous lesions were found at 2 weeks after injection and became progressively more severe at 
4–6 weeks, with the level of severity persisting up to the end of the observation period (6 months).  In 
vitro blood lymphocyte transformation tests in response to beryllium sulfate challenge were consistently 
positive with cells from beryllium oxide injected guinea pigs and consistently negative in cells from 
controls. Treatment of the guinea pigs with immunosuppressive agents (prednisone, L-asparaginase, 
C 
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cytoxan) decreased the severity of beryllium oxide-induced lung disease.  Pretreatment with beryllium 
sulfate prior to beryllium instillation delayed the development and reduced the severity of lung granuloma 
and also suppressed the delayed skin reactions to beryllium sulfate injected intradermally in guinea pigs 
intratracheally exposed to beryllium oxide.  These experiments demonstrate that the development of 
granulomas in response to beryllium involves cell-mediated immune mechanisms.  Similar studies with 
strain 2 and strain 13 guinea pigs demonstrated that strain 2 guinea pigs consistently developed chronic 
beryllium disease, while strain 13 guinea pigs did not, indicating that the immune mechanisms are 
genetically controlled in guinea pigs, and may explain the low prevalence of chronic beryllium disease in 
humans (Barna et al. 1981, 1984).  In an attempt to develop a murine model for chronic beryllium disease, 
A/J (H-2a haplotype) mice received intratracheal injections of beryllium sulfate or beryllium oxide 
calcined at 550 or 1,100 EC (Huang et al. 1992). In mice that received beryllium oxide, no histological 
differences or differences in bronchoalveolar lavage cells were found from the control mice until 
8 months after instillation.  At 8 months, there were moderate infiltrates and diverse microgranulomatous 
lesions, but these were apparently resolved at 10 months.  The mice that received beryllium sulfate 
intratracheally were preimmunized with beryllium sulfate subcutaneously.  Nonspecific inflammatory 
cells plus perivascular areas of lymphocytic infiltrates were seen at 2 weeks after beryllium sulfate 
instillation; numerous active areas containing macrophages, microgranulomas, and fibrosis were seen at 
4 weeks; more severe granulomas and fibrosis were seen at 8 weeks, but at 20 weeks the lungs were 
generally normal.  Results of tests on cells obtained by bronchoalveolar lavage showed increases in 
lymphocytes that corresponded with the time course of pathological changes.  At 2 weeks, .30% of the 
lymphocytes expressed the γ/σ T lymphocyte receptor.  Most of the lymphocytes at 4 weeks were Thy1+, 
LdT4+ (CD4+), and expressed the α/β T lymphocyte receptor.  Significant in vitro proliferation of 
bronchoalveolar lavage lymphocytes from preimmunized mice in response to beryllium sulfate was 
observed. During the acute phase (2 weeks), macrophage activation antigens were expressed, while at 
later times beyond the acute inflammatory phase, monocyte-macrophage antigens were expressed. 
Similar effects could not be induced in BALB/c (H-2d haplotype) or C57BL/6 (H-2b haplotype) mice, 
suggesting that genetic differences at the H-2 major histocompatibility complex gene complex may 
account for the differential responses to beryllium sulfate.  Another cellular mechanism by which 
beryllium is thought to induce toxicity is by interaction with the cell lysosome (Witschi and Aldridge 
1968). It has been postulated that beryllium destroys the integrity of the lysosomal membrane and 
releases lysosomal enzymes, which are injurious to the cell (Reeves and Preuss 1985). 
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3.3 GENOTOXICITY 
Genotoxic Effects. No studies were located regarding genotoxicity in humans after inhalation, oral, 
or dermal exposure to beryllium or its compounds.  CBA mice were exposed by gavage to 117 and 
71 mg/kg as beryllium sulfate corresponding to 80 and 50% of the LD50 values, respectively (Ashby et al. 
1990). The number of micronucleated polychromatic erythrocytes was not exceptional 24, 48, and 
72 hours after dosing. In vitro studies are summarized in Table 3-4.  The results of genotoxicity assays of 
soluble beryllium compounds are inconsistent; however, the carcinogenicity of beryllium is supported by 
the positive mutagenic potential reported in some of these studies.  The inconsistencies may have been 
due to the physical/chemical properties of beryllium; in particular the binding of beryllium to phosphate, 
hydroxide, or proteins in the culture media.  Beryllium nitrate was not mutagenic in the Salmonella 
typhimurium reverse mutation assay (Ames test) (Arlauskas et al. 1985).  Beryllium sulfate was 
mutagenic in the forward mutation assay in Bacillus subtilis (Kanematsu et al. 1980) but was not 
mutagenic in the Ames test, regardless of the presence of microsomal fractions (Ashby et al. 1990; 
Rosenkranz and Poirier 1979; Simmon 1979b).  Beryllium chloride was mutagenic in the reverse 
mutation assay in Photobacterium fischeri (Ulitzur and Barak 1988). Beryllium chloride was not 
mutagenic in the forward mutation assay with Escherichia coli (Zakour and Glickman 1984).  Beryllium 
sulfate did not cause gene mutations in Saccharomyces cerevisiae (Simmon 1979b).  Gene mutations 
were induced in whole mammalian cell cultures by the addition of either beryllium sulfate or beryllium 
chloride (Hsie et al. 1979; Miyaki et al. 1979).  According to one study, beryllium sulfate induced 
chromosomal aberrations in mammalian cells (Larramendy et al. 1981); however, other studies indicate 
that beryllium sulfate did not induce chromosomal aberrations in cultured mammalian cells (Ashby et al. 
1990; Brooks et al. 1989). Beryllium sulfate did not affect deoxyribonucleic acid (DNA)-repair in 
mammalian cells (Williams et al. 1989).  Differences in the positive and negative results depend on the 
assay conditions, the concentrations of the beryllium compounds in vitro, and the differences among 
bacterial strains. Thus, soluble beryllium compounds appear to be weakly genotoxic. 
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Table 3-4. Genotoxicity of Beryllium and Its Compounds In Vitro 
With Without 
Species (test system) End point activation activation Reference Compound 
Prokaryotic organisms: 
Salmonella typhimurium Gene mutation — — Arlaukas et al. 1985; Ashby et Beryllium sulfate 
al. 1990; Rosenkranz and Poirer 
1979; Simmon et al. 1979; 
Simmon 1979a 
S. typhimurium Gene mutation No data — Arlauskas et al. 1985 Beryllium nitrate 
Bacillus subtilis Gene mutation No data + Kanematsu et al. 1980 Beryllium sulfate 
Escherichia coli Gene mutation No data — Zakour and Glickman 1984 Beryllium chloride 
Photobacterium fischeri Gene mutation No data + Ulitzur and Barak 1988 Beryllium chloride 
Eukaryotic organisms: 
Fungi: 
Saccharomyces cerevisiae Gene mutation No data — Simmon 1979b Beryllium sulfate 
Mammalian cells: 
Chinese hamster ovary K1­ Gene mutation No data + Hsie et al. 1979 Beryllium sulfate 
BH4 cell 
Chinese hamster ovary cell Chromosomal aberration No data — Brooks et al. 1989 Beryllium sulfate 
Chinese hamster CHL cells Chromosomal aberration — — Ashby et al. 1990 Beryllium sulfate 
Chinese hamster V79 cells Gene mutation No data + Miyaki et al. 1981 Beryllium chloride 
Human lymphocytes Chromosomal aberration No data + Larramendy et al. 1981 Beryllium sulfate 
Rat hepatocytes DNA-repair No data — Williams et al. 1989 Beryllium sulfate 
Syrian hamster cells Chromosomal aberration No data + Larramendy et al. 1981 Beryllium sulfate 
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3.4 TOXICOKINETICS 
3.4.1 Absorption 
3.4.1.1 Inhalation Exposure 
Beryllium compounds are absorbed primarily through the lungs, but sufficient information to determine 
the rate and extent of absorption was not located. Due to an accidental leakage of beryllium dust in a 
laboratory, 25 people were exposed to an undetermined concentration for 10–20 hours (Zorn et al. 1986). 
The day after exposure, serum beryllium levels were 3.5±0.47 ppb beryllium, compared to 1.0 ppb in 
unexposed controls. Six days later, the serum level decreased to 2.4±0.3 ppb beryllium, and 2–8 weeks 
after exposure the serum levels returned to normal.  The biological half-time of beryllium was calculated 
to be 2–8 weeks. In eight men accidently exposed to .8 ng beryllium/m3 as beryllium chloride for 
4–6 hours/day for 10 days, the beryllium levels in urine and blood increased 4-fold above the levels of 
.1 ng beryllium/g of either blood or urine in unexposed individuals (Stiefel et al. 1980). 
Rats exposed to 0.034 mg beryllium/m3 as an aerosol of beryllium sulfate 7 hours/day, 5 days/week for 
72 weeks achieved steady state concentrations in the lungs in .36 weeks of exposure (Reeves and 
Vorwald 1967). The beryllium concentration in tracheobronchial lymph nodes peaked between 36 and 
52 weeks, and decreased thereafter. In guinea pigs and rats exposed to 2–40 mg beryllium/m3 as 
beryllium nitrate for 16 hours, steady-state concentrations in the blood were reached after 8–12 hours of 
exposure (Stiefel et al. 1980). 
3.4.1.2 Oral Exposure 
No studies were located regarding absorption in humans after oral exposure to beryllium or its 
compounds. 
Beryllium and its compounds are poorly absorbed from the gastrointestinal tract in animals.  Urinary 
excretion data from rats treated by gavage with radioactive beryllium chloride indicate that the cumulative 
excretion of beryllium in the urine and feces was 0.11 and 104.7% of the total dose, respectively 
(Furchner et al. 1973). In mice, dogs, and monkeys similarly exposed, the urinary output was 0.24, 0.38, 
and 3.71% of the total dose, respectively, while most of the radiolabel was excreted in the feces. 
Therefore, although intestinal absorption of beryllium varies somewhat among species, beryllium was 
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poorly absorbed in these animals.  Mice exposed to radioactive beryllium retained beryllium in the 
gastrointestinal tract (LeFevre and Joel 1986). The amount found in the tissues other than intestinal was 
<0.1%. 
Urinary excretion accounted for #0.5% of the total dose of beryllium sulfate administered to rats as 
0.019 and 0.190 mg beryllium/kg/day in drinking water for 24 weeks (Reeves 1965).  The percent 
absorption, determined as the percentage of the dose that could be recovered from the total body load and 
excreta, was #0.9% in the 0.019 mg beryllium/kg/day group and #0.2% in the 0.190 mg beryllium/kg/day 
group. Rats exposed to #31 mg beryllium/kg/day as beryllium sulfate in drinking water for 2 years 
excreted very little beryllium via the urine (Morgareidge et al. 1975).  Oral absorption of beryllium and its 
compounds may be reduced by the formation of beryllium phosphate precipitates in the alkaline 
environment of the intestine (Reeves 1965). 
3.4.1.3 Dermal Exposure 
It is unlikely that beryllium is absorbed through intact skin.  Skin ulceration in workers exposed to 
beryllium occurred only after the skin was accidentally cut or abraded (Williams et al. 1987). 
Only small amounts of beryllium were absorbed through the tail skin of rats after exposure to an aqueous 
solution of beryllium chloride (Petzow and Zorn 1974).  Beryllium has been demonstrated to bind to 
alkaline phosphatase and nucleic acids in guinea pig epidermis in vitro (Belman 1969).  This binding 
could account for the inefficient transfer of beryllium from the epidemis to the blood. 
3.4.2 Distribution 
Average concentrations of beryllium were measured in human organs as follows:  0.21 ppm in lungs; 
0.08 ppm in brain; 0.07 ppm in both the kidney and spleen; 0.04 ppm in each of liver, muscle, and 
vertebrae; 0.03 ppm in heart; and 0.02 in bone (Meehan and Smythe 1967).  Further information 
regarding the nature of exposure (e.g., environmental or occupational) or the source of the organ samples 
(e.g., autopsy or biopsy) was not provided.  A study by Krachler et al. (1999a) provides evidence that 
beryllium is transferred across the placenta and excreted via breast milk.  The levels of beryllium in 
umblical cord serum and in colostrum were higher than in maternal serum. 
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3.4.2.1 Inhalation Exposure 
In eight men exposed to .8 ng beryllium/m3, 4–6 hours/day for 10 days due to an accidental leak of 
beryllium chloride, 60–70% of the beryllium found in the blood was bound to two classes of serum 
proteins, prealbumins and γ-globulins (Stiefel et al. 1980). 
Beryllium is widely distributed to the organs of animals, as a result of pulmonary absorption. 
Immediately after rats were exposed to radioactive beryllium (beryllium sulfate and beryllium chloride) 
for 3 hours, the percentage of total body radioactivity in tissues was 60% in lungs, 0.9% in the liver, 1.5% 
in the kidney, 0.1% in the spleen, 0.4% in the heart, 1.4% in the brain, 9.5% in the muscle, 13.5% in the 
skeleton, 5.0% in the blood, and 10% in the excreta (Zorn et al. 1977).  After 408 hours, the liver, spleen, 
heart, brain, and muscle had concentrations <0.0005%; concentrations in the kidneys, skeleton, blood, 
and excreta were 0.0005, 6.8, 0.05, and 92.0%, respectively.  The beryllium concentrations in the bone 
increased until 96 hours after exposure and then decreased.  Dogs exposed to beryllium oxide calcined at 
500EC had higher beryllium concentrations in the extrapulmonary tissue, principally the liver and 
skeleton, than dogs exposed to beryllium oxide calcined at 1,000 EC, due to the greater solubility of the 
500 EC calcined product (Finch et al. 1990). The translocation of beryllium to the tracheobronchial 
lymph nodes increased and by day 64 accounted for a higher concentration than found in the lung. 
Beryllium was also detected in the liver, skeleton, and blood. 
Distribution studies in rats and guinea pigs exposed to 2–40 mg beryllium/m3 as beryllium nitrate for 
16 hours report that 60–70% of the beryllium in the blood was bound to prealbumins and γ-globulins 
(Stiefel et al. 1980). Rats and hamsters exposed to beryllium oxide did not have detectable beryllium 
concentrations in the liver, skeleton, or urine 7 days after exposure (Rhoads and Sanders 1985; Sanders et 
al. 1975). At 63 days after exposure, 1.7% of the initial alveolar deposit was present in the pulmonary 
lymph nodes in rats.  Exposure to 0.04 mg beryllium/m3 as beryllium sulfate for 90–100 days resulted in 
the following concentrations (in µg beryllium/g fresh tissue) of beryllium in rabbits:  1.6 in the lungs, 
0.02 in the femur, 0.01 in the spleen, 0.004 in the liver, and 0.003 in the kidney (Stokinger et al. 1950). 
Dogs similarly exposed had the highest concentrations in the pulmonary lymph node (0.7), followed by 
lung (0.6), femur (0.03), spleen (0.01), liver (0.01), and kidney (0.003).  In monkeys, the pulmonary 
lymph nodes (1.3) also had the highest concentrations followed by lung (1.2), spleen (0.5), femur (0.1), 
and kidney (0.01).  In cats, the concentrations of beryllium from greatest to least were lung (0.08), femur 
(0.03), liver (0.02), spleen (0.01), and kidney (0.01).  In rats, hamsters, and monkeys exposed to 0.21 or 
0.62 mg beryllium/m3 as bertrandite or beryl ore, concentrations were highest in the lung followed by 
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bone or liver, and kidney (Wagner et al. 1969).  The greater degree of distribution of beryllium sulfate, 
compared with beryllium oxide or the ores, reflects its greater solubility and absorption rate. 
3.4.2.2 Oral Exposure 
No studies were located regarding distribution in humans after oral exposure of beryllium or its 
compounds. 
Beryllium is poorly absorbed from the gastrointestinal tract in animals; however, that which is absorbed is 
distributed to the organs and tissues. Beryllium was found in the liver, large intestine, small intestine, 
kidneys, lungs, stomach, and spleen in hamsters given beryllium sulfate, beryllium oxide, or beryllium 
metal in the diet for 3–12 months (Watanabe et al. 1985).  In mice given a radioactive dose of beryllium 
chloride by gavage, the accumulation of radioactivity was greatest in the liver followed by the kidney, 
mesenteric lymph nodes, lungs, blood, and carcass, 3 hours after exposure (LeFevre and Joel 1986).  The 
pattern of beryllium distribution to tissues and organs in rats given beryllium sulfate indicated that as the 
exposure duration increases, accumulation levels also increase (Reeves 1965).  In tissue, beryllium 
concentrations were highest in the gastrointestinal tract (with contents), followed by bone, blood, and 
liver. Other studies indicate that in animals, high levels of beryllium accumulate in bone tissue as a result 
of oral exposure to the chemical or its compounds.  In rats treated by gavage with radioactive beryllium 
chloride, the greatest accumulation (other than that in the gastrointestinal tract) was detected in the bone, 
followed by viscera, pelt, and muscle (Furchner et al. 1973).  Beryllium accumulation in the bones of rats 
exposed for 2 years to dietary concentrations of the chemical was proportional to the administered dose 
(Morgareidge et al. 1975). 
3.4.2.3 Dermal Exposure 
No studies were located regarding distribution in humans or animals after dermal exposure to beryllium 
or its compounds.  The lack of data is expected because beryllium is poorly absorbed after dermal 
exposure (see Section 3.4.1.3). 
3.4.2.4 Other Routes of Exposure 
In rats receiving a single intravenous injection of radiolabelled beryllium sulfate, circulating beryllium 
was found almost exclusively in the plasma (Vacher and Stoner 1968).  Two fractions of plasma 
 
BERYLLIUM 100 
3. HEALTH EFFECTS 
beryllium were identified.  The smaller fraction was presumably bound to plasma organic acids.  In the 
larger fraction, the beryllium sulfate was converted to beryllium phosphate, which formed aggregates 
associated with plasma globulins, presumably α-globulin. The size of the aggregates appeared to increase 
with increasing beryllium sulfate doses. 
3.4.3 Metabolism 
Beryllium and its compounds are not biotransformed, but soluble beryllium salts are partially converted to 
less soluble forms in the lung (Reeves and Vorwald 1967). 
3.4.4 Elimination and Excretion 
3.4.4.1 Inhalation Exposure 
In eight men accidentally exposed to .8 ng beryllium/m3 as beryllium chloride 4–6 hours/day for 10 days, 
urinary levels were four times higher than the average levels of .1.0 ng beryllium/g in unexposed 
individuals (Stiefel et al. 1980). Accidental exposure of 25 individuals to beryllium dust for 10–20 hours 
increased serum levels to 3.5 ppb beryllium 1 day after exposure, compared to .1 ppb for unexposed 
individuals (Zorn et al. 1986). Serum levels returned to normal 2–8 weeks after exposure.  The biological 
half-life was estimated to range from 2 to 8 weeks. 
Beryllium oxide deposited in the lungs of rats was cleared in a biphasic manner (Rhoads and Sanders 
1985). In the first phase, 30% of the total lung burden was cleared; the half-life was 2.5 days.  In the 
second phase, the remaining 70% of the beryllium in the lung was cleared with a half-life of 833 days. 
The whole body clearance yielded a single-phase exponential curve with a half-life of 356 days.  Rats 
exposed to beryllium oxide were able to clear 12 and 21% (female and male, respectively) of the alveolar 
lung burden within 63 days of exposure (Sanders et al. 1975).  Hamsters, however, cleared 38 and 45% 
(female and male, respectively) of the beryllium in the alveoli.  The study indicates that male rats are 
better able to clear beryllium particles from the lungs than female rats are.  The biological half-life for 
beryllium oxide in the rat lung was estimated to be .6 months.  Approximately 95% of the beryllium was 
excreted through the feces. Rats and guinea pigs exposed to 2–40 mg beryllium/m3 as beryllium nitrate 
for 16 hours had increased concentrations of urinary beryllium (300 ng beryllium/g), compared to normal 
concentrations (2.1 ng beryllium/g) (Stiefel et al. 1980).  Rats exposed to radioactive beryllium 
compounds excreted 92% of the dose in 408 hours (Zorn et al. 1977).  In dogs exposed only via nose to 
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10 mg beryllium/m3 as beryllium oxide calcined at 500 or 1,000 EC (the solubility of beryllium oxide 
decreases as the temperature at which it is calcined increases) for sufficient durations to result in low 
(.5 µg beryllium/kg) initial lung burdens and high (36–64 µg beryllium/kg) initial lung burdens, there 
were no differences in whole-body retention with regard to initial lung burdens (Finch et al. 1990). 
Whole-body clearance after exposure to beryllium oxide calcined at 500 EC was described by a two-
component, negative exponential function.  The short-term component accounted for 59% of the initial 
lung burden and had a half-life of 54 days.  The long-term component accounted for 41% of the initial 
lung burden and had a half-life of >1,000 days.  The long-term component may have represented 
beryllium that dissolved from beryllium oxide particles and bound to extrapulmonary compartments, such 
as, bone and liver. Whole-body clearance after exposure to beryllium oxide calcined at 1,000 EC was 
described by a single-component negative exponential function with a half-life of 310 days.  Clearance 
from the lung was more rapid and greater amounts were translocated to the liver, blood, and skeleton in 
the dogs exposed to beryllium calcined at the lower temperature than in dogs exposed to beryllium 
calcined at the higher temperature.  However, lung clearance of both was described by a single-
component negative exponential function.  Clearance half-lives were 64 days for 500 EC calcined 
beryllium oxide and 240 days for 1,000 EC calcined beryllium oxide.  Fecal excretion predominated at 
early times after exposure to either beryllium oxide aerosols, and at all times for 1,000 EC calcined 
beryllium oxide.  Dogs exposed to beryllium oxide calcined at 500 EC excreted a significantly (p<0.05) 
greater total percentage of the initial lung burden of beryllium than dogs exposed to beryllium calcined at 
the higher temperature by 180 days.  Thus, beryllium oxide calcined at 500 EC was cleared more rapidly 
than beryllium oxide calcined at 1,000 EC. This is consistent with the fact that more soluble beryllium 
compounds are cleared faster than relatively insoluble beryllium compounds because the solubility of 
beryllium oxide decreases as the temperature at which it is calcined increases.  Although clearance of 
beryllium oxide calcined at the lower temperature was relatively fast during the first few days after 
exposure due to mucociliary clearance, later clearance may result from slow translocation of 
tracheobronchial lymph nodes, macrophage clearance from the pulmonary to the tracheal regions, and 
pulmonary solubilization of beryllium followed by mobilization through blood to liver and bone or 
excretion in urine. Beryllium decreased the clearance rate of radioactive plutonium oxide from the lungs 
of rats 60 and 90 days after exposure to beryllium oxide (Sanders et al. 1975).  Inhalation exposure to 
beryllium may decrease the overall rate of lung clearance by damaging alveolar macrophages. 
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3.4.4.2 Oral Exposure 
No studies were located regarding excretion in humans after oral exposure to beryllium or its compounds. 
Animals exposed to oral doses of beryllium or its compounds excrete the greatest percentage of the dose 
via the feces, which indicates that beryllium is poorly absorbed by the gastrointestinal tract.  Analysis of 
the excreta of rats exposed to 0.019 and 0.190 mg beryllium/kg/day as beryllium sulfate in the drinking 
water indicated that $99% of the dose was excreted in the feces and <0.5% was excreted in the urine 
(Reeves 1965). The excretion pattern of beryllium in the feces reached steady-state after 9 weeks (Reeves 
1965). Similarly, excretion of beryllium occurred mainly via the feces of rats exposed to 0.3, 2.8, and 
31 mg beryllium/kg/day as beryllium sulfate in the diet for 2 years (Morgareidge et al. 1975).  The feces 
contained 10.7 ppm and the urine 29.7 ppb of the 0.3 mg beryllium/kg/day dose, and a similar pattern was 
observed with the other doses. Rats, monkeys, mice, and dogs orally exposed to radioactive beryllium 
chloride excreted 98% of the dose via the feces (Furchner et al. 1973). 
3.4.4.3 Dermal Exposure 
No studies were located regarding excretion in humans or animals after dermal exposure to beryllium or 
its compounds. 
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.  
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 
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1987; Andersen and Krishnan 1994). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species. The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors.  
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations 
provides the predictions of tissue dose. Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) is 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). 
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species. 








































Chemicals in air 




Source: adapted from Krishnan et al. 1994 
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by 
inhalation, or by ingestion, metabolized in the liver, and excreted in the urine or by exhalation. 
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Figure 3-3. Conceptual Representation of a Physiologically Based
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No PBPK modeling studies were located for beryllium. 
3.5 MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms 
The absorption of inhaled beryllium depends on a number of factors, including physical and chemical 
properties of the particles (e.g., size, solubility) and the activity of alveolar macrophages.  Following 
deposition, beryllium is slowly cleared from the lung; clearance half-lives range from days to years in 
animals.  Beryllium clearance from the lungs is biphasic, the initial phase is rapid and involves clearance 
via the mucociliary escalator.  Approximately 30% of the total lung burden was cleared during the first 
phase with a half-life of 2.5 days (Rhoads and Sanders 1985).  The second phase is slower, involving 
translocation to the tracheobronchial lymph nodes, alveolar macrophage clearance, and solubilization. 
The half-life for this phase was 833 days (Rhoads and Sanders 1985).  Beryllium is poorly absorbed 
through the gastrointestinal tract; <1% of the dose is absorbed (Furchner et al. 1973; Reeves 1965).  It is 
also poorly absorbed through intact skin (Petzow and Zorn 1974; Williams et al. 1987). 
Absorbed beryllium is distributed throughout the body via blood, with the highest concentrations in the 
liver and skeleton (Finch et al. 1990; Furchner et al. 1973; Morgareidge et al. 1975; Stokinger et al. 
1950). Beryllium has been detected in breast milk (Krachler et al. 1999a), but the relationship between 
beryllium exposure and breast milk levels has not been established.  
The primary routes of elimination of absorbed beryllium is urine and feces.  In rats and dogs, whole body 
clearance of inhaled beryllium follows a single-phase exponential curve with a half-life of 300–400 days 
(Finch et al. 1990; Rhoads and Sanders 1985). 
3.5.2 Mechanisms of Toxicity 
The respiratory tract is the primary target of beryllium toxicity following inhalation exposure.  In humans, 
chronic beryllium disease and lung cancer are the principal effects observed.  In animals, the respiratory 
tract effects include emphysema, pneumonitis, and lung cancer.  Chronic beryllium disease begins as a 
sensitizing cell-mediated response to beryllium antigen that progresses to noncaseating granulomatous 
lung disease. Although the mechanism has not been fully elucidated, a number of recent studies using 
bronchoalveolar lavage (BAL) fluid from individuals with chronic beryllium disease provide information 
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on some of the components of the toxic sequence.  Beryllium, acting as a hapten, interacts with antigen 
presenting cells in the lungs (i.e., alveolar macrophages) resulting in a beryllium-peptide becoming 
physically associated with a major histocompatability (MHC) class II molecule (Newman 1996b; Saltini 
et al. 1989). The MHC class II-beryllium-peptide complex is recognized by the T lymphocyte receptor, 
with the help of CD4+ molecules.  This interaction triggers CD4+ T lymphocyte activation and 
proliferation. There is evidence to suggest that there is a selective expansion of certain CD4+ lymphocyte 
subsets. In a study by Fontenot et al. (1998), a number of individuals with chronic beryllium disease had 
an increase in the percentage of T cell receptor (TCR) variable β3 regions (Vβ3). Further work by this 
group showed that in four of five individuals with chronic beryllium disease, expansions within the 
Vβ3 region resulted in homologous or identical CDR3 amino acid sequences (Fontenot et al. 1999).  The 
expansion of the CDR3 motif appeared to be unique to chronic beryllium disease. 
The antigen-specific inflammatory response to beryllium is a cell-mediated process orchestrated by 
cytokines.  The results of several studies support the role of cytokines in chronic beryllium disease. 
Using alveolar macrophages present in BAL fluid from individuals with chronic beryllium disease, Bost 
et al. (1994) found elevated mRNA levels for tumor necrosis factor α (TNF-α) and interleukin 
(IL)-6 cytokines, as compared to levels in normal subjects.  Additionally, TNF-α levels in the BAL fluid 
were higher. Another study found that the addition of beryllium to a culture of BAL cells from chronic 
beryllium disease patients, resulted in increases in the TNF-α, IL-6, IL-2, and interferon-gamma (IFN-γ) 
(Tinkle et al. 1996). Although for many inflammatory diseases IL-10 inhibits antigen-induced T 
lymphocyte proliferation, it does not play a role in chronic beryllium disease (Tinkle et al. 1996a).  In 
chronic beryllium disease, as in other delayed-type hypersensitivity diseases, IL-2 plays an important role 
in the T lymphocyte proliferation and the regulation of IFN-γ (Tinkle et al. 1997). BAL cells from 
control subjects did not show any measurable spontaneous or beryllium sulfate-stimulated release of IL-2, 
α-sIL-2R (α subunit of the soluble IL-2 receptor), IL-4, or IFN-γ. Beryllium sulfate stimulation of BAL 
cells from chronic beryllium disease subjects resulted in the production of IL-2, α-sIL-2R, and IFN-γ, but 
not IL-4. In the absence of beryllium sulfate stimulation, the response was the same as in controls. 
Although IL-2 has a dose-dependent role in T lymphocyte proliferation, T lymphocyte proliferation is 
only partially dependent on it.  Beryllium sulfate stimulated T lymphocyte proliferation remained 
elevated in the presence of anti-IL-2 antibodies. INF-γ levels were also decreased in the presence of 
anti-IL-2 antibodies suggesting that it is also partially dependent on IL-2. 
There appears to be a genetic factor associated with susceptibility to chronic beryllium disease.  The 
MHC class II molecules play a critical role in the T lymphocyte proliferation and the development of 
BERYLLIUM 107 
3. HEALTH EFFECTS 
chronic beryllium disease; thus, MHC class II genes (human leukocyte antigen, HLA-DR, DQ, DP) 
probably play a role in susceptibility to the disease.  Analysis of the MHC class II genes shows a biased 
usage of the HLA-DPB1 gene alleles in individuals with chronic beryllium disease (Richeldi et al. 1993, 
1997; Wang et al. 1999). Genetic susceptibility to chronic beryllium disease is discussed in greater detail 
in Section 3.10. 
3.5.3 Animal-to-Human Extrapolations 
As reviewed in EPA (1998) and Finch et al. (1996), a number of animal models of human chronic 
beryllium disease have been developed, but none of the models to date mimic all aspects of the human 
disease. Numerous studies in dogs, monkeys, and rats have reported granulomatous inflammation in the 
lungs. However, the lung lesions do not histopathologically resemble chronic beryllium disease in 
humans, the effects are transient, or are not consistently associated with beryllium-specific immune 
responses. Recent studies in mice (Huang et al. 1992; Nikula et al. 1997) suggest that mice may be an 
appropriate model.  In the model developed by Huang et al. (1992), mice were preimmunized with 
beryllium sulfate and then administered a single intratracheal dose of beryllium sulfate.  A number of 
aspects of this model mimicked chronic beryllium disease, influx of CD4+ T lymphocytes in to the lungs, 
sensitization of T lymphocytes to beryllium, interstitial inflammation, and granuloma formation. 
However, these effects were observed at 8 months and were resolved by 10 months.  The study by Nikula 
et al. (1997), in which mice received a 90-minute nose-only exposure to beryllium metal, also found 
many similarities between effects observed in mice and human chronic beryllium disease.  The study 
authors concluded that this mouse model can be used to study the influence of dose, exposure pattern, and 
physicochemical form of beryllium on the development of chronic beryllium disease.  A comparison of 
the histologic characteristics of beryllium-induced disease in humans and mice is presented in Table 3-5. 
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS 
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
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Histologic findings Mice Humans 
Interstitial cellular infiltration of 
macrophages, lymphocytes, 
and variable numbers of plasma 
cells 
Mild to moderate Moderate to marked 
Granulomas Present; poorly formed Variable; absent to poorly 
formed to well formed 
Giant cells Numbers variable; may be 
scattered or associated with 
granulomas 
Numbers variable; may be 
scattered or associated with 
granulomas 
Cholesterol clefts Numerous and often seen within 
giant cells 
Numerous and often seen within 
giant cells 
Interstitial fibrosis Present in 75% of cases; 
minimal to mild 
Present in large percentage of 
cases; minimal to mild in 50% 
and moderate to marked in 50% 
Calcific inclusions Absent Present in approximately 55% 
of cases 
Hyalinzed nodules Absent Present in lung or hilar lymph 
nodes of 40% of cases 
Interstitial compact aggregates 
of lymphocytes 
Present Not described 
Beryllium Metal evident in H&E sections Increased tissue levels found by 
spectrographic and chemical 
analysis 
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terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Colborn and Clement (1992), was also used in 1996 when Congress mandated the 
Environmental Protection Agency (EPA) to develop a screening program for “...certain substances 
[which] may have an effect produced by a naturally occurring estrogen, or other such endocrine 
effect[s]...”.  To meet this mandate, EPA convened a panel called the Endocrine Disruptors Screening and 
Testing Advisory Committee (EDSTAC), which in 1998 completed its deliberations and made 
recommendations to EPA concerning endocrine disruptors.  In 1999, the National Academy of Sciences 
released a report that referred to these same types of chemicals as hormonally active agents. The 
terminology endocrine modulators has also been used to convey the fact that effects caused by such 
chemicals may not necessarily be adverse.  Many scientists agree that chemicals with the ability to disrupt 
or modulate the endocrine system are a potential threat to the health of humans, aquatic animals, and 
wildlife. However, others think that endocrine-active chemicals do not pose a significant health risk, 
particularly in view of the fact that hormone mimics exist in the natural environment.  Examples of 
natural hormone mimics are the isoflavinoid phytoestrogens (Adlercreutz 1995; Livingston 1978; Mayr et 
al. 1992). These chemicals are derived from plants and are similar in structure and action to endogenous 
estrogen. Although the public health significance and descriptive terminology of substances capable of 
affecting the endocrine system remains controversial, scientists agree that these chemicals may affect the 
synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body responsible 
for maintaining homeostasis, reproduction, development, and/or behavior (EPA 1997).  Stated differently, 
such compounds may cause toxicities that are mediated through the neuroendocrine axis.  As a result, 
these chemicals may play a role in altering, for example, metabolic, sexual, immune, and neurobehavioral 
function. Such chemicals are also thought to be involved in inducing breast, testicular, and prostate 
cancers, as well as endometriosis (Berger 1994; Giwercman et al. 1993; Hoel et al. 1992). 
There are no data to assess whether exposure to beryllium will adversely affect the endocrine system. 
3.7 CHILDREN’S SUSCEPTIBILITY 
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation. 
Relevant animal and in vitro models are also discussed. 
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Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure. Exposures of children are discussed in Section 6.6 Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964). The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948). 
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
 
BERYLLIUM 111 
3. HEALTH EFFECTS 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
Data on the toxicity of beryllium in children is limited to a case report of a child diagnosed with chronic 
beryllium disease (Eisenbud et al. 1948b).  The child lived near a beryllium manufacturing facility.  The 
only available studies on young animals are the beryllium carbonate dietary studies that found beryllium 
rickets in young rats (Guyatt et al. 1933; Jacobson 1933; Kay and Skill 1934).  The observed skeletal 
effects are not due to a direct effect of beryllium on the bone, but rather an interaction between beryllium 
carbonate and dietary phosphorus.  The potential of beryllium to induce developmental effects has not 
been adequately investigated.  A chronic study did not find developmental effects (gross and skeletal 
malformations, fetal survival, and fetal body weights were examined) in dogs exposed to beryllium 
sulfate in the diet (Morgareidge et al. 1976). However, intratracheal and intravenous exposure studies 
have found increases in fetal/neonatal mortality, internal abnormalities, and behavioral abnormalities in 
rat and mouse offsprings (Bencko et al. 1979; Mathur et al. 1987; Selivanova and Savinova 1986; Tsujii 
and Hoshishima 1979).  More details about these studies can be found in Chapter 2 and Section 3.2.2.6. 
No human or animal data were located that examined possible age-related differences in the 
toxicokinetics of beryllium.  There are no data on the toxicokinetic properties of beryllium in children or 
immature animals.  The results of a study by Krachler et al. (1999a) suggests that beryllium is transferred 
across the placenta and via maternal milk.  Beryllium levels in the umbilical cord sera and in colostrum 
were higher than maternal sera levels.  
Subsequent sections of this chapter (Sections 3.8, 3.10, and 3.11) discuss the available information on 
biomarkers, interactions, and methods for reducing toxic effects.  The available information is from adults 
and mature animals; no child-specific information was identified.  It is likely that this information will 
also be applicable to children. 
3.8 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
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substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to beryllium are discussed in Section 3.8.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by beryllium are discussed in Section 3.8.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic 
or other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in 
the biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10 “Populations That Are Unusually Susceptible”. 
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Beryllium 
There are several tests for measuring beryllium in biological fluids and tissues (Frame and Ford 1974; 
Foreman et al. 1970; Hurlburt 1978; IARC 1980; Martinsen and Thomassen 1986; Paschal and Bailey 
1986; Shan et al. 1989). These include measurement of beryllium levels in the blood and urine. 
Information regarding normal background levels of beryllium and tissue levels associated with exposure 
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levels are limited or unreliable.  Normal background levels of 1 ng beryllium/g (1 ppb) for blood (Stiefel 
et al. 1980; Zorn et al. 1986), 0.28–1 µg/L for urine (Paschal et al. 1998; Stiefel et al. 1980), and of 
0.02 µg beryllium/g (0.02 ppm) for lung tissue (Kanarak et al. 1973) have been reported.  Average 
beryllium levels in human tissues have been measured as follows:  0.21 ppm in lungs; 0.08 ppm in brain; 
0.07 ppm in both kidney and spleen; 0.04 in each of liver, muscle, and vertebrae; 0.03 ppm in heart; and 
0.02 in bone (Meehan and Smythe 1967).  However, it was not clear whether these organ samples were 
obtained at biopsy or autopsy or whether the subjects had been exposed occupationally or 
environmentally in the compilation by Meehan and Smythe (1967). 
Background urinary levels of beryllium were determined to be .1.0 µg beryllium /L  using flameless 
atomic absorption spectroscopy (Stiefel et al. 1980).  Beryllium levels in urine were analyzed in eight 
laboratory workers and compared to the levels of beryllium in the laboratory atmosphere for 30 days after 
an accidental leakage of beryllium chloride.  Figure 3-4 represents urinary levels versus atmospheric 
levels. The urinary levels appear to be directly proportional to atmospheric levels at #8 ng/m3. Based on 
serum levels of beryllium in workers accidentally exposed, the biological half-life was estimated to be 
2–8 weeks (Zorn et al. 1986). These are the only available data that associate airborne beryllium levels 
with urinary levels in humans.  A sampling of 500 urine samples collected during the NHANES III study, 
suggested that background levels of beryllium in the urine may be lower; the mean urinary level was 
0.28 µg beryllium/L (Paschal et al. 1998).  Nonetheless, urinary excretion of beryllium is irregular and 
not useful for diagnostic purposes (Reeves 1986). 
Biopsy tissue has been analyzed to determine beryllium concentrations in the body.  Lung tissue of two 
employees of a beryllium extraction and processing plant, where beryllium concentrations exceeded the 
recommended standards of 2 µg beryllium/m3 for an 8-hour day and 25 µg beryllium/m3 for a 30-minute 
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maximum level, contained 0.18 and 0.65 µg beryllium/g dry weight compared to the normal level of 
0.02 µg beryllium/g (Kanarek et al. 1973).  The subject with the higher beryllium level did not have lung 
lesions; however, the subject with the lower beryllium level had granulomas.  Thus, beryllium levels in 
lung biopsies indicate exposure to beryllium but may not confirm the presence of chronic beryllium 
disease. The presence of beryllium in lung tissue also will not indicate how recently the exposure 
occurred because the clearance of beryllium from the lungs depends upon the solubility of the beryllium 
compound (see Section 3.3.4.1).  Biomarkers of oral or dermal exposure to beryllium were not located, 
probably because very little beryllium is absorbed after exposure by these routes (see Section 3.4.1). 
3.8.2 Biomarkers Used to Characterize Effects Caused by Beryllium 
The lung is the most sensitive target organ of beryllium exposure.  As a consequence of long term 
exposure to beryllium, lung function decreases.  This decrease has been measured by spirometry, such as 
forced expiratory volume in 1 second, maximum breathing capacity, maximum mid-expiratory flow, and 
vital capacity (Andrews et al. 1969; Kriebel et al. 1988a, 1988b).  Blood gases such as carbon dioxide 
tension, oxygen tension, alveolar oxygen tension, alveolar carbon dioxide tension, and carbon monoxide 
diffusion capacity have also been analyzed. 
Radiographic examinations revealed opacities in the lung following chronic exposure to beryllium 
(Kanarek et al. 1973). X-rays have been used to determine three stages of chronic beryllium poisoning:  a 
fine diffuse granularity in the lungs, followed by a diffuse reticular pattern, followed by the appearance of 
distinct nodules. However, x-ray results cannot distinguish between chronic beryllium disease and 
sarcoidosis. A patch test using soluble beryllium salts was evaluated in 32 patients with known chronic 
beryllium disease (Curtis 1959).  The patch test was positive in all 32 patients and negative in 16 of 
18 patients with lung diseases other than chronic beryllium disease, indicating that the patch test may be 
useful in the diagnosis of chronic beryllium disease.  However, the patch test using soluble beryllium 
compounds itself may be sensitizing and may exacerbate the condition in patients with chronic beryllium 
disease (Cotes et al. 1983; Epstein 1983; Stoeckle et al. 1969; Tepper 1972). Therefore, this method is 
not recommended as a diagnostic tool.  Analysis of secretions and cells of the lower respiratory tract 
obtained by bronchoalveolar lavage is useful for detecting granulomatous lung disease; however, it alone 
cannot distinguish chronic beryllium disease from sarcoidosis (James and Williams 1985).  The presence 
of beryllium in the bronchoalveolar fluid, however, would aid the diagnosis. 
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Because chronic beryllium disease is caused by an immune reaction to beryllium, several tests have been 
developed to assess beryllium hypersensitivity.  The most commonly used test is the beryllium 
lymphocyte proliferation test (BeLPT).  This test, originally referred to as the lymphocyte blast 
transformation test (LTT or LBTT), measures cell proliferation via thymidine incorporation in cultured 
cells in the presence or absence of beryllium salts.  Both peripheral blood cells and bronchioalveolar 
lavage cells can be used in the BeLPT. In early studies, abnormal blood BeLPT results were found in 
100% of the subjects with chronic beryllium disease (Williams and Williams 1982, 1983), normal results 
in all individuals who were suspected of having chronic beryllium disease (Williams and Williams 1983), 
and abnormal results in approximately 2% of the healthy beryllium workers (Williams and Williams 
1983). Despite these results, the blood BeLPT test was not widely used because it was very difficult to 
perform and not very reproducible.  Refinement of the test methodology resulted in a more reproducible 
test that could be used as a screening tool (Newman 1996a).  A number of large-scale screening studies 
have utilized this test for identifying beryllium sensitized workers (Kreiss et al. 1993a, 1996, 1997; 
Newman et al. 2001; Stange et al. 2001).  In these studies, the majority (53–86%) of the workers with 
consistently abnormal blood BeLPT results were also diagnosed as having chronic beryllium disease. 
Using the blood BeLPT to screen workers for beryllium sensitization and chronic beryllium disease is not 
foolproof; Kreiss et al. (1993a, 1996) found a small percentage of workers with chronic beryllium disease 
and normal or inconsistent blood BeLPT results.  Deubner et al. (2001a) assessed the predictive value of 
the blood BeLPT as a screening tool for chronic beryllium disease among 129 beryllium workers.  The 
incidences of chronic beryllium disease among workers with a single unconfirmed abnormal blood 
BeLPT result, workers with confirmed abnormal blood BeLPT results, and workers with first-time double 
abnormal blood BeLPT results were 7/19 (37%), 34/75 (45%), and 17/35 (49%), respectively.  One 
limitation of the blood BeLPT is high inter- and intra-laboratory variability.  Using split blood samples, 
Stange et al. (1996b) found an 85–96% agreement rate among three laboratories; however, the agreement 
rate was only 21–33% for positive blood BeLPT results.  Similarly, Deubner et al. (2001a) found poor to 
moderate agreement in blood BeLPT results among three laboratories. 
3.9 INTERACTIONS WITH OTHER CHEMICALS 
Mortality rates were lower if rats exposed to 2.59 mg beryllium/m3 as beryllium sulfate were injected 
daily with ferric ammonium citrate beginning 4 days prior to beryllium exposure (Sendelbach and 
Witschi 1987a). The protective action of ferric ammonium citrate may be related to the ability of 
beryllium to form a complex with citrate (Reeves 1986).  In addition, the protective action of iron on 
beryllium toxicity may be related to the ability of iron to increase ferritin synthesis, making more ferritin 
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available to bind with beryllium (Lindenschmidt et al. 1986).  Ferritin chelates with beryllium to protect 
against the inhibition of phosphoglucomutase (Joshi et al. 1984). 
Ingested soluble beryllium compounds may interact with phosphate to form insoluble beryllium 
phosphate particles that are sequestered in Kupffer cells of the liver (Tepper 1972).  Diffusion of 
beryllium from the deposited particulates may cause damage to these cells and necrosis of the liver.  
Intravenous injection of rats or mice with the ammonium salt of aurine tricarboxylic acid increased the 
survival of both species that were injected intravenously with lethal doses of beryllium sulfate (White et 
al. 1951). The protective effect was observed when the aurine tricarboxylic acid was administered from 
1 hour before to 8 hours after injection of beryllium sulfate.  The protective effect was attributed to the 
ability of aurine tricarboxylic acid to complex with the beryllium ion, thereby reducing the amount of 
beryllium ion available to induce tissue injury. 
Co-exposure of Chinese hamster ovary cells to beryllium sulfate and x-rays resulted in an increased rate 
of chromatid-type exchanges compared to the rates resulting from exposure to beryllium sulfate or x-rays 
alone (Brooks et al. 1989). The increase was multiplicative rather than additive.  Experiments on cell 
cycle kinetics suggested that the multiplicative interaction occurs only in cells in the S and G2 stages. 
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to beryllium than will most persons 
exposed to the same level of beryllium in the environment.  Reasons may include genetic makeup, age, 
health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These 
parameters result in reduced detoxification or excretion of beryllium, or compromised function of organs 
affected by beryllium.  Populations who are at greater risk due to their unusually high exposure to 
beryllium are discussed in Section 6.7, Populations With Potentially High Exposures. 
There are strong data to suggest that there is genetic susceptibility factor that may predispose certain 
individuals to development of chronic beryllium disease.  A human leukocyte antigen (HLA) class II 
marker has been strongly associated with chronic beryllium disease.  Studies conducted by Fontenot et al. 
(2000) and Lombardi et al. (2001) suggest that the HLA-DP allele, in particular alleles with HLA-DP 
containing Glu at DP69, are involved in the presentation of beryllium to CD4+ T cells, which are involved 
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allelic variants of the HLA-DP gene coding for a glutamate in position 69 of HLA-DPB1 chain
 
(HLA-DPB1 Glu69) among individuals with chronic beryllium disease than in beryllium-exposed
 
individuals without the disease. The HLA-DPB1 Glu69 DNA marker was found in 5 of 6 beryllium
 
workers with chronic beryllium disease, 0 of 2 beryllium-sensitized individuals without disease and 36 of
 
119 (30%) unsensitized beryllium-exposed individuals (Richeldi et al. 1997).
 
Further analysis by Wang et al. (1999) found the Glu69 marker on the HLA-DBP1 gene was not very
 
predictive of chronic beryllium disease (predictive value of 0.36).  However, the presence of the relatively
 
rare HLA-DP allele, HLA-non*0201 DPB1 Glu69, had a predictive value of 0.57. Wang et al. (1999) also
 
found a higher percentage of homozygous Glu69 carriers in the chronic beryllium disease group as
 
compared to controls.  The study authors estimated that carriers of the Glu69/Glu69 markers or
 
non-*0201Glu69 allele accounted for 85% of the chronic beryllium disease cases and only 16% of
 
unaffected beryllium-exposed individuals.  Additional studies by this group found that most beryllium
 
sensitized individuals without chronic beryllium disease also carried rare HLA-non*0201 Glu69
 
DPB1 alleles (Wang et al. 2001).
 
Stubbs et al. (1996) also found allelic differences in the DR isotype of class II HLAs.  The
 
HLA-DRB1 alleles associated with beryllium sensitization were *0103, *09, *1302, *0403, and *0302. 

It is likely that chronic beryllium disease is a multigenetic disease with a number of genetic factors
 
contributing to the development of an immune response to beryllium.

A case control study by Maier et al. (1999) was designed to assess whether polymorphisms in the
 
angiotensin converting enzyme (ACE) were associated with chronic beryllium disease and chronic
 
beryllium disease severity.  No statistically significant associations between ACE genotype and chronic
 
beryllium disease were found in the comparisons of individuals with chronic beryllium disease to
 
beryllium-exposed controls or nonberyllium exposed controls. 

Animal data support the human data that genetically determined cellular immune mechanisms may be
 
involved in chronic beryllium disease, as indicated by studies in different strains of guinea pigs and mice. 

Intratracheal instillation of beryllium oxide (calcined at 560 EC) resulted in the development of
 
granulomatous lung disease in outbred Hartley and in strain 2 guinea pigs, but not in strain 13 guinea pigs
 
(Barna et al. 1981; 1984). Granulomatous lung disease also was produced in the F1 offspring of mated
 
strain 2 and strain 13 guinea pigs, but the severity was milder in the hybrid strain than in the strain
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to beryllium oxide were challenged by dermally applied beryllium sulfate, the strain 2 and the F1 guinea 
pigs showed positive skin tests for delayed-type hypersensitivity, while strain 13 guinea pigs did not. 
Granulomatous lung disease was also induced in strain A/J (H-2a haplotype) mice, but not in BALB/c 
(H-2d haplotype) or C57BL/6 (H-2b haplotype) mice, after intratracheal injection of beryllium sulfate, 
suggesting that genetic differences at the H-2 major histocompatibility gene complex may account for the 
differential responses to beryllium sulfate in mice (Huang et al. 1992).  These results suggest that 
genetically determined factors may make some humans more susceptible to chronic beryllium disease. 
Animal data indicate that females may be more susceptible than males to the effects of beryllium.  Female 
rats exposed to 0.034 mg beryllium/m3 as beryllium sulfate for 72 weeks had higher mortality rates and 
more severe weight loss than males (Reeves et al. 1967).  Female rats exposed to #31 mg 
beryllium/kg/day as beryllium sulfate in the diet for 2 years developed a transient glucosuria; renal effects 
were not observed in males (Morgareidge et al. 1975).  The distribution of beryllium in body tissue in 
female (bred and nonbred) and male rats exposed intratracheally to 0.6 mg beryllium/kg as radioactive 
beryllium oxide revealed the highest concentrations (other than in the lung) in the liver of female rats and 
in the kidney of male rats (Clary et al. 1975).  This corroborates the findings of Clary et al. (1972) which 
suggest that translocation of beryllium from bone to liver eventually causes a systemic disease 
characterized by weight loss and liver necrosis.  The study involves intratracheal exposure of guinea pigs 
and mice to radioactive beryllium oxide after hormone biosynthesis is inhibited by metyrapone injection. 
The results indicate that altered adrenal hormone synthesis shifts beryllium concentrations from bone to 
liver, causing weight loss. Therefore, any adverse effect on the adrenal gland may profoundly affect the 
course of beryllium disease, and a combination of adrenal dysfunction and compromised liver function 
could exacerbate beryllium disease.  Therefore, people with lowered adrenal and/or liver functionality 
may be unusually susceptible to the effects of beryllium. 
3.11 METHODS FOR REDUCING TOXIC EFFECTS 
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to beryllium.  However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to beryllium.  When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
for medical advice.  The following texts provide specific information about treatment following exposures 
to beryllium: 
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Ellenhorn MJ, Schonwald S, Ordog G, et al., eds. 1997. Ellenhorn’s Medical Toxicology:  Diagnosis 
and Treatment of Human Poisoning.  Second Edition.  Baltimore, MD: Williams & Wilkins, 1546-1548. 
Haddad LM, Shannon MW, Winchester JF, eds. 1998.  Clinical Management of Poisoning and Drug 
Overdose. Third Edition. Philadelphia, PA: WB Saunders, 792. 
3.11.1 Reducing Peak Absorption Following Exposure 
Human exposure to beryllium and its compounds occurs by inhalation, ingestion, or dermal contact.  The 
inhalation route is of greatest concern for systemic effects because beryllium and its compounds are 
poorly absorbed after ingestion and dermal contact.  General recommendations for reducing absorption of 
beryllium following acute exposure have included removing the individual from the contaminated area 
and removing contaminated clothing.  Although beryllium is poorly absorbed from the gastrointestinal 
tract, administration of milk or water has been suggested to reduce the possibility of stomach irritation 
(HSDB 2000). Chronic granulomas observed following dermal exposure are surgically removed (HSDB 
2000). Thorough washing of the skin or eyes is indicated in the case of dermal or ocular exposure, 
especially to irritating beryllium compounds, such as beryllium fluoride. 
3.11.2 Reducing Body Burden 
Beryllium is widely but slowly distributed following inhalation exposure.  The highest concentration of 
beryllium was found in bone (13.5%) of rats following 3 hours of exposure to beryllium sulfate or 
beryllium chloride (Zorn et al. 1977).  The percentage of beryllium in the bone was still high (6.8%) 
compared with other tissues following 408 hours of exposure.  After inhalation exposure, beryllium that is 
not absorbed into the bloodstream is retained in the lung (see Section 3.4.4.1).  Insoluble beryllium 
compounds, such as beryllium oxide, are retained in the lungs longer than soluble compounds and are 
associated with chronic beryllium disease.  Although beryllium compounds are poorly absorbed from the 
gastrointestinal tract (see Section 3.4.1.2), the portion that is absorbed appears to preferentially 
accumulate in bone (Furchner et al. 1973; Morgareidge et al. 1975; Reeves 1965).  In addition, relatively 
high levels of beryllium accumulated in the spleen and liver of rats after intravenous injection of 
beryllium sulfate (Lindenschmidt et al. 1986). 
A series of studies by Mathur and associates have examined the effectiveness of several agents in 
reducing beryllium body burden following parenteral exposure (no additional information on exposure 
route was provided). Decreases in blood, liver, kidney, and/or spleen beryllium levels were observed in 
rats administered a single or repeated doses of beryllium followed by a 2- to 10-day exposure to Liv-52, 
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an alternative medicine (Mathur et al. 1994) or 5 days of N-(2-hydroxyethyl)ethylene diamine triacetic 
acid (HEDTA) (Mathur et al. 1993), calcium disodium ethylenediamine tetraacetic acid (CaNa-EDTA) 
(Mathur et al. 1993), 4,5-dihydroxy-1,3-benzene disulfonic acid (tiron) (Shukula et al. 1998) 
meso-2,3-dimercaptosuccinic acid (DMSA) (Flora et al. 1995), or 2,3-dimercaptopropane 1-sulfonate 
(DMPS) (Flora et al. 1995), but not after calcium trisodium diethylene triamine pentaacetic acid 
(CaNA-DTPA) (Mathur et al. 1993) or succinic acid (Shukula et al. 1998). For absorbed beryllium, 
administration of chelating agents such as aurine tricarboxylic acid increases the urinary excretion of 
beryllium in animals (Venugopal and Luckey 1978).  However, metal chelating agents available for use in 
human clinical medicine have not been shown to be effective in reducing the toxicity of beryllium (Hall 
and Rumack 1992).  Since chronic berylliosis is associated with the retention of unabsorbed beryllium 
compounds in the lungs, enhancing the clearance of beryllium from the lungs, perhaps by 
bronchoalveolar lavage, might prevent or reduce the severity of chronic beryllium disease.  However, at 
this time there are no established methods for reducing the lung burden. 
3.11.3 Interfering with the Mechanism of Action for Toxic Effects 
As discussed in Section 3.9, pretreatment of rats with ferric ammonium citrate reduces mortality rates 
following inhalation exposure to beryllium (Sendelbach and Witschi 1978a).  This protective effect has 
been attributed to sequestering of beryllium either through formation of a beryllium-citrate complex 
(Reeves 1986), or by induced ferritin (Lindenschmidt et al. 1986).  Aurine tricarboxylic acid may reduce 
mortality by a similar mechanism (White et al. 1951).  Neither of these treatments has undergone clinical 
trial in humans. 
Parenteral administration of beryllium nitrate results in decreased hemoglobin, blood glucose, and serum 
protein levels, decreased serum alkaline phosphatase levels, increased serum transaminase activities, and 
degeneration and necrosis in the liver, kidney, and spleen.  Administration of Liv-52, HEDTA, 
CaNa-EDTA, tiron or DMPS resulted in an improvement of these effects (Flora et al. 1995; Mathur et al. 
1993, 1994; Shukula et al. 1998). The effectiveness of these treatments at lower body burdens or in 
humans is not known.  As discussed in Section 3.2.1.2, the respiratory tract can be severely affected by 
inhalation of dust containing beryllium compounds.  Inhalation exposure to high concentrations of soluble 
beryllium compounds may lead to acute chemical pneumonitis.  Prolonged inhalation of low 
concentrations of less soluble forms are more often associated with chronic beryllium disease.  Chronic 
beryllium disease may involve the induction of hyperplasia and hypertrophy of histiocytes (Policard 
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(Price and Skilleter 1985, 1986). Hypersensitivity may be due to the formation of a beryllium-protein 
complex that is antigenic.  Beryllium stimulates a population of CD4+ T cells, and this reaction can be 
blocked by antibodies to HLA Class II molecules and by antibodies to the IL-2 receptor (Saltini et al. 
1989). In some cases, the manifestations of chronic beryllium disease may be reversed by corticosteroid 
therapy (Aronchick et al. 1987; Finkel 1983; Hardy and Stoeckle 1959).  Although corticosteroids are 
used to control the clinical manifestations of chronic beryllium disease and to prevent further progression 
of the disease, steroid therapy is not without its own risks. 
Ingested soluble beryllium compounds may interact with phosphate to form insoluble beryllium 
phosphate particles that are sequestered in Kupffer cells of the liver (Tepper 1972).  Diffusion of 
beryllium from the deposited particulates may cause damage to these cells and necrosis of the liver. 
Beryllium may also be taken up by lysosomes and cause release of lysomal enzymes, and beryllium may 
interfere with DNA synthesis in the nucleus. 
It has been established that beryllium inhibits DNA synthesis (Witschi 1968, 1970).  Magnesium failed to 
influence the inhibitory effect of beryllium, although it had been shown that magnesium partly neutralizes 
the toxic effects of beryllium on fibroblasts or yeast cells (Lieben et al. 1964; Wainer 1972). 
Because of the variety of effects noted for beryllium and possible mechanisms of action for those effects, 
it is difficult to speculate regarding therapies that will interfere with specific mechanisms of action such 
that net toxic effects are reduced. Given the variety of effects possible for absorbed beryllium, the most 
effective strategy for reducing toxic effects may be to reduce the amount of free beryllium ion through 
sequestering or complexing reactions as discussed in Section 3.11.2. 
3.12 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of beryllium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of beryllium. 
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The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
3.12.1 Existing Information on Health Effects of Beryllium 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
beryllium are summarized in Figure 3-5.  The purpose of this figure is to illustrate the existing 
information concerning the health effects of beryllium.  Each dot in the figure indicates that one or more 
studies provide information associated with that particular effect.  The dot does not necessarily imply 
anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need”. A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature. 
Studies regarding adverse health effects in humans after exposure to beryllium or its compounds are 
limited (Figure 3-5).  No studies were located regarding neurological, developmental, reproductive, or 
genotoxic effects in humans following inhalation exposure to beryllium or its compounds.  Studies 
regarding death were limited to chronic inhalation exposure.  An accidental leakage of beryllium did not 
cause respiratory, hepatic, or immunological effects.  Most of the human data concerns respiratory effects 
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Figure 3-5. Existing Information on Health Effects of Beryllium 
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and lung cancer as a result of occupational exposure to beryllium or its compounds.  Immunological data 
indicate that beryllium induces a T-cell lymphocyte-mediated immune response in the lung and skin.  No 
studies were located regarding any effects in humans following oral exposure to beryllium.  Since 
beryllium is poorly absorbed through the gastrointestinal wall, effects from this route of exposure are 
unlikely.  For dermal exposure, only skin effects (ulcerations) were reported. 
The database for animals is more complete.  LC50 values have been reported for a number of beryllium 
compounds.  Systemic effects of acute, intermediate, and chronic exposure via inhalation include 
respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ 
ocular effects. Immunological and carcinogenic effects were observed in various species after inhalation 
exposure to beryllium.  No studies were located regarding neurological, developmental, reproductive, or 
genotoxic effects in animals after inhalation exposure to beryllium or its compounds.  Oral LD50 values 
were reported for many of the beryllium compounds.  No other oral exposure studies were located 
regarding acute effects in animals exposed to beryllium or its compounds.  Immunological, neurological, 
reproductive, genotoxic, and carcinogenic effects due to ingestion of beryllium are reported in the 
available literature. 
No dermal studies were located regarding death, neurological, developmental, reproductive, genotoxic, or 
carcinogenic effects in animals.  Acute dermal studies report dermatological effects of beryllium on 
sensitized animals.  Since beryllium is a T-cell activator, exposure can cause immunological effects on the 
skin. 
3.12.2 Identification of Data Needs 
Acute-Duration Exposure. The lung is the main target organ of inhaled beryllium and its 
compounds in humans (Eisenbud et al. 1948a; Van Ordstrand et al. 1945) and animals (Haley et al. 1989; 
Hart et al. 1984; Robinson et al. 1968; Sanders et al. 1975; Schepers 1964; Sendebach and Witschi 1987b; 
Sendebach et al. 1980, 1989); however, the heart, liver, kidney, adrenal (Schepers 1965), skin (Stiefel et 
al. 1980), and the hematopoietic tissue (Hall et al. 1950) in animals have also been identified as target 
organs of beryllium exposure.  The effects of occupational exposure to beryllium or its compounds 
include acute pneumonitis as a result of inhalation exposure to more soluble beryllium compounds or 
chronic beryllium disease as a result of inhalation of soluble and less soluble beryllium compounds (e.g., 
beryllium oxide) (Cullen et al. 1987; Eisenbud and Lisson 1983; Eisenbud et al. 1948a; Rossman et al. 
1988). Because an animal model that mimics all aspects of chronic beryllium disease has not been 
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identified, it is inappropriate to use animal data to derive an acute-duration inhalation MRL.  No human 
acute-duration studies were identified; thus, an acute-duration inhalation MRL was not identified.  No 
data were located regarding effects in humans after acute oral exposure to beryllium.  No acute oral MRL 
can be derived because the only acute oral data in animals involves lethality (Ashby et al. 1990; 
Kimmerie 1966; Lanchow University 1978; Venugopal and Luckey 1977).  The target organs of acute 
oral exposure of animals to low levels of beryllium are not known, but beryllium compounds are poorly 
absorbed from the gastrointestinal tract (Furchner et al. 1973; Le Fevre and Joel 1986; Morgareidge et al. 
1975; Reeves 1965). In humans and animals sensitized to beryllium, contact with beryllium and its 
soluble and insoluble compounds can cause dermatitis and skin granulomas (Belman 1969; Curtis 1951; 
Marx and Burrell 1973; Williams et al. 1987).  In general, the more soluble the compound the greater the 
sensitizing potential. Dermal effects usually occur on abraded skin.  Dermal absorption of beryllium is 
assumed to be poor and would not likely cause further systemic effects.  Dermal studies would be helpful 
to determine the amount and duration of exposure necessary for human sensitization.  Additional human 
exposure studies that examine the potential of beryllium to cause beryllium sensitization and chronic 
beryllium disease after a <2 weeks of exposure would be useful for establishing an acute-duration 
inhalation MRL. The information regarding beryllium toxicity is useful to the general population and to 
populations residing at or near hazardous waste sites, who might be subject to acute exposure. 
Intermediate-Duration Exposure. No studies were located regarding effects in humans after 
intermediate-duration inhalation exposure to beryllium or its compounds.  The available occupational 
exposure studies provide sufficient evidence that beryllium sensitization and chronic beryllium disease 
would be the most sensitive end points following intermediate-duration inhalation exposure to beryllium; 
however, no intermediate-duration studies were identified.  Several studies indicate that the lung is the 
main target organ in animals for intermediate exposure to soluble and insoluble beryllium compounds via 
inhalation (Hall et al. 1950; Schepers 1964; Schepers et al. 1957; Stokinger et al. 1950; Wagner et al. 
1969). Other target organs in animals include the heart, liver, kidney, skin, and hematopoietic tissue (Hall 
et al. 1950; Stiefel et al. 1980; Stokinger et al. 1950).  Derivation of an intermediate-duration inhalation 
MRL is precluded because there are no human intermediate-duration studies and an animal model that 
mimics all aspects of chronic beryllium disease has not been identified, thus making it inappropriate to 
derive an MRL from animal data.  There are limited data on the toxicity of ingested beryllium following 
intermediate-duration exposure.  The available animal data suggest that rickets is a critical end point 
following ingestion of beryllium carbonate (Guyatt et al. 1933; Jacobson 1933; Kay and Skill 1934).  The 
rickets do not appear to be due to a direct effect of beryllium on the bone.  Rather, the rickets are due to a 
phosphorus deficiency, which results from the binding of beryllium to dietary phosphorus in the gut. 
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Thus, the available data are insufficient for derivation of an intermediate-duration oral MRL.  Additional 
studies involving exposure to low concentrations of several beryllium compounds would be useful for 
identifying critical targets of toxicity and establishing dose-response relationships.  According to one 
study, guinea pigs were sensitized to beryllium via intradermal administration of beryllium compounds, 
with the sensitizing potential increasing with increasing solubility (Marx and Burrell 1973). 
Chronic-Duration Exposure and Cancer. Health effects in humans and animals after chronic 
exposure to beryllium and its compounds are reported in the available literature.  The lung is the main 
target organ in human (Andrews et al. 1969; Cullen et al. 1987; Eisenbud and Lisson 1983; Hardy and 
Tabershaw 1946; Kreiss et al. 1993a, 1996, 1997; Rossman et al. 1988; Stange et al. 1996b) and animals 
(Reeves et al. 1967; Vorwald and Reeves 1959; Wagner et al. 1969) after inhalation exposure to 
beryllium and its compounds.  Occupational exposure to soluble and insoluble beryllium compounds 
caused delayed granulomatous disease of the lung, known as chronic beryllium disease or berylliosis 
(Cotes et al. 1983; Cullen et al. 1987; Eisenbud and Lisson 1983; Eisenbud et al. 1949; Kreiss et al. 
1993a, 1996, 1997; Stange et al. 1996b). Acute lung inflammation was also observed after occupational 
exposure to soluble beryllium compounds (Eisenbud et al. 1948a).  These serious respiratory effects in 
humans were found even at the lowest occupational exposure concentrations, which were lower than 
concentrations used in chronic inhalation experiments in animals.  Therefore, NOAELs for respiratory 
effects due to occupational exposure or chronic inhalation exposure in animals have not been determined. 
An environmental exposure study did identify a NOAEL for chronic beryllium disease (Eisenbud et al. 
1949); however, technology available at the time of the study did not allow for the detection of beryllium 
sensitization or subclinical chronic beryllium disease and it is not known if the identified NOAEL would 
be protective for these effects. Hence, derivation of a chronic inhalation MRL is precluded.  Data were 
not located regarding effects in humans after chronic oral exposure to beryllium.  The results of a chronic 
dog study suggests that the gastrointestinal tract is a target of beryllium sulfate toxicity (Morgareidge et 
al. 1976). This study is the basis for a chronic-duration oral MRL for beryllium.  The MRL was derived 
using a benchmark dose approach and the dose-response data for small intestinal lesions in dogs 
(Morgareidge et al. 1976). Data regarding the effects of chronic dermal exposure to beryllium were 
limited to findings of dermatitis in occupationally exposed individuals (Curtis 1951; Van Ordstrand et al. 
1946; Williams et al. 1987).  Studies regarding inhalation and dermal exposure to low concentrations of 
beryllium for chronic durations would be useful for determining the respective NOAELs for respiratory 
and dermal effects.  Studies in dogs exposed to beryllium oxide by inhalation (Finch et al. 1990) and in 
guinea pigs (Barna et al. 1981, 1984) and in mice (Huang et al. 1992) exposed to beryllium oxide 
intratracheally have been performed to identify an appropriate model to elucidate the pathogenesis of 
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chronic beryllium disease in humans.  However, an animal model that exactly mimics chronic beryllium 
disease in humans has not been found.  Further inhalation studies conducted in several species of animals 
designed to identify the most appropriate animal model that mimics chronic beryllium disease in humans 
would be useful to for determining mechanisms for induction and treatment of chronic beryllium disease. 
This work is in progress (see Section 3.12.3). This information would be useful to the general population 
and to populations residing at or near hazardous waste sites. 
Data regarding occupational exposure to beryllium and its compounds appear to indicate an increased 
incidence of lung cancer (Infante et al. 1980; Mancuso 1970, 1979, 1980; Sanderson et al. 2001a; 
Steenland and Ward 1992; Wagoner et al. 1980; Ward et al. 1992).  However, the quality of some of these 
studies has been severely criticized (EPA 1987).  Animal studies indicate increases in lung cancer due to 
inhalation exposure to beryllium or its soluble and insoluble compounds (Nickell-Brady et al. 1994; 
Reeves et al. 1967; Vorwald 1968; Vorwald and Reeves 1959; Wagner et al. 1969), but these studies are 
also flawed. Nevertheless, these data and studies conducted by intratracheal, intravenous, and 
intramedullary routes taken as a whole support the carcinogenic potential of beryllium, and inhaled 
beryllium is considered a human carcinogen (IARC 2001; NTP1999, 2002); EPA considers beryllium to 
be a probable human carcinogen (IRIS 2002).  A well-conducted chronic inhalation study in rats and mice 
using several exposure levels would add confidence to the database and eliminate uncertainties due to the 
flaws in the existing studies. Beryllium has not been found to cause cancer in animals after oral exposure 
(Morgareidge et al. 1975, 1976; Schroeder and Mitchener 1975a, 1975b); although, as previously noted, 
these studies may not have been adequate to assess carcinogenic potential.  Beryllium and its compounds 
are poorly absorbed from the gastrointestinal tract.  Therefore, conducting oral studies at doses high 
enough to affect plausible target organs would be difficult. 
Genotoxicity. Genotoxicity data regarding exposure to beryllium or its compounds are contradictory.
Forward and reverse mutation bacterial assays yielded both positive (Kanematsu et al. 1980; Ulitzur and 
Barak 1988) and negative (Arlauskas et al. 1985; Ashby et al. 1990; Rosenkranz and Poirier 1979; 
Simmon et al. 1979) results for the same compounds.  The results are also contradictory for chromosomal 
aberrations induced by beryllium in mammalian cell cultures (Ashby et al. 1990; Brooks et al. 1989; Hsie 
et al. 1979; Larramendy et al. 1981; Miyaki et al. 1979; Williams et al. 1989).  Studies to examine the 
mechanism of mutagenic activity of beryllium would be useful.  Studies regarding the genotoxic potential 
of beryllium in occupationally exposed workers also would be useful, especially if exposure levels were 
related to genotoxic effects. In addition, studies regarding the in vivo genotoxic potential of beryllium in 
animals, particularly by the inhalation route, would be helpful. 
    
    
 
    
BERYLLIUM 129 
3. HEALTH EFFECTS 
Reproductive Toxicity. No studies were located regarding reproductive toxicity in humans after 
inhalation, oral, or dermal exposure to beryllium or its compounds.  A chronic duration study that allowed 
continuous mating did not find any adverse reproductive effects in dogs exposed to beryllium sulfate in 
the diet (Morgareidge et al. 1976). A study involving histological examination of rats exposed to 
beryllium sulfate in drinking water for 2 years reported no alterations of the reproductive organs 
(Morgareidge et al. 1975); beryllium compounds are not well absorbed by the gastrointestinal tract. 
Another study involving intratracheal injection of beryllium oxide in rats reported no effects on 
reproductive function (Clary et al. 1975).  Additional inhalation studies should examine reproductive 
organs in order to determine whether the potential for reproductive effects due to beryllium exposure 
exists. 
Developmental Toxicity. No studies were located regarding developmental toxicity in humans after 
inhalation, oral, or dermal exposure to beryllium or its compounds.  No developmental effects were 
observed in the offspring of dogs chronically exposed to beryllium sulfate in the diet (Morgareidge et al. 
1976); although the usefulness of this study in establishing the potential developmental toxicity of 
ingested beryllium is limited by the nonconventional study design.  No inhalation or dermal exposure 
studies examining developmental toxicity in animals were identified.  Rats injected intravenously with 
beryllium nitrate during gestation delivered pups that died soon after birth (Mathur et al. 1987).  Increased 
fetal mortality and fetal weight and increased abnormalities were observed after pregnant rats were 
injected intratracheally with beryllium oxide or beryllium chloride (Selivanova and Savinova 1986). 
Other studies in which beryllium salts were injected into pregnant mice indicated that beryllium can 
penetrate the placenta and reach the fetus and cause behavioral abnormalities in the offspring (Bencko et 
al. 1979; Tsujii and Hoshishima 1979).  Additional animal studies would be useful to determine if 
developmental effects may occur after inhalation or oral exposure to beryllium. 
Immunotoxicity. While beryllium has not been shown to be toxic to the immune system, beryllium 
and the soluble and insoluble compounds can be sensitizing and induce a cell-mediated immune response 
to beryllium (Cullen et al. 1987; Johnson 1983; Rossman et al. 1988; Saltini et al. 1989).  This heightened 
immune response to beryllium is the cause of chronic beryllium disease and certain skin lesions (Williams 
et al. 1987). Granuloma formation and dermatitis are the principal immunological effects caused by 
exposure to beryllium.  Although beryllium is not well absorbed by the gastrointestinal tract, studies 
evaluating the immunological effects of beryllium exposure to the associated lymphoid tissue would be 
useful to determine the local immunological reaction.  Intermediate-duration studies designed to 
characterize the effects on the immune system would be helpful.  The elucidation of the molecular 
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mechanisms of the immune response to beryllium and the identification of the specific T-cell families that 
are reactive to beryllium would aid in the identification and treatment of patients with chronic beryllium 
disease. In addition, identification of potential differences in allelic phenotypes between people with 
chronic beryllium and people exposed to beryllium but without chronic beryllium disease might help 
identify potentially susceptible populations based on genetic differences. 
Neurotoxicity. No studies were located regarding neurotoxicity in humans after inhalation, oral, or 
dermal exposure to beryllium or its compounds.  Histological examination of rats and dogs chronically 
exposed to beryllium sulfate in drinking water did not reveal any abnormalities in nerve tissues 
(Morgareidge et al. 1975, 1976). Beryllium is not well absorbed by the gastrointestinal tract or after 
dermal exposure; therefore, neurological effects are not expected to occur as a result of oral or dermal 
exposure. Inhalation studies involving low-level exposure to beryllium would be useful for determining 
its neurotoxicity. 
Epidemiological and Human Dosimetry Studies. The general population is exposed to 
beryllium through contaminated air, water, and food.  The highest exposure levels are incurred by 
workers in beryllium ore processing, manufacturing, or fabricating plants (Eisenbud and Lisson 1983). 
Few studies correlate beryllium exposure with effects on the respiratory system.  Epidemiology data have 
been criticized for using inappropriate cohorts and including nonexposed workers.  Studies that correlate 
occupational exposure to beryllium with cancer and other health effects would be useful and would offset 
the limitations of the now available studies. 
Biomarkers of Exposure and Effect. There are several tests for detecting beryllium in biological 
fluids and tissues (Frame and Ford 1974; Foreman et al. 1970; Hurlburt 1978; IARC 1980; Martinsen and 
Thomassen 1986; Paschal and Bailey 1986; Shan et al. 1989).  Increased levels of beryllium in urine and 
blood indicate exposure (Stiefel et al. 1980; Zorn et al. 1986). Beryllium has also been measured in 
granulomas in the lung tissue of individuals with chronic beryllium disease (Kanarek et al. 1973) and in 
the skin of beryllium sensitive individuals (Williams et al. 1987).  Laser ion mass analysis for beryllium is 
the most sensitive test for identifying beryllium on histological sections from lung or skin granulomas of 
patients with chronic beryllium disease (Williams and Kelland 1986).  A lymphocyte proliferation test has 
also been used to identify workers with chronic beryllium disease; positive test results rarely occur in 
workers who are not exposed to beryllium or its compounds (James and Williams 1985; Stokes and 
Rossman 1991). 
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Chronic exposure to beryllium can result in decreased lung function (Andrews et al. 1969; Johnson 1983). 
This decrease can be measured by spirometry such as forced expiratory volume in 1 second or forced vital 
capacity (Andrews et al. 1969; Kriebel et al. 1988a,b).  Measurements of lung function cannot distinguish 
between chronic beryllium disease and sarcoidosis, and lung opacities are not definitively captured by 
x-rays (Kanarek et al. 1973).  Lymphocyte proliferation assays on cells obtained from individuals by 
bronchoalveolar lavage are sensitive in confirming chronic beryllium disease in symptomatic individuals 
(James and Williams 1985; Rossman et al. 1988).  The lymphocyte proliferation test also distinguishes 
between chronic beryllium disease and sarcoidosis.  A less invasive method of determining sensitivity to 
beryllium would be useful, especially for monitoring health effects in individuals living at or near 
hazardous waste sites. 
Absorption, Distribution, Metabolism, and Excretion. Beryllium and its compounds are 
absorbed primarily through the lungs in humans and animals (Finch et al. 1990; Reeves and Vorwald 
1969; Stiefel et al. 1980; Zorn et al. 1986), but the available information is not sufficient to determine the 
rate and extent of pulmonary absorption.  Soluble compounds are absorbed more readily than insoluble 
compounds (Finch et al. 1990).  Information from animal studies indicates that beryllium is poorly 
absorbed from the gastrointestinal tract, with the majority of the dose excreted in the feces (Furchner et al. 
1973; Le Fevre and Joel 1986; Morgareidge et al. 1975; Reeves 1965). Dermal absorption is also poor 
(Petzow and Zorn 1974). Studies regarding the rate and extent of beryllium absorption via the lungs 
would be useful. 
The only study on the distribution of beryllium and its compounds in humans was conducted on tissue 
taken from autopsies (Meehan and Smythe 1967); distribution studies in animals exposed to beryllium via 
inhalation were more available (Finch et al. 1990; Rhoads and Sanders 1985; Sanders et al. 1975; Stiefel 
et al. 1980; Stokinger et al. 1950; Wagner et al. 1969; Zorn et al. 1977).  The target organs identified in 
these studies were the lung, lymph nodes, kidney, liver, and bone.  Distribution of beryllium is more 
widespread for the soluble compounds, reflecting the degree of absorption (Finch et al. 1990).  Rats and 
guinea pigs achieved steady state concentrations in the lungs 36 weeks after initial exposure to beryllium 
sulfate (Reeves and Vorwald 1969). Steady state concentrations in the blood were reached after 
8–12 hours (Stiefel et al. 1980). After oral exposure to beryllium metal, beryllium sulfate, or beryllium 
oxide, beryllium was distributed primarily to the liver and then to the kidneys, lymph nodes, blood, and 
bone (Le Fevre and Joel 1986; Morgareidge et al. 1975; Reeves 1965; Watanabe et al. 1985).  Studies 
investigating distribution patterns of dermally absorbed beryllium would be useful to determine if 
sensitization to beryllium can occur after dermal exposure. 
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Beryllium is not biotransformed in the body.  Studies involving the conversion of soluble beryllium 
compounds to insoluble compounds would be useful to determine the residence time of the compounds in 
the gastrointestinal tract. Studies investigating the binding of beryllium to proteins or nucleic acids would 
be useful in determining the antigenic forms of beryllium, as well as a possible mechanism for 
genotoxicity. 
Information regarding the clearance of beryllium from serum in humans (Stiefel et al. 1980; Zorn et al. 
1986) and animals (Finch et al. 1990; Rhoads and Sanders 1985; Sanders et al. 1975; Stiefel et al. 1980; 
Zorn et al. 1977) after inhalation exposure to beryllium compounds is reported in the available literature. 
Beryllium compounds are poorly absorbed by the gastrointestinal tract, and primarily eliminated in the 
feces (Furchner et al. 1973; Morgareidge et al. 1975; Reeves 1965). Studies regarding excretion after 
dermal exposure to beryllium and its compounds were not located in the available literature. 
Comparative Toxicokinetics. Studies in cats, rats, monkeys, and dogs indicate quantitative and 
qualitative differences in the distribution of inhaled beryllium to the lung, bone, spleen, and lymph nodes 
(Finch et al. 1990; Rhoads and Sanders 1985; Sanders et al. 1975; Stiefel et al. 1980; Stokinger et al. 
1950; Wagner et al. 1969; Zorn et al. 1977). No studies were located comparing the differences in 
inhalation exposures among species with respect to absorption or excretion.  Since beryllium is not well 
absorbed by the gastrointestinal tract or after dermal exposure, comparative studies for these routes of 
exposure would not be particularly valuable.  Additional comparative toxicokinetics studies regarding 
distribution, absorption, and excretion of inhaled beryllium would be helpful to determine the use of the 
appropriate animal model to study acute and chronic beryllium disease. 
Methods for Reducing Toxic Effects. Beryllium is poorly absorbed after oral and dermal 
exposure, obviating the need to develop methods to reduce absorption following these routes.  While 
beryllium is absorbed by the lungs, the major effects of inhalation exposure to beryllium are acute 
chemical pneumonitis, which is associated with soluble beryllium compounds and chronic berylliosis, 
which is associated with retention of unabsorbed less soluble beryllium compounds in the lungs (Finch et 
al. 1990). Testing of bronchoalveolar lavage to enhance beryllium clearance from the lungs might 
prevent or reduce the severity of berylliosis.  The chelating agent, aurine tricarboxylic acid, by combining 
with beryllium ions, increases the urinary excretion of beryllium in animals (Venugopal and Luckey 
1978). However, metal chelating agents available for use in human clinical medicine have not been 
shown to be effective in reducing the toxicity of beryllium (Hall and Rumack 1992).  Effects of soluble 
beryllium compounds (liver necrosis due to sequestration of insoluble beryllium phosphate formed from 
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the interaction with phosphate, acute pneumonitis, immunological effects) are probably due to beryllium 
ions (Price and Skilleter 1985, 1986). Further studies on the influence of chelating agents on beryllium-
induced effects would aid in establishing effective strategies for preventing or reducing the severity of 
these effects. Absorbed beryllium appears to preferentially accumulate in bone, and beryllium may 
substitute for calcium in bone, resulting in rickets or osteoporosis (Guyatt et al. 1933; Jacobson 1933). 
Studies could be performed to determine whether a high calcium diet would be effective in preventing the 
replacement of calcium by beryllium in bone. 
Children’s Susceptibility. No information on the toxicity of beryllium in children has been located. 
Studies that examine sensitive end points such as the lung, immune, and gastrointestinal effects in young 
animals would be useful for assessing whether children will be unusually susceptible to beryllium 
toxicity.  The available animal data are inconclusive to determine whether the developing organism is 
sensitive to beryllium toxicity.  As discussed in Chapter 2 and in Section 3.2.2.6, the only available oral 
study did not find developmental effects in the offspring of dogs chronically exposed to beryllium sulfate 
in the diet (Morgareidge et al. 1976). However, injection studies have found developmental effects (fetal/ 
neonatal mortality, internal abnormalities, and behavioral effects) (Bencko et al. 1979; Mathur et al. 1987; 
Selivanova and Savinova 1986; Tsujii and Hoshishima 1979).  Data needs relating to development are 
discussed in detail in the Developmental Toxicity subsection above.  There are some data to suggest that 
beryllium can cross the placenta and be transferred to an infant via breast milk (Krachler et al. 1999a). 
The available toxicokinetic data did not evaluate the potential differences between adults and children. 
Toxicokinetic studies examining how aging can influence the absorption, distribution, and excretion of 
beryllium would be useful in assessing children’s susceptibility to beryllium toxicity.  There are no data 
to determine whether there are age-specific biomarkers of exposure or effects or any interactions with 
other chemicals that would be specific for children.  Research in adults on methods for reducing 
beryllium toxic effects or body burdens would also be applicable to children. 
Child health data needs relating to exposure are discussed in 6.8.1 Identification of Data Needs: 
Exposures of Children. 
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3.12.3 Ongoing Studies 
Ongoing studies pertaining to beryllium have been identified and are shown in Table 3-6. 
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Table 3-6. Ongoing Studies on Beryllium 
Investigator Affiliation Research description Sponsor 
Albertini, RJ University of Vermont Biomarkers for beryllium sensitization EM 
Marian, B University of California, Screening of beryllium worker cohorts NCR 
Los Alamos National using the immun.-flow lymphocyte 
Laboratory proliferation test 
Newman, L University of Colorado Immunopathogenesis of beryllium NCR 
disease 
Rossman, M University of Pennsylvania Examination of exposure-response NCR 
relationship for various measures of 
beryllium exposure 
Kotzin, BL University of Colorado Examination of T–cell clones in NHLBI 
individuals with CBD and beryllium 
sensitized individuals 
King, TE National Jewish Medical Prevention of pulmonary fibrosis in NHLBI 
and Research Center individuals with granulomatous 
inflammation 
Newman, L National Jewish Medical Role of T–cells and mast cells in the NHLBI 
and Research Center development of pulmonary fibrosis 
Mason, RJ National Jewish Medical Immunologic regulation of pulmonary NHLBI 
and Research Center fibrosis 
Warren, JS University of Michigan Study of oxidant-induced β-chemokines NHLBI 
in granuloma formation 
Fontenot, AP University of Colorado Pathogenic cells in beryllium-induced NHLBI 
lung disease 
LA Maier National Jewish Medical Local angiotensin system in lung NHLBI 
and Research Center fibrogenesis 
Bell, J Fayetteville State Mutagenic effects of beryllium on the NIGMS 
University fidelity of DNA synthesis 
Newman, L National Jewish Medical Cytokine regulation in CBD NIEHS 
and Research Center 
Finch, GL Lovelace Biomedical and Mechanisms of granulomatous disease USDOE 
Environmental Research from inhaled beryllium 
Institute 
CBD = chronic beryllium disease; NCR = National Center for Research Resources; NHLBI = National Heart, Lung, 
and Blood Institute; NIEHS = National Institute of Environmental Health and Science; NIGMS = National Institute of 
General Medical Sciences; USDOE = U.S. Department of Energy 
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4.1 CHEMICAL IDENTITY 
Beryllium is a naturally occurring element found in earth’s surface rocks at levels of 1–15 mg/kg.  It 
appears in Group IIA of the periodic table and has two common oxidation states, Be(0) and Be(+2). 
Because of its high reactivity, beryllium is not found as the free metal in nature.  There are approximately 
45 mineralized forms of beryllium.  The important beryllium minerals in the world are beryl 
(3BeO#Al2O3#6SiO2) and bertrandite (Be4Si2O7(OH)2). Beryl has been known since ancient times as the 
gemstones: emerald (green), aquamarine (light blue), and beryl (yellow).  Information concerning the 
chemical identity of elemental beryllium and beryllium compounds is listed in Table 4-1. 
4.2 PHYSICAL AND CHEMICAL PROPERTIES 
The physical and chemical properties of beryllium and beryllium compounds are listed in Table 4-2. 
Consistent with the high charge-to-radius ratio, beryllium has a strong tendency to form compounds with 
covalent bonds; even compounds with the most electronegative elements (e.g., BeF2) have substantial 
covalent character. Although beryllium belongs to Group IIA of the periodic table, it is chemically very 
similar to aluminum, which also has a high charge-to-radius ratio.  Like aluminum, the hydroxide of 
beryllium is amphoteric (Cotton and Wilkinson 1980; Drury et al. 1978; EPA 1998). 
The interaction of cosmic-ray particles in the atmosphere produces a number of radionuclides including 
beryllium-7 (Be-7) and beryllium-10 (Be-10).  The radioactive half-life of Be-7 is 53.29 days and the 
radioactive half-life of Be-10 is 1.51x106 years (UNSCEAR 2000). 
Table 4-1. Chemical Identity of Beryllium and Beryllium Compoundsa 
Characteristic 
Synonym(s) 













Beryllium fluoride Beryllium hydroxide 
Beryllium difluoride Beryllium hydrate; 
beryllium dihydroxide 







CAS registry 7440-41-7 7787-47-5 7787-49-7 13327-32-7 1304-56-9 
NIOSH RTECS DS1750000 DS2625000 DS2800000 DS3150000 DS4025000 
EPA hazardous waste P015 b No data No data No data No data 
OHM/TADS 72116604c 7217359c 7800049c No data No data 
DOT/UN/NA/IMCO shipping UN1567/IM06.1 NA1566/IM06.1 NA1566/IM06.1 UN1566/IM06.1 UN1566/IM06.1 
HSDB 512 357 355 350 1607 





















Table 4-1. Chemical Identity of Beryllium and Beryllium Compoundsa (continued) 
Characteristic 
Beryllium phosphate 















Registered trade name(s) No data No data No data No data 









































NCI No data No data No data No data 
aAll information obtained from HSDB 2000 except where noted




CAS = Chemical Abstracts Services; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North America/International Maritime Dangerous Goods 
Code; EPA = Environmental Protection Agency; HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 













































Amorphous powder or 
crystalline solidd 










1.846 g/cm3 e 
1,175 ECb 
1.986 g/cm3 (25 EC)b 
Not applicable 
1.92 g/cm3 b 
3,787 ECb 
3.016 g/cm3 c 
No data 
No data 
Odor None None None None None 





Soluble in dilute acid and 
alkali 
Very solubleg 
Slightly soluble in 
alcohold 
0.8x10-4 mol/Lg (3.44 mg/L) 
Soluble in hot 
concentrated acid and 
alkalid 
Very sparinglyg 


















Vapor pressure 1 mmHg (1,520 EC) No data No data No data No data 
Henry’s law constant No data No data No data No data No data 
Autoignition temperature No data No data No data No data No data 
Flashpoint No data No data No data No data No data 
Flammability limits 
Conversion factorsh 
No data No data No data No data No data 





































Color Colorless Whiteb Whiteb Colorlessb Colorlessb 
Physical state Needles Crystalsb Solidb Tetragonal crystals Tetragonal crystals 




100 EC (loses 2H2O) 
Boiling point 520 EC 142 EC (decomposes)b No data Not applicable 400 EC (loses 4H2O) 
Density 1.899 g/cm3 (25 EC) 1.557 g/cm3 b No data 2.443 g/cm3 1.713 g/cm3 (10.5 EC) 
Odor None Noneb Noneb None None 





Very soluble in alcohol, 
ether, pyridine; slightly 
soluble in benzene and 
chloroform 
166 parts/100 parts 




Soluble in acetic acid 
Insoluble 
No data 
39.1 parts/100 parts 
H2O (20 EC)b 
(3.91x105 mg/L) 
Slightly soluble in H2SO4, 














Vapor pressure No data No data No data No data No data 
Henry’s law constant No data No data No data No data No data 
Autoignition temperature No data No data No data No data No data 





















 Table 4-2. Physical and Chemical Properties of Beryllium and Beryllium Compoundsa (continued) 



















Explosive limits No data No data No data No data No data 
aAll information obtained from Weast 1985 except dWindholz 1983 hThese compounds do not exist in the atmosphere in 
where noted eBallance et al. 1978 the vapor phase; therefore, an air conversion factor 
bDean 1985 fWalsh and Rees 1978 is not applicable. 























5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
5.1 PRODUCTION 
Beryllium is an element that is present in the earth’s surface rocks in amounts ranging from <1–15 mg/kg. 
The beryllium minerals of commercial interest are beryl (i.e., 3BeOCAl2O3C6SiO2) and bertrandite (i.e., 
Be4Si2O7(OH)2). In the United States, bertrandite, which contains <1% beryllium, is the principal mineral 
mined.  Outside the United States, beryl is the principal beryllium mineral mined.  In 1999, the U.S. 
Geological Survey (USGS) estimated that United States resources of bertrandite ore in Utah and Texas 
contained 21,000 metric tons of beryllium (Cunningham 1999).  Only one company, Brush Wellman, Inc. 
of Elmore, Ohio, produced beryllium in the United States in 1998.  The bertrandite ore was mined using 
open-pit methods from deposits near Spor Mountain, Utah.  In 1998, 230 metric tons of beryllium were 
mined in the United States (Cunningham 1999).  Beryllium hydroxide is the basic raw material for the 
production of beryllium metal, alloys, and compounds.  Bertrandite ore is wet milled, leached with 
sulfuric acid, and then extracted from the acid leachate with di(2-diethylhexyl) phosphate in kerosene at 
elevated temperature.  The beryllium is then treated with aqueous ammonium carbonate to form an 
aqueous ammonium beryllium carbonate complex, which is then heated to precipitate beryllium as 
carbonate. Continued heating liberates carbon dioxide and beryllium hydroxide (i.e., Be(OH)2). 
Beryllium hydroxide is then recovered by filtration.  Beryllium hydroxide is the feed material for 
products such as beryllium metal, beryllium alloys, and beryllium oxide (Ballance et al. 1978; Drury et al. 
1978). 
Beryllium metal is produced by Brush Wellman Inc. in Elmore, Ohio using the Schenzfeier-Pomelee 
purification process. The hydroxide is initially reacted with ammonium fluoride to form ammonium 
fluoroberyllate (e.g., (NH4)2BeF4), which is then heated to produce an amorphous beryllium fluoride (e.g., 
BeF2), which is reduced by magnesium metal at 900–1,300 EC to yield beryllium metal and a beryllium 
fluoride-magnesium fluoride slag.  The slag is removed by leaching with water, leaving 97% pure 
beryllium metal.  Beryllium metal may be further electrorefined to produce a higher purity material 
(Ballance et al. 1978; Drury et al. 1978).  Beryllium oxide (i.e., BeO) is the most important high purity 
commercial beryllium chemical.  It is produced by dissolving technical-grade beryllium hydroxide in 
sulfuric acid, precipitating out hydrated beryllium sulfate, which is then calcined at 1,150–1,450 EC 
(Ballance et al. 1978; Drury et al. 1978). 
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Copper-beryllium alloy is commercially the most important beryllium alloy.  Copper-beryllium master 
alloy is manufactured by an arc-furnace method in which beryllium oxide is reduced by carbon in the 
presence of molten copper at 1,800–2,000 EC. The resulting master alloy usually contains 4.0–4.25% 
beryllium by weight.  Other copper-beryllium alloys are produced by melting the master alloy together 
with virgin copper, copper scrap, and possibly other metals (Ballance et al. 1978; Drury et al. 1978). 
Brush Wellman, Inc. of Elmore, Ohio is the only processor of beryllium ores in the United States.  Brush 
Wellman, Inc. is also the leading producer and consumer of beryllium metal, alloys, and oxide.  NGK 
Metals Corporation in Reading, Pennsylvania is also a major U.S. manufacturer of beryllium alloys.  U.S. 
mine shipments steadily increased from 173 metric tons in 1994 to 230 metric tons in 1998 of beryllium 
metal equivalent.  Including imports of beryllium ore, stockpiling, and inventory uses, the apparrent U.S. 
consumption of beryllium from 1994 to 1998 has increased from 198 to 240 metric tons of beryllium 
equivalent (Cunningham 1999).  Tables 5-1 and 5-2 list the number of facilities in each state that 
manufacture or process beryllium and beryllium compounds, respectively.  Included in these tables are 
the activities and uses of beryllium and beryllium compounds and the range of maximum amounts of 
beryllium and beryllium compounds that are stored on site (TRI99 2002). 
5.2 IMPORT/EXPORT 
In 1998, 13% of the beryllium ore and metal consumed in the United States (35 metric tons) was imported 
from other countries.  All imports of beryllium ore originated from Canada.  Exports of beryllium metal 
were 60 metric tons in 1998, up from 29 metric tons in 1994.  Japan, France, the United Kingdom, and 
Germany were the major recipients of beryllium exports during this period (Cunningham 1999). 
5.3 USE 
In 1998, the use of beryllium (as an alloy, metal, or oxide) in the electronic and electrical components, 
aerospace, and defense applications accounted for >80% of its consumption (Cunningham 1999). 
Beryllium metal is used in aircraft disc brakes, x-ray transmission windows, space vehicles optics and 
instruments, aircraft/satellite structures, missile guidance systems, nuclear reactor neutron reflectors, 
nuclear warhead triggering devices, fuel containers, precision instruments, rocket propellants, 
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Table 5-1. Facilities that Produce, Process, or Use Beryllium 
Number of Minimum amount Maximum amount 
Statea facilities on site in poundsb on site in poundsb Activities and usesc 
CA 2 0 999 8, 10 
IN 2 100 999,999 9, 12 
LA 1 0 99 1, 5, 9, 13 
MO 1 1,000 9,999 8, 10 
NC 1 100,000 999,999 10, 13 
OH 1 10,000 99,999 1, 4 
OK 2 100 99,999 1, 5, 9 
PA 1 10,000 99,999 10 
SC 1 100 999 9 
UT 1 1,000 9,999 8 
WI 1 10,000 99,999 8 
Source: TRI99 2002 
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses: 
1. Produce 6. Impurity 10. Repackaging 
2. Import 7. Reactant 11. Chemical Processing Aid 
3. Onsite use/processing 8. Formulation Component 12. Manufacturing Aid 
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Table 5-2. Facilities that Produce, Process, or Use Beryllium Compounds 
Number of Minimum amount Maximum amount 
Statea facilities on site in poundsb on site in poundsb Activities and usesc 
AL 4 1,000 99,999 1, 3, 4, 5, 6, 9, 1, 13 
AR 1 1,000 9,999 1, 5 
AZ 3 10,000 9,999,999 1, 3, 4, 5, 6, 9, 1 
FL 2 0 9,999 1, 3, 4, 5, 6, 1 
GA 3 10,000 99,999 1, 3, 4, 5, 6, 1, 13 
IL 1 1,000 9,999 1, 5, 1 
IN 3 100 99,999 1, 5, 6, 9, 1, 13 
KY 5 0 99,999 1, 2, 3, 5, 6, 9, 1, 13 
MI 2 10,000 99,999 1, 5, 9, 1 
MO 1 1,000 9,999 9 
MS 1 100 999 1, 5 
MT 1 10,000 99,999 1, 3, 5, 6, 13 
NC 2 10,000 99,999 1, 3, 4, 5, 6, 1 
NM 3 100 99,999 1, 3, 4, 5, 6, 1, 13 
NY 1 100 999 1, 5 
OH 4 1,000 99,999 1, 3, 4, 5, 6, 8, 1, 13 
PA 4 100 999,999 1, 2, 3, 4, 5, 6, 7, 9, 1 
TN 2 10,000 99,999 1, 5, 8, 9 
TX 1 10,000 99,999 1, 3, 4, 5, 6, 1, 13 
UT 4 1,000 49,999,999 1, 4, 7, 8, 13 
WI 1 1,000 9,999 9 
WV 3 1,000 99,999 1, 3, 4, 5, 6, 1, 13 
WY 1 0 99 1, 5, 6 
Source: TRI99 2002 
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses: 
1. Produce 6. Impurity 10. Repackaging 
2. Import 7. Reactant 11. Chemical Processing Aid 
3. Onsite use/processing 8. Formulation Component 12. Manufacturing Aid 
4. Sale/Distribution 9. Article Component 13. Ancillary/Other Uses 
5. Byproduct 
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navigational systems, heat shields, mirrors, high speed computer, and audio components, as well as other 
uses (Ballance et al. 1978; Cunningham 1998). 
Beryllium oxide is used in high technology ceramics, electronic heat sinks, electrical insulators, 
microwave oven components, gyroscopes, military vehicle armor, rocket nozzles crucibles, thermocouple 
tubing, laser structural components, substrates for high-density electrical circuits, automotive ignition 
systems, and radar electronic countermeasure systems (Ballance et al. 1978, Cunningham 1998). 
Beryllium-copper alloys are used in a wide variety of applications because of their electrical and thermal 
conductivity, high strength and hardness, good corrosion and fatigue resistance, and nonmagnetic 
properties. Beryllium-copper alloys are manufactured into: springs; electrical connectors and relays; 
precision instruments; bushings and bearings in aircraft and heavy machinery; nonsparking tools; 
submarine cable housing and pivots; wheels and pinions; switches in automobiles; molds for injection 
molded plastics; radar; telecommunications; factory automation; computers; home appliances; 
instrumentation and control systems; tubing in oil and drilling equipment; connectors for fiber optics; and 
integrated circuits, as well as many other uses (Ballance et al. 1978; Cunningham 1998).  
5.4 DISPOSAL 
The most significant amount of beryllium waste results from pollution control methods such as solid 
particulates scrubbers. Since beryllium is a valuable element, the most desirable method of handling 
beryllium wastes is to recycle them to the producers.  Metal scrap, aqueous suspensions, and particulates 
are routinely recycled by Brush Wellman, Inc. at their production facility in Ohio (Brush Wellman 
2000a). 
The EPA has classified beryllium powder as a hazardous waste material (40 CFR Section 261.33).  Under 
the Resource Conservation and Recovery Act (RCRA), compliance with labeling and disposal procedures 
as well as obtaining permits for discharges into air and water are required for beryllium powder.  EPA 
standards require that atmospheric emissions from stationary sources be <10 g of beryllium over a 
24-hour period, and that the ambient concentration of beryllium near the stationary source be 
<0.01 µg/m3. Beryllium solid waste should be placed into impermeable, sealed bags or containers (e.g., 
drums) that are labeled in accordance with the requirements of EPA regulations (Fishbein 1981).  The 
EPA has also issued final regulations under the Clean Water Act for specific nonferrous metal 
manufacturing operations including beryllium processing facilities.  These regulations limit the discharge 
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of beryllium containing pollutants into navigable waters and into publically-owned treatment works 
(POTWs). Waste waters containing beryllium may therefore require treatment to reduce the 
concentration of beryllium.  A typical treatment method for beryllium involves steps such as chemical 
precipitation, settling clarification, neutralization, filtration, and sludge dewatering (EPA 1982, 1988a). 
Waste waters that contain permissible levels of beryllium may be discharged into streams and POTW 
facilities (EPA 1982, 1988a). 
A significant amount of beryllium waste results from pollution control methods such as containment of 
solid particulates or aqueous suspensions resulting from air-scrubbing processes.  According to the 
TRI99 (TRI99 2002), a total of 54,097 and 838,373 pounds of beryllium and beryllium compound wastes, 
respectively, were released to the environment by various industries in 1999 (see Chapter 6).  Of the total 
release of beryllium, 98.5% was disposed on land (on-site), 1.4% was released to air, and 0.1% was 
released to surface water. Likewise, of the total release of beryllium compounds, 98.2% was disposed on 
land (on-site), 0.9% was released to air, 0.4% was released to surface water, and 0.5% was injected 
underground. An additional 20,081 and 72,118 pounds of beryllium and beryllium compound wastes, 
respectively, were transferred to off-site locations within the United States.  Data regarding the trend in 
disposal practices for beryllium wastes in recent years were not located. 
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6.1 OVERVIEW 
Beryllium has been identified in at least 535 of the 1,613 hazardous waste sites that have been proposed 
for inclusion on the EPA NPL (HazDat 2002). However, the number of sites evaluated for beryllium is 
not known. The frequency of these sites can be seen in Figure 6-1.  Of these sites, 524 are located within 
the United States, 2 are located in the Territory of Guam, 2 are located in the U.S. Virgin Islands, and 
7 are located in the Commonwealth of Puerto Rico (not shown). 
Beryllium is naturally emitted to the atmosphere by windblown dusts and volcanic particles (EPA 1987). 
The major anthropogenic emission source to the environment is the combustion of coal and fuel oil, 
which releases particulates and fly ash that contain beryllium into the atmosphere (DOE 1996).  Other 
anthropogenic processes, such as ore processing, metal fabrication, beryllium oxide production and use, 
and municipal waste combustion, release only a fraction of the amounts emitted from coal and oil 
combustion (Cleverly et al. 1989; EPA 1987; Fishbein 1981).  Beryllium naturally enters waterways 
through the weathering of rocks and soils (EPA 1980).  The sources of anthropogenic release of beryllium 
to surface waters include treated waste water effluents from beryllium or related industries and the runoff 
from beryllium-containing waste sites (EPA 1980, 1981).  Deposition of atmospheric beryllium aerosols 
from both natural and anthropogenic sources is also a source of beryllium in surface waters.  Some 
beryllium compounds are naturally present in soil, but the concentration of beryllium in localized soils 
can be increased because of the disposal of coal ash, municipal combustor ash, industrial wastes that 
contain beryllium, and deposition of atmospheric aerosols. 
Beryllium released to the atmosphere from combustion processes and ore processing will probably be 
present as beryllium oxide.  Atmospheric beryllium particulates will eventually settle to the earth's surface 
by dry deposition or may be removed from the atmosphere by wet deposition (i.e., precipitation).  Upon 
reaching water and soil, beryllium will probably be retained in an insoluble form in sediment and soil and 
will be generally immobile.  Although chemical reactions may transform one beryllium compound into 
another, beryllium cannot be degraded by environmental reactions.  However, the data regarding 
transformation reactions of beryllium in water and soil are limited.  Bioconcentration of beryllium in 
plants and animals is low.  In plants, uptake of beryllium appears to be restricted to the root 
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system; no significant translocation of beryllium to the above ground parts of the plant has been observed. 
Beryllium is not expected to bioconcentrate in aquatic animals (EPA 1980). 
The average concentration of beryllium in air in the United States is 0.03 ng/m3, but the median 
concentration in cities is 0.2 ng/m3 (Bowen 1979; EPA 1987). Dissolved beryllium was detected in 
groundwater at 352 of 504 sites in the United States (6.4% of sites) with an average concentration of 
13.6 µg/L. In surface water, dissolved beryllium was detected at 85 of 504 sites in the United States 
(16.1%) with an average concentration of 23.8 µg/L (EPA 2000a).  The mean concentration of beryllium 
in U.S. soils is 0.6 mg/kg (Eckel and Langley 1988).  The beryllium concentrations in both raw carrots 
and field corn grown in the United States were <25 µg/kg (fresh weight) (Wolnik et al. 1984). 
The general population is exposed to beryllium through inhalation of air and consumption of food and 
drinking water. The total beryllium intake by the general U.S. population cannot be estimated due to the 
lack of data regarding beryllium content in food.  People who work in beryllium manufacturing, 
fabricating, and reclaiming industries are exposed to higher levels of beryllium than the general 
population. Smokers may also be exposed to higher levels of beryllium than nonsmokers because 
cigarette smoke contains beryllium (Reeves 1986). 
6.2 RELEASES TO THE ENVIRONMENT 
Releases of beryllium and beryllium compounds are required to be reported under Superfund 
Amendments and Reauthorization Act Section 313; consequently, data are available for this compound in 
the Toxics Release Inventory (TRI) (EPA 1995).  According to the TRI, a total of 74,178 pounds 
(33,647 kg) of beryllium and 910,491 pounds (412,990 kg) beryllium compounds were released to the 
environment in 1999 (TRI99 2002).  The TRI data should be used with caution because only certain types 
of facilities are required to report. This is not an exhaustive list. 
Beryllium has been identified in a variety of environmental media (air, surface water, leachate, 
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6.2.1 Air 
Anthropogenic and natural emissions of beryllium to the atmosphere from various sources are reported in 
Table 6-1. In addition to ore processing, beryllium is also released into the atmosphere during the 
production and use of beryllium alloys and chemicals.  Beryllium is released into the atmosphere from 
anthropogenic sources including the combustion of coal and fuel oil, the incineration of municipal solid 
waste (MSW), the production, use, and recycling of beryllium alloys and chemicals, and, to a minor 
extent, the burning of solid rocket fuel. According to the TRI data (TRI99 2002) shown in Tables 6-2 and 
6-3, 769 and 7,816 pounds of beryllium and beryllium compounds, respectively, were released in the 
atmosphere from alloys, chemicals, and user industries in 1999. 
Beryllium emissions from coal and fuel oil combustion account for a majority of the U.S. beryllium 
emissions from natural and anthropogenic sources (EPA 1987).  The average beryllium concentration in 
coal is between 1.8 and 2.2 µg/g (EPA 1987).  A study by the Department of Energy (DOE) and the 
University of North Dakota examined the emissions of toxic trace elements from coal-fired power plants 
(DOE 1996). The data in this study show that stack concentrations are 2–3 orders of magnitude greater 
than the range of ambient air concentrations for beryllium (DOE 1996).  The median stack concentration 
for beryllium was 0.8 µg Be/m3, and the average emission from the nine coal-fired power plants was 
22.6 pounds/year (range 0.49–55.8 pounds/year).  The estimated total emissions of beryllium in 
1990 from the 3,266 fuel oil-fired power plants in the United States was 0.45 tons (0.41 metric tons) 
(DOE 1999a). TRI release data for electric utilities of 6,988 pounds of beryllium compounds were 
reported for 1999 (EPA 1987; TRI99 2002). The largest atmospheric releases of beryllium compounds 
were reported by Roxboro Steam Electric Plant in Person, North Carolina; Mt. Storm Power Station in 
Grant, West Virginia; and FirstEnergy Power Plant in Beaver, Pennsylvania with 487, 680, and 
1,250 pounds (0.22, 0.31, and 0.57 metric tons), respectively, for the year 1999.  The TRI99 data should 
be used with caution since only certain types of facilities are required to report.  This is not an exhaustive 
list (TRI99 2002). 
In 1986, there were 494 of 7,835 incinerated municipal waste streams containing beryllium in the United 
States (Behmanesh et al. 1992).  There are 58 municipal Waste-to-Energy (WTE) facilities in the United 
States (DOE 1999a). At a municipal WTE facility in Commerce, California, stack emissions for 
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Table 6-1. Anthropogenic and Natural Emissions of Beryllium and Beryllium
 
Compounds to the Atmospherea
 
Emission source Emission (tons/year)b 
Natural 
Windblown dust 5 
Volcanic particles 0.2 
Anthropogenicc,d 
Industry 0.6 
Metal Mining 0.2 
Electric utilities 3.5 
Waste and Solvent Recovery (RCRA) 0.007 
Total 9.507 
aAdapted from Drury et al. 1978; EPA 1987; TRI99 2002

bUnits are metric tons.
 
cData in TRI are maximum amounts released by each industry.

dThe sum of fugitive and stack releases are included in releases to air by a given industry.
 
RCRA = Resource Conservation and Recovery Act; TRI = Toxic Release Inventory 
Table 6-2. Releases to the Environment from Facilities that Produce, Process, or Use Beryllium 
Reported amounts released in pounds per yeara 
Number Total on and 
Stateb 
of 









CA 3 0 No data No data No data 0 No data 0 
IN 3 0 No data No data 2,650 2,650 2,415 5,065 
LA 1 2 No data No data No data 2 No data 2 
MO 1 0 No data No data 10 10 0 10 
NC 1 38 No data No data No data 38 No data 38 
OH 6 721 27 No data 50,532 51,280 9,870 61,150 
OK 2 No data 23 No data 5 28 6,830 6,858 
PA 1 1 7 No data No data 8 966 974 
SC 1 7 No data No data 74 81 No data 81 
TN 1 No data No data No data No data No data No data No data 
UT 1 0 No data No data 0 0 No data 0 
WI 1 No data No data No data No data No data No data No data 
Total 22 769 57 0 53,271 54,097 20,081 74,178 
Source: TRI99 2002 
aData in TRI are maximum amounts released by each facility.

bPost office state abbreviations are used.
 
cThe sum of fugitive and stack releases are included in releases to air by a given facility.

dThe sum of all releases of the chemical to air, land, water, and underground injection wells.
 



















Table 6-3. Releases to the Environment from Facilities that Produce, Process, or Use Beryllium Compounds 
Reported amounts released in pounds per yeara 
Number Total on and 
Stateb 
of 









AL 6 419 250 No data 62,691 63,360 326 63,686 
AR 2 197 48 No data 9,130 9,375 1 9,376 
AZ 4 50 No data No data 16,421 16,471 1,630 18,101 
FL 3 390 250 No data 5,745 6,385 5 6,390 
GA 5 764 0 No data 76,925 77,689 No data 77,689 
IL 1 79 850 No data 8,500 9,429 No data 9,429 
IN 4 340 63 No data 40,019 40,422 3,808 44,230 
KY 5 351 1,221 No data 27,730 29,302 No data 29,302 
MD 1 No data No data No data No data No data No data No data 
MI 2 313 17 No data 15,000 15,330 250 15,580 
MO 3 10 No data No data No data 10 555 565 
MS 1 2 20 4,100 19 4,141 0 4,141 
MT 1 250 No data No data 6,900 7,150 750 7,900 
NC 4 817 403 No data 51,010 52,230 260 52,490 
NM 4 112 77 No data 47,724 47,913 39,000 86,913 
NY 1 20 0 No data 400 420 No data 420 
OH 4 450 30 No data 25,846 26,326 11,422 37,748 
PA 4 1,580 16 No data 8,700 10,296 6,411 16,707 
TN 2 256 250 No data 14,100 14,606 640 15,246 
TX 1 19 0 No data 31,400 31,419 No data 31,419 
UT 4 366 No data No data 299,952 300,318 5 300,323 


















Table 6-3. Releases to the Environment from Facilities that Produce, Process, or Use Beryllium Compounds 
(continued) 











Total on and 
off-site 
release 
WV 9 861 10 No data 70,765 71,636 6,800 78,436 
WY 1 160 No data No data 3,970 4,130 No data 4,130 
Total 73 7,816 3,510 4,100 822,947 838,373 72,118 910,491 
Source: TRI99 2002 
aData in TRI are maximum amounts released by each facility.

bPost office state abbreviations are used.
 
cThe sum of fugitive and stack releases are included in releases to air by a given facility.

dThe sum of all releases of the chemical to air, land, water, and underground injection wells.
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beryllium were measured at 0.2 µg/m3 (Hasselriis and Licata 1996). The stack emissions from individual 
municipal WTE facilities are about the same order of magnitude as stack emissions from individual coal 
fired power plants; however, the number of municipal WTE facilities in the United States is a factor of 
20 less than the number of coal fired power plants. 
Natural emission sources of beryllium include windblown dusts and volcanic particles.  The beryllium 
amounts released to the atmosphere from these sources are comparable with anthropogenic sources (see 
Table 6-1). 
Beryllium has been identified in 9 air samples collected from 535 current or former NPL hazardous waste 
sites where it was detected in some environmental media (HazDat 2002). 
6.2.2 Water 
Anthropogenic sources of beryllium release to water include industrial waste water effluents.  A
 
compilation of data for the beryllium levels in raw and treated waste water from various industrial sources
 
is available (EPA 1981). The concentrations of beryllium compounds are the highest in waste waters
 
from electric utility industries (TRI99 2002).  The total reported amounts of beryllium and beryllium
 
compounds released to surface water for 1999 were 57 pounds (26 kg) and 3,510 pounds (1,592 kg),
 
respectively, as shown in Tables 6-2 and 6-3 (TRI99 2002).
 
Deposition of atmospheric beryllium is also a source in surface waters; however, the relative significance
 
of the contribution from this source, compared to industrial discharge to surface water, cannot be
 
assessed. Beryllium also enters the waterways from the weathering of rocks and soils (EPA 1980).  Since
 
coal contains beryllium, it is also likely that beryllium will enter surface water via leaching of coal piles.
 
The industrial releases of beryllium and beryllium compounds into surface water are shown in
 
Tables 6-2 and 6-3, respectively.  The largest releases to water were reported by electric utility facilities
 
such as St. Johns River Power Park (Duval, Florida), U.S. TVA Widows Creek Fossil Plant (Jackson,
 
Alabama), Baldwin Power Station (Randolph, Illinois), and U.S. TVA Cumberland Fossil Plant (Stewart,
 
Tennessee), which reported releases of 250, 250, 850, and 1,000 pounds (0.11, 0.11, 0.39, and 0.45 metric
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Beryllium has been identified in 92 surface water and 376 groundwater samples collected from 535 NPL 
hazardous waste sites, where it was detected in some environmental media (HazDat 2002). 
6.2.3 Soil 
Beryllium is naturally present in soils and sediments.  Releases of beryllium and beryllium compounds to 
U.S. soils in 1999 as reported to the TRI are shown in Tables 6-2 and 6-3, respectively.  According to the 
TRI, 53,271 pounds (52 metric tons) of beryllium and 822,947 pounds (179 metric tons) of beryllium 
compounds were released on-site to land by facilities that manufacture or process beryllium and beryllium 
compounds (TRI99 2002).  An additional 20,081 pounds (9 metric tons) of beryllium and 72,118 pounds 
(33 metric tons) of beryllium compounds were released off-site to locations within the United States in 
1999 (TRI99 2002). 
Coal fly ash and municipal solid waste incinerator ash are disposed of in landfills and used in building 
materials (Kalyoncu 1998).  Coal fly ash contains beryllium at levels of 46 mg beryllium/kg ash 
(Stadnichenko et al. 1961). About 100 million tons of coal fly ash containing various levels of beryllium 
are generated each year (Kalyoncu 1998).  This translates to about 420 metric tons of beryllium disbursed 
as coal fly ash. 
Land application of sewage sludge containing higher than background concentrations of beryllium can be 
source of beryllium contamination of soil.  Deposition of atmospheric aerosols on terrestrial surfaces is 
another source of beryllium in soil.  Valberg et al. (1996) estimated the amount of time that it would take 
to double the ambient soil concentration of beryllium by dry deposition (at the point of maximum impact) 
near a MSW incinerator in Vermont.  Their estimate was between 468 and 2,275 years, depending upon 
the ambient concentration of beryllium in the soil.  Other quantitative data regarding the relative 
significance of these sources was not available. 
Beryllium has been identified in 353 soil and 193 sediment samples collected from 535 NPL hazardous 
waste sites, where it was detected in some environmental media (HazDat 2002). 
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6.3 ENVIRONMENTAL FATE 
6.3.1 Transport and Partitioning 
Beryllium in air is attached to particulate matter whose residence time in air is dependant upon particle 
size. A study of stack emissions from coal combustion reported that most beryllium is found on particles 
with diameters of <2.5 µm (Gladney and Owens 1976).  Particles of this size can remain airborne for 
approximately 10 days (Gladney and Owens 1976).  The transport of beryllium from the atmosphere to 
terrestrial and aquatic surfaces occurs through wet and dry deposition (EPA 1987).  By analogy to other 
elements, a typical dry deposition velocity may be estimated for beryllium particles over vegetative 
surfaces as 0.25 cm/second (EPA 1987).  The dry deposition rate of aerosol particles is a function of 
particle size, wind speed, and surface roughness. The process of wet deposition of airborne beryllium 
consists of wash-out and rain-out; wash-out involves the scrubbing of particles from the air by rain and 
rain-out involves their attachment to aerosols in clouds.  The portion of beryllium particles transported 
from the atmosphere by wet deposition has not been estimated.  Beryllium was detected but not quantified 
in rainwater from Fresno, California, which suggests that transport of beryllium from the atmosphere to 
terrestrial and aquatic surfaces occurs by wet deposition (Salo et al. 1986).  Beryllium containing soil can 
be resuspended in the atmosphere as a result of wind action. 
Beryllium is carried to rivers, lakes, and oceans by the process of land erosion.  The amount of beryllium 
transported to surface waters from the land by wind-blown soil is estimated to be relatively small (Merrill 
et al. 1960). Acid deposition has been shown to accelerate chemical weathering of soil and bedrock into 
drainage outflow, increasing the mobility of beryllium (Jagoe et al. 1993).  The estimated residence time 
of beryllium in ocean water, before it is removed from the aquatic phase by sedimentation or other 
removal processes, is between 150 and 570 years (Bowen 1979; Merrill et al. 1960). 
Beryllium binds strongly to soil fulvic acid; binding increases with increasing pH.  Beryllium also forms 
complexes with marine fulvic acids at nearly neutral pH values (Esteves Da Silva et al. 1996a).  However, 
beryllium has a much stronger affinity for clay minerals than for organic matter.  Beryllium is usually 
associated in soil with aluminum sites on clay minerals rather than with iron oxides (Lum and Gammon 
1985). It tends to displace divalent cations with smaller charge-to-ionic radius ratios (Fishbein 1981). 
For pH values #6, the distribution of beryllium between solution and solids is related to sorption at 
surface sites. At pH values >6, the solute concentration of beryllium is strongly controlled by the 
solubility of Be(OH)2 (Aldahan et al. 1999). 
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The sediment-water distribution coefficients (Kd) for beryllium are very high indicating a very low 
mobility in sediments.  At pH values >6, Kd values are very high for most soils and sediments.  For Lake 
Michigan sediments, Kd ranged between 105 and 106 (Hawley et al. 1986).  Beryllium may accumulate in 
the surface organic layer of the sediment profile; however, there is no indication as to whether the organic 
matter content of sediment affects Kd (Lum and Gammon 1985).  The presence of organic matter did not 
significantly affect the Kd for saline systems (You et al. 1989); in seawater, Kd is, on average, between 
316,000 and 794,000 (Hawley et al. 1986). 
In highly alkaline soils, the mobility of beryllium may increase as a result of the formation of soluble 
hydroxide complexes, such as [Be(OH)4 ]2- (Callahan et al. 1979; Cotton and Wilkinson 1980). In acidic 
soils (e.g., forest ecosystems), dissolved Be2+ has been found to be the prevailing beryllium species in the 
soil solution, and it should be relatively mobile in these environments (Krám et al. 1998).  However, 
leaching would not be expected to occur in less acidic soils (Hayes and Traina 1998). 
The concentration of beryllium in plants is very low (see Section 6.4.4).  Soluble forms of beryllium must 
be present for uptake to occur in plants. For collard seedlings, beryllium remains in the roots, and only 
small portions were translocated to above ground portions (Kaplan et al. 1990).  Romney and Childress 
(1965) examined uptake of 7Be in beans, barley, sunflowers, and tomato plants.  Over 95% of 7Be was 
found in the roots; very little was translocated to the foliage and fruits (Romney and Childress 1965). 
The Enrichment Ratio (ER) of beryllium in oat grain and in alfalfa grown in both microcosms and field 
plots amended with beryllium containing fly ash was 1 (Tolle et al. 1983). 
Beryllium does not bioconcentrate in aquatic organisms.  A measured bioconcentration factor (BCF) of 
19 was reported for beryllium in bluegill fish (EPA 1980).  Other investigators have reported a BCF of 
100 for freshwater and marine plants, vertebrates, and fish (Callahan et al. 1979).  Comparisons of the 
beryllium levels in bottom-feeding biota and surfaces sediments from Lake Pontchartrain, Louisiana, 
indicate similar, but somewhat lower, beryllium concentrations in biota (Byrne and DeLeon 1986).  Very 
low bioaccumulation for beryllium was observed in southern toads (Bufo terrestris) exposed directly to 
elevated levels of beryllium and other trace metals from a coal fly ash basin (Hopkins et al. 1998).  No 
evidence of the bioaccumulation of beryllium in the food chain of humans was located in the literature 
(Fishbein 1981). 
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6.3.2 Transformation and Degradation 
As an element, beryllium does not degrade in the environment; it can only change its form. 
6.3.2.1 Air 
The atmospheric emission of beryllium during ore processing is likely to occur as: beryllium, beryllium 
ore dust, beryllium hydroxide, Be(OH)2; beryllium oxide, BeO; sodium fluoroberyllate, (NH4)2BeF4; and 
beryllium fluoride, BeF2 (Fishbein 1981); from ceramic plants, atmospheric emissions are typically 
beryllium or beryllium oxide (Fishbein 1981).  The form of beryllium emitted into the atmosphere from 
thermal processes is typically beryllium oxide (EPA 1998).  It is unlikely that beryllium oxide in air will 
react with sulfur or nitrogen oxides to produce beryllium sulfates or nitrates. 
6.3.2.2 Water 
Beryllium exhibits only the +2 oxidation state in water.  The reaction of beryllium in water is controlled 
by chemical speciation by which one species is converted to another.  Beryllium is highly hydrated in 
acid solutions, which is a consequence of its high charge to size ratio.  The speciation of beryllium in 
solution is: [Be(H2O)4 ]2+, Be2(OH)3+, Be3(OH)33+, and possibly Be5(OH)73+ in acid solution (i.e., pH#6); 
and [Be(OH)4]2- in basic solution (i.e., pH>8) (Cotton and Wilkinson 1980).  In the pH range of 6–8, 
typical of most waters, the speciation of beryllium is controlled by the formation solid beryllium 
hydroxide, Be(OH)2, which has a very low solubility (solubility product, Ksp=10-21). Table 6-4 illustrates 
several precipitation reactions for beryllium under a neutral environment. 
Other transformations of environmental importance are the formation of insoluble basic carbonates, such 
as (BeCO3)2Be(OH)2, formed by reaction of dissolved carbonate with beryllium solutions and the 
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Ammonium tetrafluoroberyllate Remains soluble in a neutral 
(Ammonium beryllium fluoride) environment 





Beryllium oxide Forms insoluble beryllium 
hydroxide in a neutral 





Beryllium hydroxide Beryllium hydroxide is 
insoluble in a neutral 





Beryllium fluoride Remains soluble in a neutral 
environment 





Beryllium nitrate trihydrate Forms insoluble beryllium 
hydroxide in a neutral 





Beryllium sulfate tetrahydrate Forms insoluble beryllium 
hydroxide in a neutral 
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Beryllium oxalate trihydrate Forms insoluble beryllium 
hydroxide in a neutral 





Beryllium Basic Acetateb Forms insoluble beryllium 
hydroxide in a neutral 






Source: EPA 1998 
aMOH is a base; M in MOH signifies a cation such as sodium (Na) or potassium (K).
bBeryllium basic acetate is not a true basic salt; it is a covalent compound. 
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6.3.2.3 Sediment and Soil 
Typical transformation processes for beryllium in soil include precipitation, complexation, and anion 
exchange. Important factors affecting the transformation of beryllium in soils and sediments include: 
pH, ionic strength (i.e., salinity), concentration and distribution of species, composition of the mineral 
matrix, organic matter, biological organisms, and temperature (see Section 6.3.1).  Data suggesting the 
biotransformation of beryllium or its compounds in soil were not located. 
6.3.2.4 Other Media 
No data were located on the transformation of beryllium in media other than air, water, sediment, and soil 
in the literature. 
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
6.4.1 Air 
Beryllium in the ambient air is measured at many local, state, and national air monitoring stations across 
the United States. The data are available from the Storage and Retrieval of Aerometric Data database 
(EPA 1987). The detection limit for aerometric determination of beryllium is 0.03 ng/m3, and annual 
averages at most of these monitoring stations are listed below this concentration.  Measurements at 
100 U.S. locations indicated an average daily beryllium concentration of <0.5 ng/m3 (Drury et al. 1978; 
Fishbein 1981). Between 1982 and 1992, annual averages of beryllium in air ranged from 0.02 to 2 ng/m3 
in the urban Detroit, Michigan area. The ambient concentrations of beryllium were quite similar for all 
land use categories (e.g., residential, commercial, and industrial).  In 1985, in Jacksonville, Florida, 
beryllium was below the limit of detection in air (Del Delumyea et al. 1997). 
The ambient concentration of beryllium found in air near power stations in Castellon, Spain ranged from 
not detected to 1.61 ng/m3 (Boix et al. 2001). Beryllium concentrations in atmospheric particulate 
samples in and around a beryllium processing facility near Navi Mumbai, India were 0.48±0.42 ng/m3 
(N#397). The levels of beryllium during the monsoon season were comparatively lower and often were 
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6.4.2 Water 
Beryllium was detected in 2,760 out of 50,000 U.S. Geological Survey ambient surface water monitoring 
stations through the year 1988 with a mean concentration of 1.9 µg/L (Eckel and Jacob 1988).  The 
National Drinking Water Contaminant Occurrence Database (NDOD), which contains data from ambient 
water supplies, lists the number of detections of beryllium in surface water at several locations around the 
United States. In lakes/reservoirs, dissolved beryllium was detected at 13 of 137 sites (9.5% of sites) with 
an average concentration of 1.1±0.4 µg/L (EPA 2001).  In spring waters, dissolved beryllium was 
detected at 4 of 66 sites (6.1% of sites) with an average concentration of 99.3±42.1 µg/L (EPA 2000a).  In 
other surface waters, dissolve beryllium was detected at 227 of 1,539 sites (14.7% of sites) with an 
average concentration of 20.8±36.1 µg/L; total beryllium was detected at 182 of 943 sites (19.3% of sites) 
with an average concentration of 4.4±35.1 µg/L (EPA 2001).  The median total beryllium concentration 
of Great Lakes water samples ranged from <4 to 120 ng/L.  The percentage of beryllium in suspended 
particulates of Great Lakes water samples ranged from 2 to 88% and averaged about 50% (Rossmann and 
Barres 1988). Beryllium concentrations measured in the Houston Ship Channel ranged from 8 to 24 ng/L 
(Saleh and Wilson 1999). The concentration of total beryllium in seawater ranges from 0.02 to 0.9 ng/L, 
with an average of <0.5 ng/L (Measures and Edmond 1986; Merrill et al. 1960). 
The NDOD lists the number of detections of beryllium in groundwater water at several locations around 
the United States. In groundwater, dissolved beryllium was detected at 262 of 4,177 sites (6.6% of sites) 
with an average concentration of 13.0±50.3 µg/L; total beryllium was detected at 30 of 334 sites (9.0% of 
sites) with an average concentration of 1.7±1.8 µg/L (EPA 2000a).  The median concentration of 
beryllium in groundwater samples taken around the Denver, Colorado metropolitan area in 1993 was 
measured at <1 µg/L (Bruce & McMahon 1996).  Beryllium has been identified in 376 groundwater 
samples collected from 535 NPL hazard waste sites, where it was detected in some environmental media 
(HazDat 2002). 
Rainwater in Australia had an average beryllium concentration of 0.05–0.08 µg/L (Meehan and Smythe 
1967) and an upland environment in Great Britain had an average concentration of <0.06 µg beryllium/L 
(Neal et al. 1992). 
The average concentrations of beryllium in bottled and tap water in the United States were <0.1 and 
0.013 µg/L, respectively.  Table 6-5 summarizes some selected data on the beryllium content of drinking 
water (Vaessen and Szteke 2000). 
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6.4.3 Sediment and Soil 
Beryllium is the 44th most abundant element in the Earth’s crust.  The average beryllium concentration in 
the Earth’s crust is approximately 2–5.0 mg/kg (Drury et al. 1978; Griffitts and Skilleter 1990; Krám et 
al. 1998; Mason and Moore 1982; Reeves 1986). Beryllium occurs in silicate minerals and feldspar 
minerals.  The greatest known concentrations of beryllium are found in certain pegmatite bodies. 
Beryllium ores can contain several thousand mg beryllium per kg solid (Fishbein 1981).  Shacklette and 
Boerngen (1984) reported the average and range of beryllium concentrations in soils and other surficial 
materials in the conterminous United States as 0.63 and <1–15 mg/kg, respectively.  Frink (1996) 
summarized several different studies and reported that the most likely concentration of beryllium in 
uncontaminated soils (in the Northeast United States) ranges from <1 to 7 mg/kg.  The average 
concentrations of beryllium in the O or A horizons (sandy loam) and the B horizon (clay) in Maryland 
were 0.71 and 0.46 mg/kg respectively (Sparling and Lowe 1996).  The average and range of beryllium 
concentrations in Florida soils were 0.46 mg/kg and 0.01–5.92, respectively (Chen et al. 1999).  The 
average beryllium concentration in California soils was measured as 1.14 mg/kg (Chen et al. 1999). 
There are few beryllium rich soils in the United States, and these areas are in sparsely settled areas that 
are not important for food production (Griffitts and Skilleter 1990).  The concentration of beryllium in 
soil around beryllium processing facilities in Navi Mumbai, India ranged from 1.42 to 2.75 µg/g (Thorat 
et al. 2000). These levels were comparable to background levels reported in the literature. 
In bottom sediments of the Detroit River and western Lake Erie, concentrations of beryllium ranged from 
0.1 to 3.8 µg/g beryllium (Lum and Gammon 1985).  The beryllium levels in the sediments of Lake 
Pontchartrain, Louisiana were 0.05–0.5 µg/kg (dry weight) (Byrne and DeLeon 1986).  The concentration 
of beryllium in sediments from the Neosho River in southeastern Kansas ranged from 0.52 to 1.1 µg/g dry 
weight in 1992 (Allen et al. 2001). Beryllium has been identified in 353 soil and 193 sediment samples 
collected from 535 NPL hazardous waste sites, where it was detected in some environmental media 
(HazDat 2002). 
Table 6-5. Beryllium Content of Drinking Water 
Content (µg/kg) 
Number of 
Product samples Mean Range Technique Reference 
Mineral water (bottled) 
Spain: 
Lanjaron 3 — 0.12±0.01 IEF Capitan et al. 1989 
Ortigosa del Monte 3 <0.6 <0.06 IEF Capitan et al. 1989 
United States: 
All samples 72 <0.1 <0.1–5.2 ICP Allen et al. 1989 
Domestic samplesa 18 <0.1 <0.1–0.2 ICP Allen et al. 1989 
European samplesb 54 <0.1 <0.1–5.2 ICP Allen et al. 1989 
Poland: 
Nieszawa 3 0.17 — ET-AAS Szczepaniak and Szymanski 1996 
Zywiec Zdrój 3 0.15 — ET-AAS Szczepaniak and Szymanski 1996 
Tap Water 
Spain-Granada 3 — 0.09±0.01 IEF Capitan et al. 1989 
Germany-Mainz — 0.008c <0.005±0.009 ET-AAS Reichert 1973 






















samples Mean Range Technique Reference 
Saudi Arabia-Riyadh 
(schools) 
59 1.24c 0.4–2.17 ICP-MS Al-Saleh 1996 








Fonds et al. 1987 
Van de Veld-Koerts et al. 1994 
United States — 0.013c 0.01–0.7 — APHA 1992 




— = Not specified; ET-AAS = electrothermal atomic absorption spectrometry; ICP = inductively coupled plasma spectroscopy; ICP-MS = inductively coupled 
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6.4.4 Other Environmental Media 
The beryllium concentration in several foods, fruits, and fruit juices from around the world are shown in 
Tables 6-6 and 6-7. The median concentration of beryllium in the 38 foods listed in Table 6-6 is 
22.5 µg/kg fresh weight (excluding kidney beans) and the range of concentrations is <0.1–2,200 µg/kg 
fresh weight. The highest concentrations (in µg/kg fresh weight) were reported for kidney beans (2,200), 
crisp bread (112), garden peas (109), parsley (77), and pears (65).  The average concentration of 
beryllium in fruit and fruit juices listed in Table 6-7 is 13.0 µg/L, and the concentrations ranged from not 
detected to 74.9 µg/L. 
The beryllium concentration in the tissue of bottom fish (e.g., English sole or Parophrys vetulus) from 
Commencement Bay, Tacoma, Washington was 6 µg/kg (Nicola et al. 1987).  Beryllium levels in oysters 
and clams in Lake Pontchartrain, Louisiana were 0.051 and 0.083–0.38 µg/g dry weight, respectively 
(Byrne and DeLeon 1986).  A U.S. FDA survey of concentrations of beryllium and other elements in 
oysters and clams collected from U.S. coastal areas in use for shellfish production ranged from not 
detected to 0.002 mg/kg wet weight (Capar and Yess 1996).  In 1991, the concentration of beryllium in 
mussels species from the Neosho River, Kansas were 0.02–0.04, not detected–0.02, 0.03, and 
0.02–0.04 µg/g dry weight for pimpleback (n=3) sampled at Cottonwood River; Kansas, monkeyface 
(n=2) sampled at Humboldt, Kansas; monkeyface (n=1) sampled at Leroy, Kansas; and monkeyface (n=4) 
sampled at Oswego, Kansas, respectively (Allen et al. 2001). 
The concentration of beryllium in pipping black-crowned night herons from Pea Patch Island in Delaware 
Bay, a major shipping area that receives anthropogenic releases of toxic substances, ranged from not 
detected to 0.028 µg/g dry weight.  At Middle Island (a coastal reference site without contamination 
located in Rehoboth Bay, Delaware), the concentration of beryllium in pipping black-crowned night 
herons ranged from not detected to 0.021 µg/g dry weight (Ratter et al. 2000). 
Beryllium has been detected in orchard leaves and in various trees and shrubs in the United States at 
concentrations of 26 and <1 µg/kg, respectively (IARC 1980).  The beryllium content of 
macrohydrophytes derived from various habitats in Poland ranged from 0.7 to 136.6 µg/g.  The beryllium 
concentrations varied with the plant species and the particular degree of water contamination in their 
respective environments (Sarosiek and Kosiba 1993).  Beryllium levels were below detection limits (not 
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Table 6-6. Beryllium Content of Various Fresh Foods 
Concentration (µg 
Be/kg fresh weight) 
Number of 
Product samples Mean Range Technique Reference 
Bananas, pulp 400 4.2 ND–18 — Cowgill 1981 
Beans 3 0.07 ND–0.07 F Meehan and Smythe 1967 
Beans, kidney — 2,200a — ICP-AES Awadallah et al. 1986 
Cabbage 1 0.2 — F Meehan and Smythe 1967 
Cabbage 95 0.091 ND–0.50 ICP-MS Bibak et al. 1999 
Cane sugar: 
brown — 30 — — Hamilton and Minski 1973 
demerara — 6 — — Hamilton and Minski 1973 
refined — 2 — — Hamilton and Minski 1973 
granulated — 0.2 — — Hamilton and Minski 1973 
Carrots, raw — <25 — — Wolnik et al. 1984 
Clams, hardshell 31 2±3 — ICP-AES Caper and Yess 1996 
Clams, softshell 10 <2 — ICP-AES Caper and Yess 1996 
Crabs 6 15 10–20 F Meehan and Smythe 1967 
Crisp bread — 112a — Flame AAS Zorn and Diem 1974b 
Coriander — 34a — ICP-AES Awadallah et al. 1986 
Corn, field — <25 — — Wolnik et al. 1984 
Dill — 59a — ICP-AES Awadallah et al. 1986 
Egg plant —  26a — ICP-AES Awadallah et al. 1986 
(aubergine) 
Fish, whole: 
Mullet 8 11 1.6–19 F Meehan and Smythe 1967 
Blackfish 4 11 3.7–18 F Meehan and Smythe 1967 
Fish, whole: 
Mullet 2 1.5 ND–2.6 F Meehan and Smythe 1967 
Blackfish 1 0.4 — F Meehan and Smythe 1967 
Garden pea — 109a — ICP-AES Awadallah et al. 1986 
Green pepper — 42a — ICP-AES Awadallah et al. 1986 
Hen eggs, yolk 1 0.2 — F Meehan and Smythe 1967 
Hen eggs, yolk, and 1 0.06 — F Meehan and Smythe 1967 
white 
Honey 
Eucaliptus — 0.18±0.09 — ICP-MS Bettinelli et al. 2000 
Robinia — 0.38±0.02 — ICP-MS Bettinelli et al. 2000 
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Table 6-6. Beryllium Content of Various Fresh Foods (continued) 
Concentration (µg 
Be/kg fresh weight) 
Number of 
Product samples Mean Range Technique Reference 
Lettuce — 16a — Flame AAS Zorn and Diem 1974 
Meat 3 4 4–5 GC-ECD Kaiser et al. 1972 
Milk 100 0.2 ND–0.7 F Meehan and Smythe 1967 
Mushrooms 1 1.6 — F Meehan and Smythe 1967 
Mushrooms, 1,303 9 <5–36 ET-AAS Seeger et al. 1984 
European wild 
Orange juices — <1 — — McHard et al. 1980 
Oysters 59 0.6 0.2–5.4 F Meehan and Smythe 1967 
Oysters, east coast 93 <2 — ICP-AES Capar and Yess 1996 
United States 
Oysters, west coast 40 <2 — ICP-AES Capar and Yess 1996 
United States 
Parsley — 77a — ICP-AES Awadallah et al. 1986 
Peanuts, kernels 2 0.5 0.3–0.8 F Meehan and Smythe 1967 
Pears — 65a — ICP-AES Awadallah et al. 1986 
Potatoes — 59a — ICP-AES Awadallah et al. 1986 
Potatoes — 33a — Flame AAS Zorn and Diem 1974 
Potatoes 41 0.4–0.6 0.2–1.4 ET-AAS Hofele et al. 1994 
Rice 3 4 3–5 GC-ECD Kaiser et al. 1972 
Rice, peeled — 72a — Flame AAS Zorn and Diem 1974 
Tomatoes 1 0.2 — F Meehan and Smythe 1967 
Tomatoes 17a — Flame AAS Zorn and Diem 1974 
Vegetable marrow —  20a — ICP-AES Awadallah et al. 1986 
(pumpkin) 
aOriginal data based on dry weight; concentrations are recalculated to fresh weight. 
— = not specified; AAS = atomic absorption spectroscopy; AES = atomic emission spectroscopy; 
ET-AAS = electrothermal atomic absorption spectrometry; F = fluorimetry; GC-ECD = gas chromatography electron 
capture detection; ICP-AES = inductively coupled plasma-atomic emission spectroscopy; ICP-MS = inductively 
coupled plasma-mass spectrometry; ND = not detected 
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Table 6-7. Beryllium Content of Various Fruits and Fruit Juices 
Product Number of samples Mean (µg/L) Range 
Apple juice 4 22.5 ND–43.6 
Citrus fruit 
Ruby red grapefruit 1 1.3 — 
Lime 1 ND — 
Tangerine 1 0.8 — 
Grape cultivars 3 4.4 <0.1–7 
Lemon products 
CA lemon 1 17.4 —
 
Bottled lemon 1 17.0 —
 
Lemonade 1 55.3 —
 
Orange juice 5 2.8 ND–2.8
 
Papaya (pulp) 3 74.9 64.5–84.1
 
Pear (pulp) 1 37.3 —
 




Apricot 1 <0.1 —
 
Peach 1 ND —
 
Plum 1 1.6 —
 
Prune 1 3.6 —
 
Sour cherry 1 1.5 —
 
Tomato sauce 2 42.4 39.8–45.0 
Tropical fruit 
Banana 1 1.5 — 
Kiwi 1 3 — 
Mango 1 4.5 — 
Pineapple 1 <0.1 — 
Source: Barnes 1997 
— = not specified; ND = not detected 
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specified) in vegetation in the immediate vicinity of a municipal solid waste (MSW) incinerator near 
Catalonia, Spain (Meneses et al. 1999). 
Beryllium levels of 0.47–0.74 µg per cigarette have been detected in three brands of German cigarettes; 
2–10% of the beryllium was found in the cigarette smoke (Reeves 1986).  In a literature review 
undertaken by Smith et al. 1997, yields of 0–0.0005 µg beryllium per cigarette have been reported for 
domestic cigarette brands.  Beryllium was detected in only 4 of 12 studies in which it was a target element 
(Smith et al. 1997). 
The beryllium concentration in coal ash is on average 46 mg/kg in the United States (Stadnichenko et al. 
1961). Beryllium concentrations in ammonia, nitrate, and phosphorus fertilizers used in agriculture 
ranged from <0.2 to 13.5 µg/g (Raven and Loeppert 1997). 
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
The general population is exposed to trace amounts of beryllium by inhalation of air and ingestion of 
drinking water and food. If the average concentration of beryllium in air is assumed to be <0.03 ng Be/m3 
(see Section 6.4.1), and it is further assumed that a normal U.S. adult inhales approximately 20 m3 of air 
per day, then the inhalation exposure for a U.S. adult would be approximately <0.6 ng Be/day.  This value 
may be somewhat higher for persons living near sources of beryllium emission.  Similarly, if the 
concentration of beryllium in average U.S. drinking water is 0.5 µg/L (see Section 6.4.2), and the 
consumption rate of drinking water by a normal adult is assumed to be 2 L/day, the exposure from 
drinking water would be 1 µg per day.  Reliable data regarding the daily exposure rate to beryllium from 
food consumption are lacking.  It has been estimated that the daily intake of beryllium from U.S. food is 
0.12 µg (EPA 1987). This estimate is based on an arbitrary value for beryllium content of a total diet 
sample of 0.1 ng per g food and a daily consumption of 1,200 g of food (EPA 1987).  In a study 
examining the trace element concentrations of foodstuffs in Tarragona, Spain, beryllium was below the 
detection limit (0.02 µg/g) in the following food groups: meat, seafood, cereals, seeds, vegetables, roots/ 
tubers, fruits, milk, dairy products, eggs, and sugar (Llobet et al. 1998).  In another study examining, the 
trace element concentrations of food samples via hospital diets in Japan, the average daily intake of 
beryllium was determined to be 84.4 µg/day (Muto et al. 1994).  Other investigators have reported the 
total daily intake of beryllium in the range of 5–100 µg/day (Emsley 1998; Tsalev and Zaprianov 1984; 
Vaessen and Szteke 2000). 
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The mean concentration of beryllium in urine of about 500 nonoccupationally exposed individuals in the 
United States according to the 3rd National Health and Nutrition Examination Survey was 0.22 µg/g of 
creatinine (Paschal et al. 1998). Other studies reported mean urinary beryllium concentrations ranging 
from <0.03 to 0.4 µg/L for persons not occupationally exposed (Apostoli and Schaller 2001).  Tsalev and 
Zaprianov (1984) reported that approximately 10 µg Be/day is excreted (on average) in human feces. 
Using the estimated daily fecal concentration, the exposure to beryllium by this method is within the 
range of estimates determined from total diet studies as discussed previously.  Beryllium concentrations 
in other human tissues and fluids are: blood 0.01–3.6 µg/L, bone 3 µg/kg, hair 5–8 µg/kg, liver 2 µg/kg, 
muscle 0.8 µg/kg, nails <10 µg/kg, plasma or serum <4 µg/L, and tooth <0.01 µg/kg (Emsley 1998; 
Tsalev and Zaprianov 1984). 
In a study of German cigarettes, tobacco was found to contain 0.47–0.74 µg beryllium per cigarette and 
2–10% passes into the smoke during smoking (Reeves 1986).  Some cigarettes contain small amounts of 
beryllium, and increases of blood and urine beryllium have been associated with smoking (Tsalev and 
Zaprianov 1984). In another review focusing on cigarettes from the United States, yields of 0–0.0005 µg 
Be per cigarette have been reported in 4 of 12 studies of smoke measurements; however, 8 of 12 studies 
failed to detect beryllium at any concentration (Smith et al. 1997).  Nevertheless, smokers may have a 
higher probability of exposure to beryllium than the nonsmoking population. 
People who work in industries where beryllium is present have a greater probability of inhalation 
exposure than nonoccupational groups. The estimated daily-weighted average beryllium exposure levels 
for some workers in a plant that extracted and produced beryllium metal were >50 µg/m3 during the 
mid-1960s.  Beryllium exposure levels were >30 µg/m3 during the mid-1970s.  After 1977, this plant 
complied with the OSHA maximum TWA concentration of 2 µg/m3 (Kriebel et al. 1988a). The TWA 
personal air concentration for beryllium in a precious metal refinery in 1983 ranged from 0.22 to 
42.3 µg/m3 (Cullen et al. 1987). Recent occupational exposure measurements of beryllium at the Rocky 
Flats Environmental Technology Site in Colorado were conducted in the main beryllium production 
building. Mean concentrations of beryllium were measured for area and breathing zone monitors as 
0.16 and 1.04 µg/m3, respectively (Stange et al. 1996a).  At the Cardiff Atomic Weapons Establishment in 
the United Kingdom, annual mean area and personal sampling concentration ranges of beryllium were 
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Workers who do not change their work clothes at the end of the work day can increase the probability of 
home contamination with beryllium.  Fabrics experimentally exposed at a beryllium production worksite 
contained up to 2.8 mg Be/m2 (NIOSH 1995). Workers’ family members may be exposed when workers 
come home wearing beryllium-contaminated clothing.  Resuspended beryllium dust concentrations in air 
from unwashed clothing can reach levels of 0.64 µg/m3. The shaking of contaminated clothes can 
administer an inhalation dose of approximately 17 µg beryllium (NIOSH 1995).  In another study, 
beryllium concentrations in machine shop workers’ personal vehicles were measured.  The highest 
concentrations of beryllium were measured on the driver’s floor of the workers’ vehicles at 
19 µg/Be/foot2 (Sanderson et al. 1999). 
It is likely that dental technicians who work with beryllium-containing dental alloys without using 
appropriate handling safeguards may be exposed to higher levels of beryllium than the normal population 
(Bauer et al. 1988). 
A National Occupational Exposure Survey conducted by NIOSH during 1981–1983 estimated that 
13,869 workers were potentially exposed to beryllium and 7,045 workers to beryllium compounds in the 
workplace (NIOSH 1989a). 
6.6 EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from 
adults in susceptibility to hazardous substances are discussed in 3.7 Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults. 
The developing human’s source of nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
Specific information on the exposure of children to beryllium is limited.  An x-ray health survey was 
conducted in 1948 in the neighborhood surrounding a beryllium manufacturing facility in Lorain, Ohio. 
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In this survey, 2,000 children were examined, and none of the children exhibited signs of chronic 
berylliosis disease (AEC 1948).  As with adults in the general population, small exposures in children 
occur from normal ingestion of food and drinking water and inhaling air.  These exposures may be higher 
in areas with naturally high beryllium soil levels, and near beryllium processing sites, electric power 
plants, and waste sites containing beryllium.  A study by Krachler et al. (1999a) provides suggestive 
evidence that beryllium is transferred across the placenta and excreted via breast milk.  The levels of 
beryllium in umblical cord serum and in colostrum were higher than in maternal serum.  The average 
concentrations of beryllium in the umbilical cords of healthy newborn children were measured for arterial 
(1.3 µg/L), venous (0.8 µg/L), and mixed (0.6 µg/L) sera (Krachler et al. 1999b).  No information on 
beryllium levels in amniotic fluid, meconium, or neonatal blood was located. 
At waste sites, beryllium that is found in excess of natural background levels is most likely to be in soil, 
and presents a special hazard for young children.  Hand-to-mouth activity and eating contaminated dirt 
will result in oral exposure to beryllium.  The hazard in this case depends on the form of beryllium 
present at the waste site. Beryllium in soil at waste sites is almost entirely in the form of insoluble oxides 
and hydroxides of beryllium which would be expected to be less available than more soluble forms (see 
Section 6.3.1). 
Other home exposures are unlikely since no household products or products used in crafts, hobbies, or 
cottage industries contain significant amounts of beryllium except in copper-beryllium wire, which is 
used in and around the home in electronics or other electrical devices. 
Beryllium exposure to children from parents’ work clothes, skin, hair, tools, or other objects from the 
workplace is possible if the parent uses beryllium at work.  In a report to Congress by NIOSH, several 
historical cases of home contamination by beryllium were reported (NIOSH 1995).  The most recent case 
was in 1992, suggesting that cases of beryllium home contamination may still be occurring.  The majority 
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6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Several populations are at high risk for beryllium exposure.  Individuals with the highest risk include 
people who are occupationally exposed to beryllium from manufacturing, fabricating, or reclaiming 
industries. There have been no reports of diseases attributable to beryllium exposure as a result of 
beryllium ore mining operations (Eisenbud and Lisson 1983; EPA 1987; Hamilton and Hardy 1974). 
People living near beryllium-emitting industries may be at a slightly increased risk of beryllium exposure 
due to contact with beryllium-contaminated dust within the household, as opposed to ambient air levels. 
Occupationally exposed workers who carry beryllium dust on their clothes from the workplace to their 
home may increase the risk of beryllium exposure to their family members (EPA 1987).  However, it is 
common today for beryllium industries to provide and launder employee's work clothes.  The National 
Emission Standard for Hazardous Air Pollutants (NESHAPS) restricts the amount of beryllium emitted 
into the environment by industries that process beryllium ores, metals, oxides, alloys, or wastes.  The 
NESHAPS can be met by complying with either a 10 g per 24-hour emission limit or by meeting an 
ambient air concentration of 0.01 µg/m3 of air averaged over a 30-day period (EPA 1982).  Machine 
shops machining alloys containing #5% beryllium by weight are excluded from regulation under the 
NESHAPS emission standard (see 40 CFR Part 61, subpart C 61.30(b) 2001).  No new cases of beryllium 
disease in people living near beryllium-processing industries have been reported in the past several years, 
probably because the past exposures were relatively high compared to present levels of beryllium in the 
ambient and workplace air (EPA 1987; NIOSH 1995). 
Individuals may be exposed to high levels of beryllium from implanted dental prostheses (EPA 1987). 
The highest concentration of beryllium released from base metal alloy used as dental crowns measured in 
an artificial oral environment was 8 µg/day per crown (Tai et al. 1992).  The mantles of some lanterns 
used by campers contain approximately 600 µg of beryllium, and most of the beryllium becomes airborne 
during the first 15 minutes when a new mantle is used (Fishbein 1981).  Therefore, people who camp 
outdoors and use these mantles are possibly exposed to higher than normal levels of beryllium.  A small 
percentage of the population is sensitive to very low concentrations of beryllium, but there is no evidence 
that sensitivity develops at beryllium concentrations present in food or water, or that sensitivity is 
aggravated by ingestion of beryllium.  No other special groups at risk were identified (EPA 1980). 
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6.8 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of beryllium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of beryllium. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The relevant physical and chemical properties of beryllium are 
known (see Section 4.2). Additional information regarding the chemical forms of beryllium in coal fly 
ash and aerosols produced by specific industrial processes, and the mode by which beryllium compounds 
are incorporated into biological systems would be useful.  Additional information about the chelation of 
beryllium (especially about chelating agents that may be used in the development of beryllium-specific 
chelation therapy) would also be useful. 
Production, Import/Export, Use, Release, and Disposal. Data regarding the production, 
import/export, and use of beryllium and beryllium compounds are available (see Sections 5.1 through 
5.3). According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. 
Section 11023, industries are required to submit chemical release and off-site transfer information to the 
EPA. The TRI is updated yearly and provides a list of industrial production facilities and emissions. 
As reported in Tables 6-2 and 6-3, the most significant amount of beryllium and beryllium compounds 
from production and use facilities is disposed of on land.  Little is known about the methods used for land 
disposal of beryllium, except that small amounts of beryllium waste are discharged into public sewers 
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(TRI99 2002). Additional data examining the method used for land disposal of beryllium waste and the 
routes by which beryllium might find its way from land disposal sites into groundwater would be useful. 
Environmental Fate. For solids, there is a need to determine uptake factors into edible portions of 
plants and not just adherence to the root structure.  Dry or wet deposition from the atmosphere to soil and 
water can occur. Little experimental data on the particle size and residence time of beryllium and 
beryllium compounds present in the ambient atmosphere are available.  Additional data examining the 
possible chemical transformation reactions of beryllium and its half-life in air would be useful.  Data 
regarding the dominant types of sorption mechanisms for beryllium (e.g., ion exchange vs. chemical 
sorption) for different mineral and environmental conditions are limited.  Additional information 
elucidating the fate of beryllium with respect to its chemical speciation in soil is necessary.
Bioavailability from Environmental Media. Although the absorption of specific beryllium 
compounds from skin contact, inhalation, and ingestion have been studied in animals (see Section 3.3.1), 
the bioavailability of beryllium or its compounds from contaminated air, water, soil, or plant material may 
differ significantly from the studied values.  Additional information on the dependence of absorption of 
beryllium on such parameters as chemical form, extent of sorption in the host medium, and other possible 
variables would be useful. 
Food Chain Bioaccumulation. Beryllium does not bioconcentrate to high levels in aquatic animals 
(EPA 1980), although the bioconcentration in bottom-dwelling animals may be higher than non bottom-
dwelling animals (Byrne and DeLeon 1986).  There is no evidence of biomagnification of beryllium 
within terrestrial or aquatic food chains (Fishbein 1981).  Further studies establishing the 
biomagnification potential for beryllium would be useful.  Data regarding the intake of beryllium from 
food are lacking (Vaessen and Szteke 2000; Wolnik et al. 1984).  The accuracy of the available database 
of beryllium in foods is questionable (Vaessen and Szteke 2000).  More reliable concentration 
information is needed on levels of beryllium in food stuff to reduce or eliminate the uncertainties in 
estimating the dietary intake of beryllium (Vaessen and Szteke 2000).  Such information would be 
important in assessing the contribution of food to the total intake of beryllium from different pathways. 
Exposure Levels in Environmental Media. Some data on the levels of beryllium in air and 
drinking water are available. Limited data regarding the ambient concentration of beryllium near 
beryllium-containing hazardous waste sites in the United States are available.  These monitoring data are 
important for assessing the potential health risk for individuals living near the waste sites (Eckel and 
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Langley 1988).  Nationwide monitoring data determining the levels of beryllium in U.S. drinking water at 
a detection limit <10 ng/L would be useful.  Reliable and more recent monitoring data for the levels of 
beryllium in air, drinking water, soil (particularly at NPL sites), and food would be useful in estimating 
exposure from each source.  Remedial investigations and feasibility studies conducted at the NPL sites 
contaminated with beryllium will add to the available database on exposure levels in environmental 
media.  Investigations at these sites will also increase the current knowledge regarding the transport and 
transformation of beryllium at hazardous waste sites. 
Exposure Levels in Humans. Beryllium levels in the urine and lung of both the control and 
occupationally exposed populations are available (Kanarek et al. 1973; Stiefel et al. 1980).  No data on 
the beryllium levels in body tissues or fluids of populations living near hazardous waste sites or coal-fired 
power plants are available. Such information would be useful in assessing exposure levels for this 
population. Further studies regarding the possibility of increased exposure to beryllium via dental 
implants may be useful. 
Exposures of Children. Children will be exposed to beryllium in the same manner as adults in the 
general population (i.e., ingestion of food and water, and inhalation of air). 
Child health data needs relating to susceptibility are discussed in Section 3.12.2 Identification of Data 
Needs: Children’s Susceptibility. 
Exposure Registries. The Beryllium Case Registry (BCR) was established at Massachusetts General 
Hospital, Boston, Massachusetts in 1952 and taken over by NIOSH in the late 1970s.  Since its transfer to 
NIOSH, no additional cases were added. Presently, the BCR is not an active registry.  This element is not 
currently one of the compounds for which a subregistry has been established in the National Exposure 
Registry.  The element will be considered in the future when chemical selection is made for subregistries 
to be established. The information that is amassed in the National Exposure Registry facilitates the 
epidemiological research needed to assess adverse health outcomes that may be related to the exposure to 
this element. 
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6.8.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2001) database provides additional information obtainable 
from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1.  These 
studies are summarized in Table 6-8. 
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Table 6-8. Ongoing Studies on Human Exposure to Beryllium 
Investigator Affiliation Subject	 Sponsor 
Peters, EL Chicago State	 Fluctuating asymmetry in National Institute of 
University	 isopods as indicator of General Medical 
hazardous metals in urban Sciences 
area 
Grew, ES University of Maine	 Beryllium in antarctic NSF 
ultrahigh-temperature 
granulite-facies rocks and 
its role in partial melting of 
the lower continental crust 
Source: FEDRIP 2001 




7. ANALYTICAL METHODS 
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring beryllium, its metabolites, and other biomarkers of exposure and effect to 
beryllium.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other 
methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA). 
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision. 
7.1 BIOLOGICAL MATERIALS 
Methods used for the analysis of beryllium in biological materials are reported in Table 7-1.  Reviews of 
beryllium analysis methods in biological media have been published (Delves 1981; Tsalev and Zaprianov 
1984). Although the level of beryllium in urine may be informative of the current exposure level, it is not 
useful for quantitative exposure analysis.  In contrast, the level of beryllium in blood, serum, or plasma is 
predictive of the intensity of current exposure from certain beryllium compounds (Tsalev and Zaprianov 
1984; see Section 3.4.2). Neither flame atomic absorption spectroscopy (AAS) nor atomic emission 
spectroscopy (AES) have adequate sensitivity for measuring beryllium concentrations found in body 
fluids and tissues. The determination of beryllium levels in these matrices using the preceding techniques 
requires elimination of spectral interferences.  Graphite furnace (or electrothermal) atomic absorption 
spectroscopy with background correction (deuterium or Zeeman effect) and inductively coupled plasma 
atomic emission spectroscopy (ICP-AES) are common analytical methods for beryllium.  These 
techniques have the sensitivity and accuracy to determine the content of beryllium in body fluids and 
tissues (Delves 1981). To avoid sample contamination, stainless steel needles should be avoided for the 
collection of whole blood samples.  Certain polyethylene sample collection tubes with added heparin as 
an anticoagulant may contaminate whole blood samples (Paudyn et al. 1989).  A gas chromatographic 
method to detect beryllium in whole blood down to a concentration level of 0.02 µg/mL is available 
(Taylor and Arnold 1971).  Krachler et al. (1999b) measured beryllium in umbilical cord serum, 
colostrum, and maternal serum at concentrations to <1 µg/L using inductively coupled plasma mass 
Table 7-1. Analytical Methods for Determining Beryllium in Biological Materials 
Analytical method Sample detection 
Sample matrix Preparation method limit Percent recovery Reference 
Blood Add EDTA; acidify GC/EC ~20 µg/L 44–117% Taylor and Arnold 
1971 
Blood (dog) Add sodium hydroxide; 
dissolve by heating; chelate 
with tri-fluoroacetylacetone; 
extract with benzene 
GC/EC No data 95–117% Frame and Ford 1974 
Urine Dilute with nitric acid ICP-MS 0.1 µg/L No data Paschal et al. 1998 
Urine Acidified urine precipitated 
with excess ammonium 
hydroxide; centrifuge, dissolve 
in nitric acid and add 
lanthanum 
GFAAS 0.01 µg/L 94–110% Hurlburt 1978 
Urine Dilute with a matrix modifier GFAAS 0.05 µg/L 107%; 94–98% Paschal and Bailey 
1986; Shan et al. 1989 
Urine (human 
and rat) 
Add EDTA to aqueous sample; 
adjust to pH 6; add trifluoro­
acetylacetone in benzene; 
extract 
GC/EC 1 µg/L 68–123% Foreman et al. 1970 
Feces Digest; dry ash; dissolve 
residue in acid 
GFAAS 1 µg/kg; ~2 µg/kg 108%; 90–110% Delves 1981; Hurlburt 
1978 
Fingernails Acid digestion; dry ash; 
dissolve in acid 
GFAAS ~2 µg/kg 90–110% Delves 1981 
Hair-fingernails Dissolve in nitric acid­
perchloric acid (1:1) 













Table 7-1. Analytical Methods for Determining Beryllium in Biological Materials (continued) 
Analytical method Sample detection 
Sample matrix Preparation method limit Percent recovery Reference 
Liver (bovine) Wet-ash tissue in a mixture of Fluorescence No data No data IARC 1980 
acids; chelate with spectroscopy 
acetylacteone; extract 
(chloroform); acidify chelate 
with 2-hydroxy-3-naphthoic 
acid reagent 
Lung tissue Sample subjected to dry or wet ICP-AES 0.075 mg/kg No data Martinsen and 
ashing Thomassen 1986 
Lung tissue Dry; acid digestion; dilute in GFAAS No data No data Baumgardt et al. 1986 
acid; standard addition 
EDTA = ethylenediaminetetraacetic acid; GC/EC = gas chromatography-electron capture; GFAAS = graphite furnace atomic absorption spectrometry; ICP-AES = 
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spectroscopy (ICP-MS).  Another relative method for the detection of beryllium is Laser Ion Mass 
Analysis (LIMA).  This analysis method uses a laser beam to ionize elements (e.g., beryllium) in a small 
section of tissue and detects the elements by time-of-flight mass spectrometry (MS) (Williams and 
Kelland 1986). 
Standard reference materials (SRMs) are useful to determine the accuracy of an analytical method.  A 
standard reference urine (SRM=2,670) with a certified beryllium concentration is available from National 
Institute of Standards and Technology (Shan et al. 1989). 
7.2 ENVIRONMENTAL SAMPLES 
Methods used to analyze beryllium in environmental media are presented in Table 7-2.  The standard test 
methods approved by EPA and NIOSH for beryllium analysis in ambient and occupational samples are 
included in Table 7-2. Environmental samples analyzed by atomic absorption spectroscopy and gas 
chromatography (GC) require pretreatment to remove interfering substances and increase sensitivity 
(EPA 1987). At high concentrations (500 mg/kg), aluminum and silicon interfere with the analysis of 
beryllium by atomic absorption spectroscopy.  Separation of these elements is achieved by chelation and 
extraction with an organic solvent. High concentrations of iron interfere with the 243.86 nm beryllium 
emission line used in ICP-AES (Vaessen and Szteke 2000).  A method using laser spark spectroscopy has 
been used for the direct determination of trace quantities of airborne beryllium collected on filters 
(Cremers and Radziemski 1985).  A recent analytical advance is laser induced breakdown spectroscopy 
(LIBS), a real time technique (Langner et al. 1997).  This technique has been used to monitor worker 
exposure to beryllium in 30-second sample intervals (Langner et al. 1997). 
The following SRMs for beryllium in environmental samples are available from the National Institute of 
Standards and Technology: San Joaquin soil, SRM=2,709; Montana soil 1, SRM=2,710; Montana soil 
2, SRM=2,711; coal, SRM=1,632; fly ash, SRM=1,633; trace elements in water, SRM=1,643; orchard 
leaves, SRM=1,571; and filter media, SRM=2,676 (Chang et al. 1982; Epstein et al. 1978; Gladney and 
Owens 1976; Namiesnik and Zygmunt 1999).  SRMs are available for beryllium in soils and sediments 
from Canadian Certified Reference Materials Project (CCRMP), National Research Council of Canada 
Table 7-2. Analytical Methods for Determining Beryllium in Environmental Samples 
Sample detection Percent 










Wet ash collection filter with 
mixture of HNO3/HCl mixture; 
concentrate; add HNO3/LiCl 
solution 
Dissolve collection filter matrix 
in HF; add HNO3; water; boil; 
dilute 
None 
Dry collection filter; add HNO3 
and sulfuric acid; solubilize with 
concentrated HCI 
Filter collection, acid digestion 
Filter collection, acid digestion 
Acidify with HNO3; evaporate 
under heat; add HCl or HNO3 
Acidify with HNO3 





Laser spark technique 
Direct current plasma 
AES 
GFAAS (method 7102) 
GFAAS (method 7300) 
AAS (aspiration­
method 210.1) 


































Scott et al. 1976 























Table 7-2. Analytical Methods for Determining Beryllium in Environmental Samples (continued) 
Sample detection Percent 
Sample matrix Preparation method Analytical method limit recovery Reference 
Water Digest; acidify; dilute	 ICP-MS (method 0.1 µg/L No data AOAC 1995 
933.14) 
Seawater	 Add specific volumes of EDTA, GC/EC 0.02 ng/L 93–104% Measures and 
sodium acetate, benzene and Edmond 1986 
Hfta to collected seawater; rinse 
organic phase with NaOH; UV 
oxidize 
Sediment	 Extract dry sample with HCI DCP-AES 0.02 µg/g No data Lum and Gammon 
solution 1985 
Soil and Acid digest in bomb; dilute ICP-AES (method No data No data ASTM 1999 
sediment D1971-A) 
Soil, sludge, Acid digestion of sample ICP-AES (method 0.3 µg/L 97.7–100% EPA 1988c 
sediments, and 6010) 
other solid 
wastes 
Solid (coal ash)	 Acid digest in bomb; dilute with GFAAS 0.14–4.8 µg/L No data Pougnet et al. 1985 
acid 
Oils and waxes	 Add potassium permanganate FAAS or ICP-AES No data No data OSW 2000 
with heat; acidify; digest with (method 3031) 


















Dissolve in HNO3; dry, then treat 










Awadallah et al. 
1986 
Food Freeze-dry or blender-grind food 
composites; solubilize with
ICP-AES 2.5 µg/kg No data Wolnick et al. 1984 
HNO 3, HClO4, H2SO4, or HCl 2 µg/kg 98% Capar and Yess 
1996 
AAS = atomic absorption spectrometry; AES = atomic emission spectrometry; AOAC = Association of Official Analytical Chemists; APHA = American Public 
Health Association; ASTM = American Society for Testing and Materials; DCP-AES = direct current plasma-atomic absorption spectroscopy; 
EDTA = ethylenediamine tetraacetic acid; FAAS = flame atomic absorption spectrometry; GC/EC = gas chromatography-electron capture; GFAAS = graphite 
furnace atomic absorption spectrometry; GFAES = graphite furnace atomic emission spectrometry; HCI = hydrochloric acid; HClO4 = perchloric acid; 
HF = hydrogen fluoride; Hfta = 1,1,1-trifluoro-2,4-pentanedione; HNO3 = nitric acid; H2SO4 = sulfuric acid; ICP-AES = inductively coupled plasma-atomic 
emission spectrometry; ICP-MS = inductively coupled plasma-mass spectrometry; LiCl = lithium chloride; NaOH = sodium hydroxide; NIOSH = National Institute 
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NRCC and the U.S. Geological Survey (USGS): soil, SO 1; soil-sandy, SO 2; soil-limestone til, SO 3; 
soil-silty, SO 4; arable soil, TILL 2; Lake sediment, IKSD 4; sediment MESS-1; sediment BCSS-1; and 
marine sediment, MAG 1 (Namiesnik and Zygmunt 1999; Waldichuk et al. 1987). 
7.3 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of beryllium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of beryllium.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.
Exposure.  As discussed in Section 3.8.1, the beryllium level in blood/serum/plasma is an accurate 
biomarker of exposure to certain forms of beryllium (James and Williams 1985; Stokes and Rossman 
1991; Zorn et al. 1986). The level of beryllium in normal blood is 1 µg/kg (Zorn et al. 1986).  No 
analytical method capable of determining beryllium in blood at or below this level has been reported in 
the literature. The routine analytical methods presently available are useful for detecting beryllium levels 
in the blood of occupationally exposed persons. 
Effect.  There are several methods for measuring effects due to beryllium exposure (see Section 3.8.2). 
An antigen-specific lymphocyte proliferation test confirms exposure and may be useful in early diagnosis 
of individuals with chronic beryllium disease; several methods for the lymphocyte proliferation test have 
been reported (Bobka et al. 1997; Kreiss et al. 1989; Mroz et al. 1991; Rossman et al. 1988; Stokes and 
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Rossman 1991).  Another method that can be used for the positive diagnosis of chronic beryllium disease 
when other symptoms are evident is LIMA of histological sections of lung or skin granulomas.  LIMA 
can detect parts per million (or mg/kg) levels of beryllium in these tissues (Williams and Kelland 1986). 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. The concentration of beryllium in approximately 95% of drinking waters in the United States is 
<0.01 µg/L (EPA 1980; Iwan 1987). Although a few methods are available (see Table 7-2) to detect 
beryllium at such low concentrations, no routine methods are available to quantify beryllium 
concentrations in most U.S. drinking waters.  Similarly, the detection limit for beryllium in fresh 
vegetables by the commonly used analytical method (see Table 7-2) is 2.5 µg/kg.  At this detection limit, 
beryllium was not found in two foods tested (Wolnik et al. 1984).  Developing a routine analytical 
method to detect low levels of beryllium in foods would be useful.  The data on the levels of beryllium in 
drinking water and total diet samples from ambient sources are significant in determining background 
levels of daily intake from these routes. 
7.3.2 Ongoing Studies 
The FEDRIP database lists an ongoing National Institute of Environmental Health and Sciences study by 
Jolly et al. at ELS Technology, Inc. (Lakewood, Colorado) that is investigating a portable low-cost 
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8. REGULATIONS AND ADVISORIES 
A chronic-duration oral MRL of 0.002 mg beryllium/kg/day was derived for beryllium.  This MRL is 
based on a benchmark dose (defined as the 95% lower confidence limit of the dose corresponding to a 
10% increase in the incidence of small intestine lesions compared to controls) of 0.56 mg 
beryllium/kg/day.  The benchmark dose was divided by an uncertainty factor of 100 (10 for extrapolation 
from animals to humans and 10 for intrahuman variability) and a modifying factor of 3 (to account for the 
lack of a study that supports the gastrointestinal effects found in the Morgareidge et al. [1976] dog study 
and the uncertainty as to whether the benchmark dose level is the NOAEL). 
A chronic oral reference dose (RfD) of 0.002 mg beryllium/kg/day has been derived and verified by EPA 
for beryllium (IRIS 2002).  The RfD is based on a benchmark dose of 0.46 mg beryllium/kg/day for small 
intestine lesions in dogs exposed to beryllium sulfate in the diet for 33–172 weeks (Morgareidge et al. 
1976). This benchmark concentration was divided by an uncertainty factor of 300 to account for 
extrapolation from animals to humans (10), human variability (10), and database gaps (3), particularly 
adequate reproductive and developmental toxicity studies and studies examining immunological end 
points. The chronic-duration oral MRL and the RfD were both derived using a benchmark analysis and 
the same incidence data set.  The difference in the benchmark doses is due to the differences in the 
mathematical model fit to the incidence data (ATSDR used a probit model with a chi-square goodness-of­
fit statistic p-value of 0.9999 and EPA used a weibull model with a chi-square goodness of fit statistic 
p-value of 0.96) and the higher number of significant figures that EPA used to express beryllium doses. 
A chronic inhalation reference concentration (RfC) of 0.02 µg/m3 has been derived for beryllium (IRIS 
2000). The RfC is based on two human studies finding chronic beryllium disease in workers at a facility 
manufacturing beryllia ceramics (Kreiss et al. 1996) and in residents living near a beryllium 
manufacturing facility (Eisenbud et al. 1949).  The Kreiss et al. (1996) study identified a LOAEL of 
0.55 µg/m3 for beryllium sensitization and subclinical chronic beryllium disease, and the Eisenbud et al. 
(1949) study identified a NOAEL of 0.01–0.1 µg/m3 for chronic beryllium disease.  The LOAEL 
identified in the Kreiss et al. (1996) study was used for the operational derivation of the RfC.  This 
LOAEL was divided by an uncertainty of 10 to account for less-than-chronic exposure duration (1), use 
of a LOAEL (3), human variability (1), and database limitations (3), particularly the poor quality of 
exposure monitoring in the co-principal studies and other epidemiology studies. 
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NTP (1999, 2002) lists beryllium and certain beryllium compounds (beryllium-aluminum alloy, beryllium 
chloride, beryllium fluoride, beryllium hydroxide, beryllium oxide, beryllium phosphate, beryllium 
sulfate, beryllium zinc silicate, and beryl ore) as substances reasonably anticipated to be carcinogens. 
IARC (2001) has classified beryllium and beryllium compounds in Group 1, carcinogenic to humans, and 
EPA classifies inhaled beryllium in Group B1, a probable human carcinogen (IRIS 2002). 
The international, national, and state regulations and guidelines regarding beryllium in air, water, and 
other media are summarized in Table 8-1. 
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Table 8-1. Regulations and Guidelines Applicable to Beryllium 
Agency	 Description Information Reference 
INTERNATIONAL 
Guidelines: 
IARC	 Carcinogenicity classification— 






ACGIH Beryllium and compounds (as Be) 
TLV (8-hour TWA) 
STEL (15-minute TWA) 
DOD	 Requires notification to the EPA 
when conducting operations, 
construction, or modification of a 
source of hazardous air 
pollutants—beryllium 
EPA	 National emission standards for 
hazardous air pollutants— 
beryllium emissions to the 
atmosphere from rocket-motor test 
sites 
National emission standards for 
hazardous air pollutants—if 
combustion products from the 
firing of beryllium propellant are 
collected in a closed tank 
National emission standards for 
hazardous air pollutants 
Beryllium emissions to the 
atmosphere from stationary 
sources 
Request approval from the 
Administrator to meet an 
ambient concentration limit on 
beryllium in the vicinity of the 
stationary source 






Shall not exceed EPA 2001i 
75 µg minutes/m3 of 40CFR61.42 
air within the limits of 
10–60 minutes, 
accummulated during 
any 2 consecutive 
weeks, in any area in 
which an effect 
adverse to public 
health could occur 
Emissions from such EPA 2001i 
tank shall not exceed 40CFR61.42 
2 g/hour and a 
maximum of 10 g/day 
EPA 2001l 
40CFR61.32 
Shall not exceed 
10 grams over a 
24-hour period 
0.01 µg/m3, averaged 
over a 30-day period 
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Table 8-1. Regulations and Guidelines Applicable to Beryllium (continued) 
Agency Description Information Reference 
NATIONAL (cont.) 
NIOSH Beryllium and beryllium 
compounds (as Be) 





OSHA PEL (8-hour TWA)—beryllium and 
beryllium compounds (as Be) 






5 µg/m3 OSHA 2001a 
29CFR1910.1000 
Table Z-2 
Acceptable maximum peak above 
the acceptable ceiling 
concentration for an 8-hour shift 
25 µg/m3 OSHA 2001a 
29CFR1910.1000 
Table Z-2 
for a maximum duration of 
30 minutes—beryllium and 
beryllium compounds 
PEL (8-hour TWA) for construction 
workers—beryllium and beryllium 
compounds (as Be) 
2 µg/m3 OSHA 2001c 
29CFR1926.55 
PEL (8-hour TWA) for shipyard 
workers—beryllium and beryllium 
compounds (as Be) 
2 µg/m3 OSHA 2001b 
29CFR1915.1000 
Welding or cutting indoors, 
outdoors, or in confined spaces 
involving beryllium-containing 




using local exhaust ventilation and 
airline respirators 
USC Listed as a hazardous air USC 2001 
pollutant—beryllium compounds 42 USC 7412 
b. Water 
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Table 8-1. Regulations and Guidelines Applicable to Beryllium (continued) 
Agency Description Information Reference 
NATIONAL (cont.) 
EPA Land disposal restrictions; 





1.22 mg/L TCLP 
EPA 2001e 
40CFR268.48 
MCLG—beryllium 0.004 mg/L EPA 2001g 
40CFR141.51(b) 
MCL—beryllium 0.004 mg/L EPA 2001f 
40CFR141.62(b) 
National recommended water 
quality criteria for human health for 
consumption of beryllium 
Water and organism 
Organism only 
EPA has not 
calculated human 
health criteria for this 
contaminant 
EPA 1999a 










FDA Bottled water allowable limit— 
beryllium 
0.004 mg/L FDA 2001 
21CFR165.110 
d. Other 
ACGIH Carcinogenicity classification— 
beryllium and compounds 
A1d ACGIH 2001 












Health based limits for exclusion 
of waste-derived residue— 
beryllium 
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Table 8-1. Regulations and Guidelines Applicable to Beryllium (continued) 
Agency Description Information Reference 
NATIONAL (cont.) 
EPA Identification and listing of 
beryllium powder as a hazardous 
waste—hazardous waste number 
P015 EPA 2001d 
40CFR261.33(e) 
Reportable quantity regarded as a 
CERCLA hazardous substance 
under Section 307(a) of the Clean 
Water Act 
Beryllium and compounds 
Beryllium chloride, beryllium 





Standards for management of 
hazardous waste 
Unit risk 






Toxic chemical release reporting; 
community right-to-know, effective 
date for reporting—beryllium 
01/01/87 EPA 2001k 
40CFR372.65 
Toxic pollutant designated 
pursuant to Section 307(a)(1) of 




 NTP Carcinogenicity classification-
beryllium and compounds 
Known human 
carcinogens 





North Carolina Toxic air pollutant—beryllium 
Chronic toxicant (24 hours) 4.1x10-6 mg/m3 
BNA 2001 
Vermont Hazardous ambient air 
standardf—beryllium, total 
1.3x10-3 µg/m3 VT Agency of 
Natural 
Resources 1998 
Washington Acceptable source impact levels 
(at 10-6 risk), annual average— 
beryllium and compounds 
4.2x10-4 µg/m3 WA Dept. of 
Ecology 1998 
Wisconsin Hazardous air contaminants 
without acceptable ambient 
concentrations requiring 
application of best available 
control technology—beryllium and 
beryllium compounds (as Be) 
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Table 8-1. Regulations and Guidelines Applicable to Beryllium (continued) 
Agency	 Description Information Reference 
STATE (cont.) 
b. Water 








Drinking water guideline— 0.007 µg/L HSDB 2001 
beryllium 
California Primary MCL—beryllium 0.004 mg/L	 CA Dept. of 
Health Services 
2000 
Hawaii MCL—beryllium 0.004 mg/L	 HI Dept. of Health 
1999a 
Toxic pollutant standards— HI Dept. of Health 
beryllium 1999b 
Freshwater 
Acute 43 mg/L 
Chronic No standard 
Saltwater 
Acute No standard 
Chronic No standard 
Fish Consumption	 0.038 mg/L 
Kansas	 Water quality standards— KS Dept. of
 
beryllium, total Health and
 
Aquatic life 130 mg/L Environ. 1999 
Acute 5.3 mg/L 
Chronic 
Public health 0.13 mg/L 
Food procurement 4.0 mg/L 
Domestic water supply 








New Jersey Groundwater standards—	 NJ Dept. of 
beryllium Environ. 
Groundwater quality criteria 0.008 µg/L Protection 1993 
PQL 20 µg/L 
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Table 8-1. Regulations and Guidelines Applicable to Beryllium (continued) 
Agency Description Information Reference 
STATE (cont.) 
Rhode Island Beryllium 
Groundwater quality standard 




South Dakota MCL for community and non-
transient non-community water 
systems—beryllium 
0.004 mg/L SD Dept. of 
Environ. & Natural 
Resources 1998 
Vermont Groundwater quality standard— 
beryllium 
Enforcement standard 




c. Food No data 
d. Other 







Massachusetts Human health-based toxicity 
values—beryllium 
Chronic oral RfD 




Minnesota Health risk limits 
Slope factor 




aGroup 1: carcinogenic to humans
bPotential occupational carcinogen 
cDWEL: A lifetime exposure concentration protective of adverse, non-cancer health effects that assumes all of the 
exposure to a contaminant is from a drinking water source.
dA1: confirmed human carcinogen. The agent is carcinogenic to humans based on the weight of evidence from 
epidemiologic studies.
EB1: probable human carcinogen
fIndicates value derived using an inhalation cancer potency factor 
ACGIH = American Conference of Governmental Industrial Hygienists; BNA = Bureau of National Affairs; 
CERCLA = Comprehensive Environmental Response Compensation and Liability Act; CFR = Code of Federal 
Regulations; DOD = Department of Defense; DOE = Department of Energy; DWEL = drinking water equivalent 
level; EPA = Environmental Protection Agency; FDA = Food and Drug Administration; HSDB = Hazardous 
Substances Data Bank; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to 
life or health; IRIS = Integrated Risk Information System; MCL = maximum contaminant level; MCLG = maximum 
contaminant level goal; NIOSH = National Institute for Occupational Safety and Health; OSHA = Occupational 
Safety and Health Administration; PEL = permissible exposure level; PQL = practical quantitation limits; 
REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; 
STEL = short-term exposure limit; TCLP = toxicity characteristic leaching procedure; TLV = threshold limit value; 
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by a sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%. The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.   
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples.  They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen—A chemical capable of inducing cancer. 
Case-Control Study—A type of epidemiological study which examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure. These may suggest 
some potential topics for scientific research but are not actual research studies. 
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Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research but are not actual research studies. 
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups which examines the 
relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment. 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero 
death. 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
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Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
Immunological Effects—Functional changes in the immune response. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo—Occurring within the living organism. 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air which has been 
reported to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for a 
specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(LO) (LDLO)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
Lethal Dose(50) (LD50)—The dose of a chemical which has been calculated to cause death in 50% of a 
defined experimental animal population. 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a minimal risk 
level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 




Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer. 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) which represents the best estimate of relative risk (risk as a ratio of the 
incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who 
were not exposed to the risk factor). An odds ratio of greater than 1 is considered to indicate greater risk 
of disease in the exposed group compared to the unexposed. 
Organophosphate or Organophosphorus Compound—A phosphorus containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
Pharmacokinetics—The science of quantitatively predicting the fate (disposition) of an exogenous 
substance in an organism. Utilizing computational techniques, it provides the means of studying the 
absorption, distribution, metabolism and excretion of chemicals by the body. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models: data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments 
which, in general, do not represent real, identifiable anatomic regions of the body whereby the 
physiologically-based model compartments represent real anatomic regions of the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically-based dose-
response model which quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 
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describe the biological effect (response) produced by the system following exposure to an exogenous 
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates and, possibly membrane permeabilities.  The models also utilize biochemical information 
such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also called 
biologically based tissue dosimetry models. 
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentrations for up to a 10-hour workday during a 40-hour 
workweek. 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime. 
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL-from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 
24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 





Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic, that is associated with an increased occurrence of disease or other health-related 
event or condition. 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed. 
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 min 
continually.  No more than four excursions are allowed per day, and there must be at least 60 min 
between exposure periods. The daily Threshold Limit Value - Time Weighted Average (TLV-TWA) may 
not be exceeded. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect. 
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Toxicokinetic—The study of the absorption, distribution and elimination of toxic compounds in the 
living organism. 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest­
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of one can be used; 
however a reduced UF of three may be used on a case-by-case basis, three being the approximate 
logarithmic average of 10 and 1. 
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ATSDR MINIMAL RISK LEVEL AND WORKSHEETS
 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 
99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly 
with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances 
most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
above the MRL does not mean that adverse health effects will occur. 
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MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically  compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as a hundredfold below levels 
that have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agencywide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public.  They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles.  Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels.  For additional information 
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease 








Chemical Name: Beryllium and Compounds 
CAS Number: 
Date: May 16, 2002 
Profile Status: Third Post Public Comment Draft 
Route: [ ] Inhalation  [X] Oral 
Duration: [  ] Acute  [ ] Intermediate  [X] Chronic 
Key to Figure: 11 
Species: Dogs 
Minimal Risk Level: 0.002 [X] mg beryllium/kg/day   [ ] ppm 
Reference: Morgareidge K, Cox GE, Gallo MA. 1976. Chronic feeding studies with beryllium in dogs. 
Food and Drug Research Laboratories, Inc. Submitted to the Aluminum Company of America.  Alcan 
Research and Development, Ltd., Kawecki-Berylco Industries, Inc., and Brush-Wellman, Inc. 
Experimental design: (human study details or strain, number of animals per exposure/control groups, sex, 
dose administration details):  Groups of five male and five female Beagle dogs were fed a diet containing 
0, 5, 50 or 500 ppm beryllium as beryllium sulfate tetrahydrate (0, 0.1, 1, and 12 mg beryllium/kg/day for 
males and 0, 0.2, 1, and 17 mg beryllium/kg/day for females) for 172 weeks. The basal diet was a 
commercial dog chow (Purina®) moistened with warm water; the dogs were given access to the food for 
1 hour/day.  After 33 weeks, a group of five male and five female dogs was added to the study and fed a 
diet containing 1 ppm (0.02 and 0.03 mg beryllium/kg/day for males and females, respectively); duration 
of exposure for this group was 143 weeks. The following parameters were used to assess toxicity: daily 
observations, food consumption, body weight, hematology and serum clinical chemistry (blood samples 
collected after 1, 3, 6, 16, 18, 24, 30, and 36 months of exposure), urinalysis (samples collected after 1, 3, 
6, 18, 24, 30, and 36 months of exposure), organ weights (heart, liver, kidney, brain, spleen, pituitary, 
thyroids, adrenals, and gonads), and histopathology of the spleen, thymus, pancreas, lungs, gonads, 
stomach, small and large intestines, urinary bladder, heart, aorta, muscle, adrenals, thyroids, lymph nodes, 
salivary glands, gallbladder, liver, kidneys, pituitary, brain, spinal cord, skin, mammary gland, bone 
marrow, and eyes. 
Effects noted in study and corresponding doses: Two moribund animals in the 500 ppm group were 
sacrificed during week 26; the remainder of the animals in the 500 ppm group were killed during 
week 33. Overt signs of toxicity in the 500 ppm group included lassitude, weight loss, anorexia, and 
visibly bloody feces.  A slight anemia (slight decreases in erythrocyte, hemoglobin, and hematocrit; 
statistical analysis not reported), more apparent in the females than in the males, was observed after 3 and 
6 months of exposure; however, there were no alterations in the bone marrow and none of the animals 
was seriously affected.  The study authors noted that the anemia may have been related to the 
gastrointestinal tract hemorrhages rather than a direct effect of beryllium on the hematological system. 
All animals in the 500 ppm group showed fairly extensive erosive (ulcerative) and inflammatory lesions 
in the gastrointestinal tract. These occurred predominantly in the small intestine, and to a lesser extent in 
the stomach and large intestine, and were regarded by the authors as treatment-related.  All of the animals 
with stomach or large intestinal lesions also had lesions in the small intestine, except for one animal with 
stomach lesions only.  This animal had stomach lesions that were very localized and not very severe. 
Erythroid hypoplasia of the bone marrow, bile stasis and vasculitis in the liver, and acute inflammation in 
the lymph nodes were also observed in the 500 ppm group; these effects are likely to be secondary to the 







One dog in the 50 ppm group died after 70 weeks.  Ulcerative gastrointestinal lesions were observed in 
this animal.  No beryllium-related hematological, serum chemistry, urinalysis, organ weight, or body 
weight alterations were observed in the groups exposed to <500 ppm beryllium.
Dose and end point used for MRL derivation: The chronic-duration oral MRL for beryllium w 
calculated using a benchmark dose method that involves fitting mathemat 
response data for ulcerative lesions of the small intestine of dogs exposed 
diet (Morgareidge et al. 1976). Because there were no apparent sex-related dif 
of these lesions, the incidence data for the male and female dogs were com 
doses for the males and females were averaged. The dose-response data are p 
Dietary Concentration (ppm) IncidenceDose (mg beryllium/kg/day)
0 0 0/10 
1 0.025 0/10 
5 0.15 0/10 
50 1 1/10 
500 14.5 9/10 
For this analysis, the benchmark dose (BMD) was defined as the dose corresp 
the incidence of small intestine lesions compared to controls; the BMDL is 
limit on the BMD. EPA’s BenchMark Dose Software (version 1.3) was used to fit 
models (Gamma, Logistic, Log-Logistic, Multistage, Probit, Log-Probit, Quanta 
Quantal-Quadratic, and Weibull) to the incidence data. Model fit was judge 
associated with the chi-square goodness-of-fit statistic generated by the m 
inspection of the plot of observed and predicted values. The probit model p 
the incidence data; the observed and predicted incidences are illustrated b 
fits the data using the maximum likelihood method and the following equ 
background (1-background) x CumNorm(intercept slope x log(dose)), wher 
cumulative normal distribution function. A BMDL of 0.56 mg beryllium/kg/d 
model. 
[ ] NOAEL [ ] LOAEL [X] Benchmark dose (BMDL) 
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Figure 1.  Observed and Predicted (by Probit Model) Incidences of Intestinal Lesions in Dogs exposed 
to Beryllium in the Diet. 
Uncertainty Factors used in MRL derivation: 
[X]	  10 for use of a extrapolation from animals to humans 
[X]	  10 for human variability 
[X]	 3 modifying factor to account for the lack of a study that supports the gastrointestinal effects 
found in the Morgareidge et al. [1976] dog study and the uncertainty as to whether the 
benchmark dose level is the NOAEL. 
Was a conversion factor used from ppm in food or water to a mg/body weight dose? 
Yes. Daily doses were estimated using the estimated TWA body weights of 13.0, 12.7, 13.8, and 12.3 kg 
for males in the 1, 5, 50, and 500 ppm groups, respectively, and 10.2, 10.3, 11.2, and 8.6 kg for females, 
respectively and the reported average food intake of 300 g/day.










Other additional studies or pertinent information that lend support to this MRL:
 
Gastrointestinal effects have not been reported in rats (Morgareidge et al. 1975; Schroeder and Mitchener
 
1976a) or mice (Schroeder and Mitchener 1976b) chronically exposed to dietary beryllium.
 






Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, 
weight-of-evidence discussions for human health end points by addressing the following questions. 
1.	 What effects are known to occur in humans? 
2.	 What effects observed in animals are likely to be of concern to humans? 
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
The chapter covers end points in the same order they appear within the Discussion of Health Effects by 
Route of Exposure section, by route (inhalation, oral, dermal) and within route by effect.  Human data are 
presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  In vitro 
data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered 
in this chapter. If data are located in the scientific literature, a table of genotoxicity information is 
included. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal risk levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 




Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for 
inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic).  These 
MRLs are not meant to support regulatory action; but to acquaint health professionals with exposure 
levels at which adverse health effects are not expected to occur in humans.  They should help physicians 
and public health officials determine the safety of a community living near a chemical emission, given the 
concentration of a contaminant in air or the estimated daily dose in water.  MRLs are based largely on 
toxicological studies in animals and on reports of human occupational exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses for lifetime exposure (RfDs).  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest NOAEL that does not 
exceed any adverse effect levels.  When a NOAEL is not available, a lowest-observed-adverse-effect 
level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed. 
Additional uncertainty factors of 10 must be used both for human variability to protect sensitive 
subpopulations (people who are most susceptible to the health effects caused by the substance) and for 
interspecies variability (extrapolation from animals to humans).  In deriving an MRL, these individual 
uncertainty factors are multiplied together.  The product is then divided into the inhalation concentration 
or oral dosage selected from the study.  Uncertainty factors used in developing a substance-specific MRL 
are provided in the footnotes of the LSE Tables. 
Chapter 3 
Health Effects 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (3-1, 3-2, and 3-3) and figures (3-1 and 3-2) are used to summarize health effects and illustrate 
graphically levels of exposure associated with those effects.  These levels cover health effects observed at 
increasing dose concentrations and durations, differences in response by species, minimal risk levels 
(MRLs) to humans for noncancer end points, and EPA's estimated range associated with an upper- bound 
individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a 
quick review of the health effects and to locate data for a specific exposure scenario.  The LSE tables and 
figures should always be used in conjunction with the text.  All entries in these tables and figures 
represent studies that provide reliable, quantitative estimates of No-Observed-Adverse-Effect Levels 
(NOAELs), Lowest-Observed-Adverse-Effect Levels (LOAELs), or Cancer Effect Levels (CELs). 
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The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
LEGEND 
See LSE Table 3-1 
(1)	 Route of Exposure One of the first considerations when reviewing the toxicity of a substance using 
these tables and figures should be the relevant and appropriate route of exposure.  When sufficient 
data exists, three LSE tables and two LSE figures are presented in the document.  The three LSE 
tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE 
Table 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation (LSE Figure 3-1) 
and oral (LSE Figure 3-2) routes. Not all substances will have data on each route of exposure and 
will not therefore have all five of the tables and figures. 
(2)	 Exposure Period Three exposure periods - acute (less than 15 days), intermediate (15–364 days), 
and chronic (365 days or more) are presented within each relevant route of exposure.  In this 
example, an inhalation study of intermediate exposure duration is reported.  For quick reference to 
health effects occurring from a known length of exposure, locate the applicable exposure period 
within the LSE table and figure. 
(3)	 Health Effect The major categories of health effects included in LSE tables and figures are death, 
systemic, immunological, neurological, developmental, reproductive, and cancer.  NOAELs and 
LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are 
further defined in the "System" column of the LSE table (see key number 18). 
(4)	 Key to Figure Each key number in the LSE table links study information to one or more data points 
using the same key number in the corresponding LSE figure.  In this example, the study represented 
by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the 2 
"18r" data points in Figure 3-1). 
(5)	 Species The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. 
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6)	 Exposure Frequency/Duration The duration of the study and the weekly and daily exposure 
regimen are provided in this column.  This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to 1,1,2,2-tetrachloroethane via 
inhalation for 6 hours per day, 5 days per week, for 3 weeks.  For a more complete review of the 
dosing regimen refer to the appropriate sections of the text or the original reference paper, i.e., 
Nitschke et al. 1981. 
(7)	 System This column further defines the systemic effects.  These systems include: respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. 
"Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. 
In the example of key number 18, 1 systemic effect (respiratory) was investigated. 
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(8)	 NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which no 
harmful effects were seen in the organ system studied.  Key number 18 reports a NOAEL of 3 ppm 
for the respiratory system which was used to derive an intermediate exposure, inhalation MRL of 
0.005 ppm (see footnote "b"). 
(9)	 LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the study 
that caused a harmful health effect.  LOAELs have been classified into "Less Serious" and 
"Serious" effects. These distinctions help readers identify the levels of exposure at which adverse 
health effects first appear and the gradation of effects with increasing dose.  A brief description of 
the specific end point used to quantify the adverse effect accompanies the LOAEL.  The respiratory 
effect reported in key number 18 (hyperplasia) is a Less serious LOAEL of 10 ppm.  MRLs are not 
derived from Serious LOAELs. 
(10)	 Reference The complete reference citation is given in Chapter 9 of the profile. 
(11)	 CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiologic studies.  CELs are always considered serious 
effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report 
doses not causing measurable cancer increases. 
(12)	 Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found in 
the footnotes. Footnote "b" indicates the NOAEL of 3 ppm in key number 18 was used to derive an 
MRL of 0.005 ppm. 
LEGEND 
See Figure 3-1 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13)	 Exposure Period The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the intermediate and chronic exposure periods are illustrated. 
(14)	 Health Effect These are the categories of health effects for which reliable quantitative data exists. 
The same health effects appear in the LSE table. 
(15)	 Levels of Exposure concentrations or doses for each health effect in the LSE tables are graphically 
displayed in the LSE figures.  Exposure concentration or dose is measured on the log scale "y" axis. 
Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in mg/kg/day. 
(16)	 NOAEL In this example, 18r NOAEL is the critical end point for which an intermediate inhalation 
exposure MRL is based. As you can see from the LSE figure key, the open-circle symbol indicates 
to a NOAEL for the test species-rat. The key number 18 corresponds to the entry in the LSE table. 
The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see 
entry 18 in the Table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table). 
(17)	 CEL Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived.  The diamond 
symbol refers to a Cancer Effect Level for the test species-mouse.  The number 38 corresponds to 
the entry in the LSE table. 
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(18)	 Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the 
upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are 
derived from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of 
the cancer dose response curve at low dose levels (q1*). 
































































































































































































































































































































































































































































































ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
ACOEM American College of Occupational and Environmental Medicine 
ACGIH American Conference of Governmental Industrial Hygienists 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AOEC Association of Occupational and Environmental Clinics 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase 
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotranferase 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DOL Department of Labor 




DOT/UN/ Department of Transportation/United Nations/
 NA/IMCO     North America/International Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 
FSH follicle stimulating hormone 
g  gram  
GC gas chromatography 
gd gestational day 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
HPLC high-performance liquid chromatography 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank 
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System
Kd adsorption ratio 
kg kilogram 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LCLo lethal concentration, low 
LC50 lethal concentration, 50% kill 
LDLo lethal dose, low 
LD50 lethal dose, 50% kill 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LT50 lethal time, 50% kill 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
m meter 
MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 
MCL maximum contaminant level 
MCLG maximum contaminant level goal 
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mmHg millimeters of mercury 
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
NHANES National Health and Nutrition Examination Survey 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic 
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PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
PID photo ionization detector 
pg picogram 
pmol picomole 
PHS Public Health Service 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RTECS Registry of Toxic Effects of Chemical Substances 
RQ reportable quantity 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase 
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
VOC volatile organic compound 
WBC white blood cell 
WHO World Health Organization 
> greater than 
$ greater than or equal to 
= equal to 
< less than 
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q1* cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
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ocular effects  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23, 61, 74, 85, 125 
  
odds ratio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49, 50, 53 
  
partition coefficients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  140, 141
 
PBPD  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  102 
  
PBPK  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102-105
 
Permissible Exposure Level . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  200 
  
pharmacodynamic  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  102 
  
pharmacokinetic  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102-105
 
physiologically based pharmacodynamic (see PBPD)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  102 
  
physiologically based pharmacokinetic (see PBPK)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  102, 104
 
precipitation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11, 148, 149, 161-164
 
Public health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1, 6, 9, 11, 19, 20, 68, 69, 109, 123, 178, 183, 189, 190, 195, 199
 
pulmonary fibrosis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47, 57, 135 
  
RCRA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  147, 153
 
reference dose (see RfD)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  193, 200
 
regulations  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9, 147, 148, 193-196, 198, 200
 
renal effects  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59, 60, 84, 119 
  
reportable quantity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  198 
  
Resource Conservation and Recovery Act (see RCRA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  147, 153
 
RfD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  193, 197, 200
 
sediment  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2, 11, 149, 151, 158, 160, 164, 166, 188, 190
 
sedimentation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57, 159 
  
selenium  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  112 
  
SMR  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66-69, 71, 72 
  
soil  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1-3, 8, 9, 11, 149, 151, 158-160, 164, 166, 176, 179, 180, 186, 188, 190
 
solubility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21, 55, 63, 74, 98, 99, 101, 105, 115, 127, 140, 141, 160, 161
 
Standardized mortality ratio (see SMR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  66 
  
Superfund  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  151 
  
surface water . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3, 11, 148, 151, 157, 158, 165
 
thyroid  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  84 
  
time-weighted average (see TWA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  69, 200 
  
tomato . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  160, 172
 
total diet studies  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  174 
  
toxicokinetic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19, 111, 134
 
Toxics Release Inventory (see TRI) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  151 
  
TRI  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151-154, 156, 158, 178, 184
 
tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6, 73, 87 
  
TWA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  69, 174, 195, 196, 200
 
Type II  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55 
  
vapor phase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  142 
  
vapor pressure  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  140, 141
 
